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Michael Thomas Englander 
 
Contemporary interpretations of Crick’s original Adaptor Hypothesis view both the amino 
acid and the tRNA body as passive participants during aminoacyl-tRNA (aa-tRNA) 
selection by the ribosome. Recent experimental evidence investigating tRNA mutants that 
miscode due to mutations that lie outside the anticodon as well as data from the unnatural 
amino acid mutagenesis field that shows that different unnatural amino acids, when 
esterified to the same suppressor tRNA, produce different amounts of protein, suggest 
that aa-tRNA selection is considerably more complex than originally envisioned in 
Crick’s Adaptor Hypothesis and that aa-tRNA selection may extend to the amino acid 
itself. Here, using D-aa-tRNAs as substrates on natural, fully modified tRNAs and a 
highly purified in vitro translation system, we demonstrate that D-aa-tRNAs inhibit 
catalysis at the ribosomal peptidyl-transferase center (PTC), substantiating our hypothesis 
that the ribosome is in fact sensitive to the structure of the amino acid. 
The implications of these results affects multiple disciplines. First, we provide a 
rationale for the impaired incorporation of unnatural amino acids widely observed in the 
unnatural amino acid mutagenesis field and demonstrate that D-amino acids can be 
incorporated into protein using the ribosome. Second, we show that D-aa-tRNAs inhibit 
translation at a previously undetected mechanistic step in the elongation cycle of protein 
synthesis that occurs after incorporation into peptide. This step presumably arises from 
the presence of the D-amino acid at the C-terminus of the nascent peptide which impedes 
structural rearrangements of the PTC that normally partition the PTC between an active 
and inactive conformation.  
Perhaps most significantly, the incorporation of D-amino acids into protein is a 
plausible mechanism that might underlie human disease states. Analagous to editing 
defective synthetases that mischarge natural amino acids in vivo resulting in protein 
misfolding phenotypes, we predict that the aminoacylation of D-amino acids and 
subsequent incorporation into proteins by the ribosome in vivo would lead to similar 
defects, thereby explaining the near universal conservation of D-aminoacyl-tRNA 
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Chapter 1   
Introduction 
 
1.1 The Central Dogma and the Fidelity of Protein Synthesis  
The central dogma of molecular biology [1] articulates that the hereditary polymer 
composed of deoxyribonucleic acid (DNA) bases contains information that is first 
transferred to an intermediate composed of ribonucleic acid (RNA) bases, termed 
messenger RNA (mRNA), and that the information contained in this message provides 
the precise order for amino acids of a given protein (Figure 1.1). This flow of information, 
from DNA to RNA to protein, is fundamental to all living organisms and is itself 
governed by two distinct processes, transcription and translation. Transcription is the 
process through which one single stranded DNA template is copied into mRNA and is 
catalyzed by the DNA dependant RNA polymerase enzyme. Translation is the process 
through which amino acids are polymerized in the order specified by the mRNA template 
and is catalyzed by the ribosome with the aid of several translation factors. Defining the 
specificity of the translational machinery (TM) in general and the ribosome in particular 
with respect to the amino acid substrate has been the driving motivation behind my 
doctorate work.   
 The genetic code is determined by arranging the four DNA nucleotide bases, adenine 
(A), guanine (G), cytosine (C) and thymine (T) into three non-overlapping nucleotide 
base units, termed codons. Codons can be comprised of three of the same nucleotide 
bases (for example, AAA) or of any combination of the four nucleotide bases (for 
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example ATG). In mRNA and transfer RNA (tRNA), thymine is replaced by uridine (U). 
Each codon encodes a specific amino acid, and the precise trinucleotide sequence that 
comprises the mRNA codon is read by the adaptor tRNA molecule, which possesses a 
three nucleotide sequence, termed the anticodon, that forms Watson-Crick base pairs with 
the cognate mRNA codon in the ribosome. Because the tRNA bears a specific amino acid 
at its 3’-CCA terminus along with the anticodon, the tRNA is the molecular representation 
of the genetic code, linking the mRNA codon to the amino acid it encodes.  
 The fidelity of protein synthesis is thought to be maintained by both the 
aminoacyl-tRNA synthetase enzymes (aaRS), responsible for the esterification of tRNA 
with cognate amino acid, and the ribosome, responsible for selecting the correct 
aminoacyl-tRNA (aa-tRNA) based on the mRNA codon. Each of the twenty amino acids 
has its own corresponding aaRS, and aminoacylation of tRNA by the aaRS is a highly 
specific process with error rates of 2.5x10-5 [2-4]. The aaRS enzymes can discriminate 
natural amino acids with similar side chains with high degrees of accuracy. For example, 
while the isoleucine aaRS is capable of misacylating tRNAIle with Val, this synthetase has 
evolved an editing site [5-6] that will then hydrolyze mischarged Val-tRNAIle, effectively 
reducing the extent of mischarging of Val onto tRNAIle to 1 in every 40,000 [2,3-4]. 
Given the high degree of fidelity of the aaRS enzymes for charging tRNA with natural 
amino acids, it is perhaps surprising that these enzymes can charge tRNA with unnatural 
amino acids. Calendar and Berg first demonstrated the capability of the tyrosine aaRS to 
aminoacylate tRNATyr with D-Tyr, though the enzyme performs this reaction at a slower 
rate than the aminoacylation of tRNATyr with L-Tyr. Various backbone and side-chain 
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analogues have also been misacylated onto tRNA by the aaRS enzymes, including amino 
acid side-chain analogues, N-methylated amino acids, and amino acids with substitutions 
off of the α-carbon [7].  
Figure 1.1 The Central Dogma. The genetic information contained in DNA is transcribed into mRNA 
by the RNA polymerase enzyme. The mRNA is translated into protein by the ribosome. 
 
As the central biomolecule of the TM, the ribosome must select the correct aa-tRNA 
from a pool of aa-tRNA substrates as dictated by the mRNA template. Measurement of 
the rates of dipeptide formation for ten different Escherichia coli (E. coli) aa-tRNAs on 
cognate (3 complementary base pairs between the codon and the anticodon) mRNA 
codons revealed that these substrates were incorporated with nearly identical rates, 
suggesting that the ribosome deals with its aa-tRNA substrates with equal efficiency [8]. 
The ribosome possesses a kinetic proofreading mechanism for discriminating against 
incorporation of aa-tRNA bearing near-cognate (one mismatch between the codon and the 
anticodon) or non-cognate (two or three mismatches between the codon and the anticodon) 
anticodons, and the mechanism through which this selection is achieved evolved from 
Crick’s original Adaptor Hypothesis [9].  
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1.2 The Adaptor Hypothesis  
Crick postulated the existence of twenty nucleic acid adaptor molecules and that 
mechanistically, these adaptors would form base pair interactions with the mRNA 
template analogous to base pairing in the DNA double helix [9]. Remarkably, Crick’s 
“Adaptor Hypothesis” preceded both the resolution of the first tRNA sequence, then 
termed sRNA (or soluble RNA) [10] and even knowledge of the tRNA anticodon. Crick’s 
Adaptor Hypothesis laid the foundation for a view of aa-tRNA selection focused almost 
exclusively on the interactions between the mRNA codon and the tRNA anticodon, a view 
that excludes any potential contribution of the amino acid itself. 
Seminal proof of the Adaptor Hypothesis was provided by Chapeville et al. who 
chemically reduced Cys-tRNACys with Raney Nickel to generate misacylated 
Ala-tRNACys (the reduction was not quantitative, so Cys-tRNACys was also present in the 
crude preparation) and analyzed the incorporation of this misacylated aa-tRNA into 
polypeptide product [11]. Using an E. coli based cell extract translation system containing 
a poly UG mRNA template, the similarity in rate and extent of incorporation of 
Cys-tRNACys and Ala-tRNACys into poly-Cys and poly-Ala peptide product, respectively, 
strongly suggested the incorporation of alanine into polypeptide through the cysteine 
codon [11]; analysis of the hydrolyzed polypeptide product by TLC electrophoresis 
unambiguously established the validity of this conclusion [11]. Several other follow-up 
studies with natural and unnatural amino acids misacylated onto natural tRNAs, including 
the incorporation of DOPA and of phenyllactic acid [12,13], demonstrated that other 
amino acids could be reassigned to different codons, supporting the idea that the tRNA 
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was paramount during aa-tRNA selection by the ribosome and lead to the widespread 
view that the ribosome was in fact blind to the structure of the amino acid. Indeed, in his 
1963 review Crick concluded “the amino acid goes where the sRNA directs and has no 
further control over its destination [14].”  
  
1.3 The Ribosome and the Contemporary Framework of the 
Elongation Cycle of Protein Synthesis 
The ribosome is a massive ~2.5x106 MW [15] ribonucleoprotein composed of two 
subunits of unequal size. In bacteria, the larger 50S subunit harbors the 
peptidyl-transferase center, where peptide bond formation is catalyzed. The smaller 30S 
subunit harbors the decoding center where the ribosome matches the correct anticodon of 
the aa-tRNA with the cognate mRNA codon. Three tRNA binding sites span the 
intersubunit space of the ribosome: the aminoacyl-tRNA binding site (A-site), the 
peptidyl-tRNA binding site (P-site) and the exit (E-site) site (Figure 1.2). The first step in 
the elongation cycle is the delivery of aa-tRNA in ternary complex with EF-Tu and GTP 
to the ribosome, where cognate aa-tRNA is selected based on the interaction between the 
mRNA codon and the tRNA anticodon. Second, once fully accommodated into the 
ribosomal A-site, peptide bond formation occurs as the A-site aa-tRNA acts as the 
peptidyl-tRNA acceptor, leaving the P-site tRNA deacylated. Third, translocation of the 
A-site peptidyl-tRNA into the P-site, and the deacylated P-site tRNA into the E-site, is 
promoted by EF-G and results in both the movement of the mRNA by one codon and an  
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Figure 1.2. The E. coli 70S Ribosome. X-ray crystallographic structure depicting relative locations of 
the peptidyl-transferase center and the decoding center within the large, 50S and small, 30S subunit, 
respectively. tRNAs in the A-, P-, and E- sites. Structure from Protein Data Bank (PDB) 2J00 and 
2J01.  
 
A-site vacant of aa-tRNA. Because the peptidyl-tRNA has been translocated from the A- 
to the P-site, the empty A-site is capable of selecting a new aa-tRNA based on the new 




Figure 1.3. Elongation cycle of protein synthesis. The elongation cycle of protein synthesis is 
comprised of three major steps: 1) aa-tRNA selection, where the aa-tRNA is delivered to the ribosomal 
A-site in ternary complex with EF-Tu and GTP 2) peptide bond formation, where the aa-tRNA acts as 
a peptidyl tRNA acceptor in the A-site and 3) translocation, where the peptidyl-tRNA moves from the 
A- to the P-site, catalyzed by EF-G. Once in the P-site, the nascent peptide on the peptidyl-tRNA is 
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peptidyl-tRNA donor once a new aa-tRNA has been properly selected in the A-site. This 
process continues until the full-sequence of amino acids dictated by the mRNA template 
has been synthesized (Figure 1.3).  
 
 
1.3.1 Aminoacyl-tRNA Selection 
The interaction between the mRNA codon and tRNA anticodon has been the focus of 
biochemical [16-18], structural [19-21] and dynamic studies [22-23] that have addressed 
the question of how the ribosome can select the correct aa-tRNA from a larger pool of 
twenty different aa-tRNAs with both a high degree of speed and accuracy. These studies 
have led to the construction of a high resolution structural and mechanistic model that 
describes the ability of the ribosome to select aa-tRNA based solely on the 
codon-anticodon interaction.       
The thermodynamics of binding between the codon and anticodon alone, however, 
are not enough to explain the low level of misincorporation observed in vivo, where the 
ribosome has been shown to misincorporate the wrong amino acid once in every 103~104 
attempts [4]. While the thermodynamic stability  (∆∆G)  of non-cognate aa-tRNA can 
explain the high levels of fidelity observed, the thermodynamic stability  (∆∆G)  
between near-cognate aa-tRNA is not in accord with the high levels of accuracy exhibited 
by the TM [4]. To explain this paradox, a kinetic proofreading model was proposed 
[24-25] and biochemical studies demonstrated this model’s validity in describing the 
ribosome’s ability to achieve a high degree of accuracy during aa-tRNA selection [26-28]. 
In this scheme (Figure 1.4), the ribosome monitors the mRNA codon-tRNA anticodon 
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interaction in two separate steps, termed initial selection and proofreading, separated by 
an irreversible step, the hydrolysis of GTP by EF-Tu. The overall fidelity of selection, 
then, is the product of the fidelity observed in each individual step. Biochemical 
competition experiments monitoring dipeptide formation, where ribosomes programmed 
with an mRNA bearing a phenylalanine codon were confronted with ternary complexes 
containing equal concentrations of the cognate Phe-tRNAPhe and the near-cognate 
Leu-tRNALeu aa-tRNAs, revealed that in vitro the ribosome can select cognate aa-tRNA 
over near-cognate aa-tRNA with 450 fold selectivity [29]. Kinetic studies comparing 
individual rate constants during selection of cognate Phe-tRNAPhe versus near-cognate 
Leu-tRNALeu demonstrated that the ribosome actively increases the forward rate constants 
of both GTPase activation and accommodation for cognate Phe-tRNAPhe [17,27], leading 
to a view that cognate aa-tRNAs are able to successfully navigate the selection steps 
based on an induced fit mechanism. Indeed, crystallographic work from Ramakrishnan  
 
Figure 1.4. Kinetic proofreading and the mechanism of aa-tRNA selection. The ribosome monitors 
the interaction between the mRNA codon and the tRNA anticodon in two places, first during initial 
selection and second during proofreading. These steps are separated by the irreversible step of GTP 
hydrolysis by EF-Tu. Thus, the overall fidelity is the product of the discrimination of both the initial 
selection and proofreading steps. 
 
and co-workers conclusively demonstrated that conserved ribosomal RNA (rRNA) 
residues A1492, A1493 and G530 (E. coli numbering, unless otherwise noted) form 
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A-minor interactions that monitor the geometry of the minor groove of the first and 
second position base pairs of the codon-anticodon pair and stabilize the interaction of 
cognate anticodons with mRNA in the decoding center, and that these interactions are not 
formed with aa-tRNAs bearing near-cognate anticodons [21,30]. The thermodynamic 
stability of the A-minor interaction can explain the high fidelity of protein synthesis [31]. 
The energy provided by these interactions in the decoding center may also accelerate the 
accompanied conformational rearrangements, termed domain closure, characterized by 
the rotation of the head and shoulder domains toward the center of the 30S subunits [30], 
that take place within the 30S subunit upon decoding of a cognate aa-tRNA in the 
decoding center [32].  
 
1.3.2 Peptide Bond Formation 
Because of the high fidelity of aa-tRNA selection, only aa-tRNA bearing a cognate 
anticodon to the mRNA codon are able to accommodate and be granted access into the 
peptidyl-transferase center (PTC) and take part in the peptidyl transferase reaction. 
Analysis of the activation enthalpy, entropy and free energy of ribosome catalyzed 
peptidyl-transfer versus a ribosome free model suggested that the ribosome functions 
primarily as an “entropy trap”, where the >107 fold rate enhancement achieved by the 
ribosome in catalyzing peptide bond formation is achieved predominantly by the precise 
positioning of aa-tRNA substrates and the lowering of the reaction entropy [33]. 
Consistent with this view, the universally conserved 3’-CCA end of the tRNA is 
recognized by conserved rRNA nucleotides in both the A- and P-sites of the 50S subunit. 
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Biochemical studies have demonstrated that C75 of the A-site tRNA base pairs with the 
universally conserved rRNA nucleotide G2553 of the A loop (comprised of nucleotides 
U2552-C2556) rRNA in the A-site of the 50S subunit [34] and that C74 of the P-site 
tRNA base pairs with the universally conserved G2252 of the P loop (G2250-C2254) 
rRNA in the P-site of the 50S subunit [35]. Biochemical studies have also revealed that 
the 2’-OH of A-76 of the P-site tRNA plays a prominent role in the rate enhancement 
observed in the catalysis of peptide bond formation by the ribosome [36], leading to a 
substrate assisted catalysis mechanism where the 2’-OH of A-76 of the P-site tRNA 
serves as a proton shuttle during the peptidyl-transferase reaction [36-38] and to stabilize 
an active conformation of the PTC [39]. X-ray crystallographic work using the 50S 




Figure 1.5. Conformational rearrangements in the PTC (A) The PTC in its inactive conformation. 
Water (red) is sterically excluded by conserved rRNA nucleotides (orange) from deacylating the ester 
linkage of the P-site bound peptidyl-tRNA (green, blue and red) (B) The P-site rearranges into its 
active conformation upon binding of the A-site substrate CChPmn (green), but not ChPmn (light 
green). This rearrangement optimally positions the ester linkage for attack by the α-NH2 of the A-site 
aa-tRNA (blue arrow). A transition-state analogue (TSA, black) is also depicted (TSA; black). (A) and 
(B) are reproduced from [40]. 
 
 
A.                               B. 
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analogs have confirmed both the substrate assisted catalysis and the entropy trap 
mechanisms, revealing that the PTC transitions between an inactive and an active 
conformation depending on the occupancy of the A-site [40] (Figure 1.5). When the 
A-site is vacant, conserved rRNA nucleotides enclose and protect the ester linkage of the 
P-site tRNA from hydrolysis by water, characteristic of the PTC in its inactive 
conformation (Figure 1.5A). Upon recognition of the 3’-CCA of tRNA by the A-loop 
rRNA in the A-site, the ester linkage of the P-site tRNA is reoriented and the PTC 
rearranges such that the α-NH2 of the A-site tRNA is in optimal position to attack, 
conformational rearrangements that lead to the PTC in its active conformation [40] 
(Figure 1.5B). Taken together, these biochemical and structural studies suggest that the 
mechanism through which the PTC catalyzes peptidyl transfer is by precisely positioning  
    
 
 
Figure 1.6. rRNA nucleotides in the PTC. Structural model of the PTC with a transition state 
analog (grey) reveals that U2585 (yellow), A2451 (red), U2506 (blue) and A2602 (green) are four 
conserved rRNA nucleotides that form part of the innershell of the PTC. These nucleotides have 
been mutated without effecting the peptidyl transferase reaction. Figure reproduced from [41]. 
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aa-tRNA substrates. Interestingly, mutation of rRNA bases that were speculated to be 
involved in the catalytic reaction due to their close proximity to reactive groups observed 
in X-ray crystal structures [40] have had minimal effects on the peptidyl-transferase 
reaction (Figure 1.6) [41-44]. Despite the fact that the Haloarcula marismortuis X-ray 
structure of the 50S subunit demonstrates that the nascent polypeptide on the P-site 
peptidyl-tRNA and the amino acid on the A-site aa-tRNA are tightly packed against 
universally conserved rRNA nucleotides involved in conformational gating of the PTC, 
the role of the amino acid in potentially gating the transition of the PTC from its active to 
its inactive conformation has yet to be determined. 
The ability of nascent peptides to modulate gene expression through translation arrest 
supports the possibility that the amino acid itself might be sensed during the elongation 
cycle. Biochemical work on the tryptophanase (tna) operon has shown that the short 
twenty-four amino acid leader peptide TnaC stalls at the stop codon at codon twenty-five 
of the mRNA when TnaC-tRNAPro is in the P-site and a tryptophan residue at codon 
twelve is in the exit tunnel [45-46]. This nascent peptide mediated ribosomal stalling 
occurs when the inducer, tryptophan, is present, and renders the PTC inactive with the 
antibiotic puromycin and release factors [45-46]. Similarly, the expression of the 
antibiotic resistance gene ermA was shown to be modulated by the presence of a specific 
nascent peptide in the exit tunnel and an inducing antibiotic, rendering the PTC unable to 
catalyze peptide bonds with a subset of amino acids, suggesting that the exit tunnel can 
cooperate with the ribosomal A-site to stall translation [47]. The synthesis of SecA is also 
mediated by nascent peptide mediated ribosomal arrest. The coding sequence in the SecA 
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mRNA is not translated because an RNA helix forms a structural block to its translation 
[48-49]. A nascent peptide within SecM, an upstream gene in the mRNA that also codes 
for SecA, stalls in the absence of SecA allowing for the unfolding of the mRNA 
secondary structure and efficient translation of SecA [48-49]. Taken together, these 
findings clearly establish that the 50S subunit of the ribosome is able to sense nascent 
peptides within its exit tunnel and suggest that the ribosome might even be able to sense 
the structure of the amino acid. 
 
1.3.3 Translocation 
Translocation is a highly dynamic step in the elongation cycle, requiring the 
movement of the A-site bound peptidyl-tRNA to the P-site along with the movement of 
the ribosome along the mRNA such that a new codon occupies the A-site. Chemical 
footprinting studies [50] demonstrated that a “hybrid state” forms spontaneously upon 
peptide bond formation. In this hybrid state, the 3’-CCA ends of the tRNAs protect 
nucleotides in the E- and P-sites of the 50S subunit, whereas the anticodons of these 
tRNAs protect nucleotides in the P- and the A-sites in the 30S subunit. Consequently, 
tRNAs occupy the P- and A-sites with respect to the 30S subunit and the E- and P-sites 
with respect to the 50S subunit, characterizing the hybrid A/P and P/E state (denoting the 
30S A/50S P site and the 30S P/50S E sites) [51]. In contrast, in the classical state both 
the anticodon and the 3’-CCA end of the P- and the A-site tRNAs reside in the P- and 
A-sites of both the 30S and 50S subunits (30S A/50S A and 30S P/50S P). Cryo-EM 
reconstructions of 70S complexes with EF-G revealed that the hybrid state is 
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characterized structurally by a counterclockwise rotation of the 30S subunit relative to the 
50S subunit, termed “ratcheting”, in addition to the formation of an intramolecular 
contact between the L1 stalk and the deacylated tRNA in the P/E state [19,52-53]. 
Dynamic studies using smFRET have demonstrated the existence of an equilibrium 
between tRNAs in the classical and hybrid states [22-23], and that EF-G acts as a 
Brownian ratchet that locks the ribosome in the hybrid state, preventing fluctuations back 
to the classical state, and thus driving the translocation reaction forward [53-55].  
 Once the hybrid state is stabilized by EF-G binding, the ribosome must move the 
mRNA and the anticodon loops of the tRNAs with respect to the 30S subunit. The 
mechanism underlying the conformational rearrangements that allow the ribosome to 




1.4 Challenges to Contemporary Interpretations of the Adaptor 
Hypothesis 
Contemporary interpretations of Crick’s Adaptor Hypothesis [9] have led to the 
widespread view that the ribosome is blind to the structure of the amino acid and that the 
interaction between the mRNA codon and the tRNA anticodon is paramount during 
aa-tRNA selection. While decades of work seeking to address the question of how the 
ribosome can select the correct aa-tRNA out of a pool of twenty aa-tRNA substrates with 
both a high degree of speed and accuracy has produced biochemical, genetic, and more 
recently structural and dynamic studies that have supported the importance of the 
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codon-anticodon pair, the role of the amino acid, however, has rarely been addressed. 
Two lines of experimental evidence challenge contemporary interpretations of Crick’s 
Adaptor Hypothesis. The first line of evidence details the involvement of tRNA elements 
outside the anticodon [58-59] that effect aa-tRNA selection. The second line of evidence 
details engineering work striving to incorporate unnatural amino acids into proteins 
(unnatural amino acid mutagenesis) [60-61]. Taken together, these lines of evidence show 
that aa-tRNA selection is considerably more complex than envisioned in the Adaptor 
Hypothesis and suggest that aa-tRNA selection might extend to the amino acid itself. 
 
1.4.1 The tRNA 
 The existence of the Hirsh suppressor and other mutant tRNAs that facilitate 
miscoding through mutations in structural elements in the tRNA body that lie outside of 
the anticodon fundamentally challenges the assertion that the codon-anticodon interaction 
is paramount during aa-tRNA selection.  
The surprising discovery that a guanine to adenine mutation at position 24 (G24A) in 
the D-stem of tRNATrp, quite distinct from this tRNA’s anticodon, conferred upon this 
mutant tRNA the ability to suppress the near-cognate UGA stop-codon in vivo was the 
first direct evidence supporting the hypothesis that there exist other elements outside of 
the tRNA anticodon that might influence tRNA selection [62-63]. Now called the Hirsh 
suppressor tRNA after its discoverer, this G24A mutant tRNATrp was shown to suppress 
the UGA stop codon in vitro in a cell extract translation system [64] and later, using 
purified translation components, rates for each step within the modern kinetic  
 16     Chapter 1 Introduction 
 
Table 1.1. An active role for the tRNA body during aa-tRNA selection. The Hirsh suppressor G24A 
mutant tRNATrp accelerates both the rate of GTPase activation (k3) and accommodation (k5) on the 
near-cognate UGA codon by ~10 fold compared to wild-type tRNATrp on the same codon. Data is 
reproduced from [58]. 
 
proofreading scheme (Table 1.1) were measured [58]. Pre-steady state kinetic 
measurements revealed that the Hirsh tRNA accelerated the rate constants for both 
GTPase activation (k3) and accommodation (k5) by ~10-fold on mRNA bearing the 
near-cognate UGA codon compared to wild-type tRNATrp, while exhibiting similar 
kinetics to wild-type tRNATrp on mRNA bearing the cognate UGG codon. Additionally, 
the endpoint of a dipeptide synthesis reaction, or the ability of both wild-type and Hirsh 
tRNA to convert fMet to fMet-Trp, was higher on the near-cognate UGA stop codon for 
the Hirsh tRNA versus wild-type tRNATrp [58]. Recent X-ray crystal structures have 
suggested that the mechanistic basis for the Hirsh tRNA’s enhanced miscoding capability 
on the near-cognate codon lies in its ability to stabilize the distorted (or bent) 
conformation of this mutant tRNA, caused by delivery of aa-tRNA to the ribosome in 
complex with EF-Tu [65-66]. During the first steps of aa-tRNA selection, the tRNA 
anticodon samples the mRNA codon in the A-site while the aa-tRNA is bound to EF-Tu 
[23,66-67]. Correct codon recognition leads to the distortion, or bending, of the tRNA 
because the anticodon has formed hydrogen bonds with the codon while the aminoacyl 
end of the tRNA is still bound by EF-Tu. The result is the formation of the A/T state, 
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representing the tRNAs occupancy in both the ribosomal A-site and in complex with 
EF-Tu (Figure 1.7) [66]. An exocyclic amine of adenine at position 24 of the Hirsh tRNA 
has been observed in X-ray structures forming an internal hydrogen bond with the 
exocyclic oxygen of G44 when the Hirsh tRNA is in the A/T configuration [65]; there is 
no such hydrogen bonding in the WT tRNATrp in the A/T state, suggesting that the G24A 
mutation facilitates miscoding on the near-cognate UGA stop codon by stabilizing the A/T 
state [65]. 
 
Figure 1.7. The tRNA is distorted in the A/T state.  When the proper codon-anticodon interaction 
is established and the aa-tRNA is still bound to EF-Tu, the aa-tRNA is distorted (purple). Upon GTP 
hydrolysis by EF-Tu and full accommodation into the A-site (blue), this distortion is relieved. This 
figure is reproduced from [66].   
 
There are other examples of mutations outside the tRNA anticodon that effect  
aa-tRNA selection. A9C tRNATrp is another D-stem mutant able to misread a near-cognate 
UGA stop codon, and it does so ~18-fold better than wild-type tRNATrp [68]. The A9 
forms a base triple with the A23-U12 pair in the distorted D-stem in the A/T conformation; 
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mutation of A9 to cytosine weakens this base triple, leading to greater flexibility in 
allowing this tRNA to access the A/T state [65]. As a consequence of this increased 
flexibility, EF-Tu is still positioned for GTP hydrolysis on the near-cognate UGA codon 
[65]. Pre-steady state kinetic experiments of both GTPase activation and dipeptide 
formation demonstrated that mutating the rare A32-U38 nucleotide pair at the top of the 
anticodon loop of E. coli tRNAAla to U32-A38 conferred upon this mutant tRNA the 
ability to miscode near-cognate GUC and AUC codons, while maintaining the ability to 
decode the cognate codon [59,69], much like the Hirsh tRNA. Biochemical studies 
investigating the effect of mutations into the C27-G43 Watson-Crick basepair in the 
anticodon stem of tRNATrp revealed that this mutation increased the frequency of 
misreading of the first wobble position [70-71]. Elements within the T-stem of the tRNA 
have also been shown to influence the rate of peptide bond formation by modulating the 
binding affinity to EF-Tu; tRNAs with mutant sequence elements in the T-stem that lead 
to tighter EF-Tu binding are consequently released more slowly when this enzyme 
hydrolyzes GTP, slowing down the rate of peptide bond formation, kpep [72-73]. 
 The Hirsh tRNA and other mutant tRNAs that miscode clearly demonstrate that 
structural elements in the tRNA body that lie outside the anticodon affect aa-tRNA 
selection. These findings call into question the contemporary view that the tRNA is a 
static adaptor and raise the possibility that aa-tRNA substrate selection might even extend 
all the way to the amino acid itself.   
  
1.4.2 The Amino Acid 
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The ability to selectively and site specifically incorporate unnatural amino acids into 
protein, varying either the amino acid backbone or side-chain, created a novel approach to 
the study of protein structure and function [74-78]. While this methodology has proven 
valuable in solving fundamental questions that were otherwise not addressable with 
preexisting technologies, experimental data from the unnatural amino acid mutagenesis 
field [61,79-81] offers indirect evidence supporting the hypothesis that aa-tRNA substrate 
selection may extend all the way to the amino acid itself.  
Methods for the in vitro site specific incorporation of unnatural amino acids into 
proteins take advantage of the ability to 1) mutate a codon within the mRNA encoding the 





Table 1.2 Unnatural amino acid 
incorporation data. Data obtained for 
natural and unnatural amino acids using 
the unnatural amino acid mutagenesis 
methodology. These data show that 
unnatural amino acids lead to lower 
amounts of protein synthesized 
depending on the unnatural amino acid 
and tRNA utilized in the in vitro extract 




These data are reproduced from [61].  
 
 
Figure 1.8. Unnatural amino acid mutagenesis. General 
scheme for the in vitro incorporation of unnatural amino 
acids into protein. The scheme is reproduced from [61].  
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aminoacylated with the unnatural amino acid to recognize the stop codon 3) in vitro 
transcribe this tRNA and 4) chemically aminoacylate unnatural amino acids onto tRNA, 
typically by using T4 RNA ligase to append unnatural amino acids synthesized onto 
pdCpA dinucleotides with in vitro transcribed tRNAs lacking the 75th and 76th position 
3’-CA nucleotides [61,79] (Figure 1.8). Data collected using this methodology from the 
Schultz group using an E. coli extract based transcription and translation system for 
synthesizing protein (Table 1.2) demonstrated that different unnatural amino acid 
analogues, when chemically esterified to the same tRNAPhe(CUA) (the CUA decodes the 
UAG Amber Stop codon), produced different quantities of protein. Experiments measured 
the ability of tRNAPhe(CUA) to suppress a UAG stop codon inserted into position 66 of 
RTEM β-lactamase and produce full-length protein (Table 1.2). Whereas the inclusion of 
para-flourophenylalanine-tRNAPhe(CUA) into the in vitro extract based translation system 
produced 2.1 µg/mL of protein, inclusion of ABPA (3-amino-2-benzylpropionic 
acid)-tRNAPhe(CUA) and D-Phe-tRNAPhe(CUA) into the same system produced no protein 
(Table 1.2). Inclusion of Para-NO2-Phe-tRNAPhe(CUA) yielded 3.0 µg/mL protein, close to 
the 2.9 µg/mL protein obtained when Phe-tRNAPhe(CUA) was included in the extract based 
translation system (Table 1.2). Despite the fact that these translations were run for 30 
minutes, it is possible that the reaction was not complete at this timepoint. Allowing these 
translations to run for an additional 15 minutes, for example, may have led to the 
production of more protein [61]. Similar methodologies were employed to investigate 
amino acid backbone analogue incorporation into position 82 of T4 lysozyme [81], 
revealing that lactic acid, pipecolic acid, N-methylalanine, cyclopropylglycine and 
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α-aminoisobutyric acid, when chemically acylated to a suppressor tRNAPhe(CUA) derived 
from yeast, synthesized full-length T4 lysozyme with 30%, 43%, 24%, 28% and 23% 
yield, respectively, compared to a wild-type control [81]. Because these translations 
contained only information at the 30 minute timepoint, and the experimenters did not 
determine whether or not the amount of protein produced had in fact plateaued at this 
timepoint (for example, by performing a timecourse experiment measuring the amount of 
protein produced at multiple timepoints), these protein yields are assumed. While 30 
minutes is a reasonable timepoint for the endpoint of a translation reaction containing 
only natural amino acids (the ribosome synthesizes 20 peptide bonds per second [82]), the 
rate of translation elongation with unnatural amino acids is unknown. 
 More recently, an in vitro translation system with purified components capable of 
reassigning unnatural amino acids for incorporation using sense codons was designed 
[83-84]. The use of purified components necessary for efficient protein synthesis, 
including initiation factors IF-1, IF-2 and IF-3, elongation factors EF-Tu, EF-Ts and EF-G, 
and the ribosome, has several main advantages over the extract based system. First, this 
methodology eliminates competition for the stop codon between endogenous release 
factors present in the extract based system and the suppressor tRNA. Second, potential 
hydrolytic activity from aaRS enzymes, and even the possibility that some other factor 
present in the extract based system might be working to inhibit incorporation of the 
unnatural aa-tRNA, is also eliminated. Additionally, the use of a tRNA bearing an 
anticodon mutated to suppress a sense codon, as opposed to a stop codon, increases 
significantly the amount of potential codons for reassignment, as there are only three stop 
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codons in the genetic code. Nevertheless, results obtained using this in vitro translation 
system, comprised of purified components and lacking any of the endogenous 
competitive factors described above, showed short polypeptides comprised of unnatural 
amino acids were able to be synthesized, but were produced with less product yield than a 
wild-type control. When the unnatural amino acid 2-amino-4-pentenoic acid (eU), was 
chemically acylated onto the non-natural tRNAAsn based “tRNAAsnB(GGU)” bearing an 
anticodon mutated to suppress the threonine ACC sense codon, fMet-eU5-Val 
septapeptide was synthesized with less than 1/3 the yield as the wild-type, fMet-Thr5-Val, 
septapeptide [83].  
Direct mechanistic conclusions from the in vitro translation systems described above 
are not possible for several reasons. As previously noted, suppressor tRNAs compete with 
endogenous release factors for the stop codon in extract based translation studies. In the 
study described above using an in vitro translation system with purified components, 
synthesis of the short peptide fMet-eU5-Val was monitored by the incorporation of 
radiolabeled valine, the seventh position amino acid. The consequence of this set-up is 
that unreactive intermediates that may have formed, for example fMet-eU dipeptide, are 
not observed. Similarly, extract based transcription and translation methodologies relying 
on the suppression of a stop codon for synthesis of full-length protein report only on the 
synthesis of full-length protein. Additionally, the use of in vitro transcribed tRNAs raises 
the formal possibility that the tRNA itself might be playing a role in the varying 
translation reaction endpoints observed with unnatural amino acids. In vitro transcribed 
tRNAs lack modifications that natural tRNAs possess and bear anticodons mutated to 
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suppress either stop or sense codons. Indeed, modifications to the tRNA have been shown 
to be important for decoding [85] and preventing frameshifting [86] while nucleotides 
adjacent to the tRNA codon are thought to form an “extended anticodon”; the integrity of 
this whole unit is necessary for uniform decoding by the ribosome [87-88].    
Collectively, however, these and other studies [60,78,89] using unnatural amino acids 
suggest that the TM might in fact be sensitive to the structure of the amino acid. If 
contemporary interpretations of the Adaptor Hypothesis are true, and the ribosome is 
indeed blind to the structure of the amino acid, then why are different unnatural amino 
acids incorporated into protein or peptide with different yields when esterified to the same 
suppressor tRNA? In the context of the kinetic proofreading scheme for aa-tRNA 
selection (Figure 1.4), where aa-tRNA that are rejected during i) initial selection or ii) 
proofreading can, in theory, rebind EF-Tu and reinitiate the selection process, the yields 
observed in the above experiments are even more puzzling. How can an unnatural amino 
acid be incorporated with yields ranging from 8% - 98% efficiency [90] relative to a 
wild-type control in the context of the kinetic proofreading scheme? One can imagine an 
unnatural amino acid that is simply too big, and for steric reasons, cannot be incorporated 
at all by the TM. But in the context of the kinetic proofreading scheme for aa-tRNA 
selection, one would expect that any unnatural amino acid capable of incorporation would 
reach the same endpoint as wild-type aa-tRNA provided that 1) the unnatural 
aminoacyl-tRNA (U-aa-tRNA) is in excess over limiting ribosome complexes and 2) the 
system is given enough time so that the unnatural amino acid can undergo multiple 
unproductive cycles where it is rejected by the ribosome before finally successfully 
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traversing the steps of aa-tRNA selection. Given that the above non-extract based 
experiments were done with an excess of U-aa-tRNA over ribosome complexes and 
allowed to run for 30 minutes before quenching, the yields observed in the experiments 
described above are confounding and suggest that some element of the TM might be 
responsible for the inability of many unnatural amino acids to produce protein or short 
peptides in yields that are comparable to a natural amino acid control using in vitro 
translation systems. 
Recent work has begun to address the question of the role of the amino acid during 
aa-tRNA selection. Using an in vitro translation system containing purified components, 
natural, fully modified tRNAs, and capable of achieving in vivo rates of protein synthesis, 
Effraim et al. examined the ability of misacylated natural amino acids to navigate the 
canonical aa-tRNA selection steps. Competition experiments demonstrated small but 
reproducible (at most 4-fold) differences between the overall selectivity of native versus 
misacylated aa-tRNA pairings and smFRET assays revealed that misacylated tRNAs 
sample the A-site upon delivery with EF-Tu with an approximately 3-fold higher 
frequency than correctly acylated aa-tRNAs, suggesting that the ribosome is indeed 
sensitive to the misacylated aa-tRNA pairing [91]. Another study measuring the rates of 
both peptide bond formation (kpep) and GTP hydrolysis (kGTP) for the imino acid proline, 
using natural, fully modified tRNAPro revealed that this imino acid exhibited 3-6 fold 
slower kpep than Phe-tRNAPhe [92], depending on the phenylalanine and proline codons 
used in the mRNA template. Because kGTP was similar between Pro-tRNAPro and 
Phe-tRNAPhe for the majority of mRNA codons coding for each of these aa-tRNAs, these 
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results suggest that the N-methyl group of proline might interfere with peptidyl transfer 
itself, in addition to possibly hindering aa-tRNA accommodation [92]. These studies build 
on earlier work demonstrating that the amino acid and the tRNA each contribute 
independently to the thermodynamics of both EF-Tu and ribosomal A-site binding 
[93-96]; tRNAs that bind EF-Tu or the ribosomal A-site more tightly are typically 
coupled with amino acids that bind more weakly, or vice versa. The preponderance of 
evidence suggests that the distinct differences between thermodynamic affinities of 
individual amino acids and between individual tRNAs are combined such that the 
aa-tRNA interacts uniformly with the ribosome and EF-Tu [72], the slow rate of dipeptide 
formation for Pro-tRNAPro being an exception.   
  
1.5 Conclusions  
Crick’s original Adaptor Hypothesis laid the foundation for a mechanistic framework 
for aa-tRNA selection that holds the interaction between the mRNA codon-tRNA 
anticodon pair paramount during aa-tRNA selection by the ribosome. Since Crick’s 
insight, much has been learned about the tRNA, the ribosome, and the dynamic interplay 
between the two as the aa-tRNA navigates the canonical selection steps, peptide bond 
formation, and the translocation steps that comprise the elongation cycle of protein 
synthesis. However, comparably little has been studied seeking to identify the role of the 
amino acid in these processes.  
Two lines of evidence suggest that aa-tRNA substrate selection is considerably more 
complex than originally envisioned in the Adaptor Hypothesis. First, the existence of 
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tRNA structural elements that lie outside the anticodon that influence both the rate and 
yield of mutant suppressor tRNA incorporation demonstrated that the tRNA itself is not 
just a static adaptor. Second, the identity of the amino acid esterified to suppressor tRNAs 
(that decode stop or sense codons) influences the yield in both in vitro extract based 
protein synthesis systems and in vitro protein synthesis systems using purified 
components. The use of in vitro transcribed tRNAs, lacking modifications that natural 
tRNAs possess and bearing mutated anticodons, complicate the interpretation of the data 
obtained using unnatural amino acid mutagenesis methodologies, as it is formally 
possible that the absence of these tRNA elements themselves contribute to the reduction 
in protein yields observed using this methodology. Nevertheless, the phenomenon of 
varying incorporation yields observed across numerous studies [61,79,81], where 
unnatural amino acids are incorporated into peptide with yields that are a fraction of a 
wild-type aa-tRNA control, suggests that the amino acid might be playing a role in being 
discriminated against by the ribosome and the TM. Seeking to characterize the role of the 
amino acid within the high resolution mechanistic and structural framework of the 
elongation cycle of protein synthesis and potentially provide an explanation for the 
observed yield phenomenon with unnatural amino acids has been the motivation for my 
Ph.D. thesis work.  
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Experiments with Amino Acid Backbone Analogues 
 
2.1 Background 
The ability of the TM to incorporate amino acid backbone analogues has been tested 
using various in vitro translation systems [1-3]. N-methyl and α-methyl amino acids have 




Figure 2.1. Incorporation of amino acid backbone analogues. (a) Extract based in vitro translation 
system using pdCpA ligation of unnatural amino acids onto tRNAPhe(CUA) and full-length protein 
synthesis as the assay read-out. (1) alanine (2) N-methyl alanine (3) α-amino isobutyric acid (AIB) (4) 
D-Alanine. Yields are normalized to an Ala-tRNAAla wild-type control, which represented 100% 
incorporation. Data in panel (a) from [1]. (b) Purified component based in vitro translation system 
using pdCpA ligation of unnatural amino acids onto tRNAAsnB(GAC) and tripeptide synthesis as the 
assay read-out. (1) alanine (2) N-methyl alanine (3) α-amino isobutyric acid (AIB) (4) D-Alanine (5) 
phenylalanine (6) N-methyl phenylalanine (7) α-methyl phenylalanine (8) D-phenylalanine (9) 
β-phenylalanine. Yields are normalized to a Val-tRNAVal wild-type control, which represented 100% 
incorporation. ND = not detected. Data in panel (b) from [3]. 
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substrates for the TM (Figure 2.1.a (2), (3) and 2.1.b. (2), (3), (6), (7)) [1,3]. Despite the 
fact that α-methyl amino acids have incorporated, D-amino acids have been widely 
reported as substrates that are not incorporated by the TM (Figure 2.1.a (4) and 2.1.b. (4), 
(8)) [1,3].  
 
2.2 Limitations to Previous Methodologies  
  The in vitro translation systems utilized to generate incorporation yields for the 
amino acid backbone analogues described above suffered from the inability to 
characterize intermediates that may have formed during translation experiments. The in 
vitro extract based translation systems utilized by Schultz and coworkers [1-2,4] used  
polyacrylamide gel electrophoresis (PAGE) to read-out full-length protein synthesized in 
their experiments as a result of stop codon suppression by a U-aa-tRNA. Put simply, 
PAGE could not resolve whether or not the U-aa-tRNA was unable to be incorporated by 
the TM or if it was incorporating and arresting the ribosome once incorporated. Similarly, 
Cornish and coworker’s purified components based in vitro translation system typically 
used a radioactive third amino acid as the read-out in a tripeptide synthesis translation 
where fMet was the first amino acid and the U-aa-tRNA under study was at the second 
position [3]. In this experimental set-up, information regarding the amount of unreacted 
fMet or fMet-U-aa that might have been formed during these tripeptide experiments was 
lost because incorporation of the third, radioactive amino acid was necessary to observe 
co-migration of ribosome synthesized tripeptide translation products with authentic 
marker peptides using HPLC (high performance liquid chromatography) analysis [3].  
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2.3 The Position of a Methyl Backbone Substituent Affects 
Different Steps of the Elongation Cycle of Protein Synthesis 
Marking a significant advance in the endeavor to understand the mechanistic basis 
for the varying yield phenomenon widely observed in the unnatural amino acid 
mutagenesis field, we shifted to using f-[3H]Met-tRNAfMet as the first amino acid in the 
synthesis of f-[3H]Met-X-Glu, where X represented the U-aa-tRNA to be tested in a 
tripeptide synthesis assay using a highly purified in vitro translation system [5-6]. Several 
elements of in vitro extract based or purified component based translation systems 
remained, however, including i) the use of an mRNA that encoded only three codons, in 
addition to a 5’ shine delgarno sequence [3] (and therefore occupied the A- and P-sites 
only and did not span the intersubunit space between the ribosomal A-site and the head of 
the ribosome) ii) chemical synthesis and ligation of unnatural amino acids using the 
pdCpA method and iii) the use of in vitro transcribed tRNAAsnB(GAC) to suppress the valine 
sense codon [3]. Nevertheless, the use of f-[3H]Met-tRNAfMet as the first amino acid in a 
tripeptide synthesis assay enabled mechanistic information to be obtained that was 
unavailable using previous methodologies. 
Using this methodology and analyzing translation products using reverse phase high 
performance liquid chromatography (HPLC), clear patterns emerged regarding the effects 
of adding a methyl substituent to the amino acid backbone and inverting the 
stereochemistry at the α-carbon. As a control, a fMet-Phe-Glu tripeptide synthesis 
translation was performed (Figure 2.2.1 and Figure 2.3 (1)) demonstrating that at the early 
10 second timepoint, virtually all f-[3H]Met-tRNAfMet is converted to tripeptide. When  
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Figure 2.2. Subtle modifications to the amino acid backbone effect different stages of the 
elongation cycle. HPLC traces of in vitro translation reactions of natural and unnatural amino acids 
chemically esterified to tRNAAsnB(GAC). By using f-[3H]Met-tRNAfMet as the first amino acid in a 
tripeptide synthesis reaction, fMet-X-Glu, unreacted intermediates are clearly observed. (1) 
X=L-Phenylalanine, 10 second translation; (2a-c) X=N-Methyl-Phenylalanine, 10 second, 5 minute 
and 30 minute translations, respectively; (3) X=α-Methyl-Phenylalanine, 5 minute translation; (4) 
X=D-Phenylalanine, 30 minute translation; (5) X=β-Phenylalanine, 30 minute translation. Unreacted 
dipeptide in (3) and (4) is highlighted by red arrows.  
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Figure 2.3. Summary of HPLC traces. Yield data and comparative rate data that was obtained 
by tripeptide translations using f-[3H]Met-tRNAfMet as the first amino acid in a tripeptide synthesis 
reaction, fMet-X-Glu, as analyzed by HPLC. Unreacted dipeptide intermediates for (3) 
X=α-Methyl-Phenylalanine and (4) X=D-Phenylalanine were not observable using pre-existing 
methodologies. HPLC traces that supported the rate information in (3) and (4) are not shown in the 
previous figure (Figure 2.2); only a timecourse for fMet-N-Methyl-Phenylalanine at 10s, 5 minutes 
and 30 minutes is provided. ND = not detected. 
 
N-methyl-Phe was tested, tripeptide fMet-N-methyl-Phe-Glu was formed, but at a slower 
rate than the Phe control, as this reaction was not complete at either the 10 second or the 5 
minute timepoints (Figure 2.2.2a-c and Figure 2.3 (2)). Interestingly, it appeared that the 
tripeptide reaction was limited by the slower formation of fMet-N-methyl-Phe dipeptide, 
as once dipeptide was formed it was immediately converted to tripeptide (Figure 2.2.2a-c 
and Figure 2.3 (2)) 
 Results analyzing both α-methyl-Phe and D-Phe were particularly compelling. 
Consistent with previous reports demonstrating that α-methyl-Phe was a substrate for the 
TM [1,3], α-methyl-Phe converted a substantial amount of fMet to tripeptide, 
fMet-α-methyl-Phe-Glu, after 5 minutes (Figure 2.2.3 and Figure 2.3 (3)). Intriguingly, a 
significant amount of dipeptide remained unreacted (Figure 2.2.3 and Figure 2.3 (3)). Full 
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inversion of the stereochemistry using D-Phe resulted in a similar, yet more pronounced, 
effect than the addition of just a methyl substituent to the α-carbon. D-Phe was able to 
form quantitative amounts of dipeptide, yet the dipeptide synthesized was only able to 
form a small amount of tripeptide (Figure 2.2.4 and Figure 2.3 (4)) even after 30 minutes. 
This result contrasted sharply with previous studies from both the Schultz and Cornish 
laboratories that did not observe incorporation of D-Ala or D-Phe in their respective 
systems (Figure 2.1.a (4) and 2.1.b (4) and (8)) [1,3].  Finally, adding a methyl group 
within the backbone itself rendered β-Phe unable to form dipeptide (Figure 2.2.5 and 
Figure 2.3 (5)). 
 
2.4 Future Directions 
 In showing that unreacted dipeptide intermediates formed as a result of incorporating 
unnatural amino acids during tripeptide translation reactions, the preliminary experiments 
described above suggested that the ribosome was likely responsible for discriminating 
unnatural amino acids. While the slow dipeptide formation observed with N-methyl-Phe, 
α-methyl-Phe and D-Phe (Figure 2.2 and 2.3) might be a result of a defect in EF-Tu 
binding, impairment in the ability to convert di- to tripeptide as a consequence of 
incorporating α-methyl-Phe or D-Phe could only be a ribosomal defect. Although we 
were unable to rule out any possible effects of using the non-natural suppressor 
tRNAAsnB(GAC), this data clearly suggested that protrusions from the α-carbon might in 
fact be mediating the ribosome’s ability to convert di- to tripeptide after the unnatural 
amino acid had been incorporated into dipeptide. Curiously, α-methyl amino acids were 
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capable of incorporating into full-length protein using Schultz’s extract based system and 
into tripeptide using Cornish’s purified components based in vitro translation system, yet 
neither approach observed incorporation of D-amino acids [1,3]. Finally, the ability to 
precisely define the specific mechanistic step during the conversion from di- to tripeptide, 
be it translocation, catalysis in the PTC, or another phenomenon such as pepdtidyl-tRNA 
drop-off, awaited further experimental work. 
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Chapter 3   
The Ribosome Discriminates the Structure of the Amino Acid at 
its Peptidyl-Transferase Center 
 
3.1 New Methods 
Experiments examining the effects of modifying the amino acid backbone structure 
(Section 2.3) added to the growing evidence supporting the hypothesis that aa-tRNA 
selection might, in fact, extend all the way to the amino acid itself. The use of 
f-[3H]Met-tRNAfMet allowed for the direct observation of intermediates in tripeptide 
synthesis translation reactions that were otherwise non-detectable using other methods and 
suggested that a subsequent step after U-aa-tRNA incorporation into dipeptide might be 
involved in the reduction in yield observed with unnatural amino acids. However, to 
unambiguously establish a mechanistic role for the amino acid during either aa-tRNA 
selection or during subsequent steps during the elongation cycle, several new methods were 
necessary.  
 
3.1.1 Ribozyme Misacylation of Natural tRNAs 
The use of an in vitro selected ribozyme [1] allowed for misacylation of natural and 
unnatural amino acids onto natural, fully modified tRNAs, and, consequently, eliminated 
the suppressor tRNA as a potential cause for the yield defects widely observed in the 
unnatural amino acid mutagenesis community [2]. This ribozyme technology was perfected 
by Suga et al. in 2006 [1], and we began using it in the laboratory soon after. Two small 
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46nt and 45nt ribozymes, termed dFx and eFx, respectively, containing GGU nucleotides at 
their 3’ ends (Figure 3.1.a and 3.1.b) and therefore capable of forming Watson-Crick 
interactions with the universally conserved 3’-CCA end of tRNA, were in vitro selected for 
binding affinity to either the phenyl ring of a dintrobenzylester (DBE) (dFX) or the phenyl 
ring of phenylalanine-cyanomethylester (CME) (eFx) (Figure 3.1.c) [1]. As a result, both 
ribozyme’s act by bringing the tRNA and amino acid substrates in close proximity such that  
  
the 2’-OH of adenine at position 76 of the tRNA attacks the ester linkage of either the CME 
or the DBE [1]. The eFx and CME substrate combination is used for aminoacylation of 
phenylalanine or other aromatic amino acid derivatives [1]. The eFx can bind the phenyl 
ring, and glycolonitrile acts as the leaving group (Figure 3.1.c). The use of the dFx 
 
Figure 3.1. Ribozymes and substrates. 
(a) Cartoon of the dFx ribozyme base 
pairing with the 3’-CCA of tRNA. (b) 
Cartoon of the eFx ribozyme base 
pairing with the 3’-CCA of tRNA. (c) 
Cyanomethyl ester (CME) and 
dintrobenzyl ester (DBE) substrates. 
Virtually any side chain can be added as 
X for the DBE, as the dintrobenzyl ester 
acts as the leaving group during 
aminoacylation by the dFx ribozyme. In 
contrast, only phenylalanine or aromatic 
amino acid derivatives can be 
aminoacylated using eFx and CME. 
Cartoons are reproduced from [1].  
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ribozyme and DBE substrate allows for the successful aminoacylation of most natural or 
unnatural amino acids, with the exception of aromatic amino acids, such as phenylalanine 
[1]. The dFx ribozyme takes advantage of the fact that the nitrogenated phenyl ring, critical 
for binding to the dFx ribozyme, also acts as the leaving group during the aminoacylation 
reaction, enabling the charging of virtually any amino acid (Figure 3.1.c) [1].  
 
3.1.2 Electrophoretic Thin Layer Chromatography 
Instead of continuing to use HPLC analysis to separate translation products, a method 
more amenable to kinetic studies, electrophoretic thin layer chromatography (eTLC), was 
employed. In these experiments D- or L-amino acid active ester of high optical purity [3] 
was charged onto natural, post-transcriptionally-modified tRNA using either the eFx 
ribozyme for D/L-phenylalanine or the dFx ribozyme for D/L-valine and D/L-lysine [1]. 
Ternary complexes of elongation factor Tu, guanosine triphosphate, and aa-tRNAs 
(EF-Tu(GTP)aa-tRNAs) were delivered to limiting quantities of ribosomal complexes 
pre-initiated on an mRNA encoding the appropriate di- or tripeptide and bearing 
f-[35S]Met-tRNAfMet at the ribosomal P site (Figure 3.2.a). After translating, reactions were 
quenched with base to liberate either f-[35S]Met or peptide products from tRNA. After base 
quenching, reactions were spotted onto a TLC plate which was then placed in a tank 
containing a low pH buffer. A current was then applied to separate products (Figure 3.2.b). 
 
3.2 D-amino Acids Exhibit Translation Disorders During the 
Elongation Cycle 
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Figure 3.2. Experimental set-up and eTLC analysis. a) Tripeptide translation reactions 
were carried out by mixing pre-formed EF-Tu(GTP)aa-tRNA ternary complexes containing 
D-aa-tRNA and the third position L-aa-tRNA with pre-formed 70S initiation complexes containing 
70S ribosomes, mRNA, and f-[35S]Met-tRNAfMet, all pre-equilibrated to 37 °C.  Unless otherwise 
noted, concentrations of each component are described in Chapter 5. Reactions were quenched at 
the indicated time points by addition of potassium hydroxide to hydrolyze polypeptide products 
from tRNA. b) eTLC separation of radiolabeled peptide products from unreacted f-[35S]Met. 
 
To test the hypothesis that the TM is exquisitely sensitive to the structure of the amino 
acid, we chose to alter the stereochemistry of the aa-tRNA. In addition to being a backbone 
analogue that inhibited multiple steps of the elongation cycle during preliminary 
investigations that used an in vitro transcribed suppressor tRNA (Section 2.3, Figure 2.2 
and 2.3), it is highly probable that cells must contend with D-aa-tRNAs in nature: (i) several 
D-amino acids, including D-Ala in E. coli [4] and D-Ser in the human central nervous 
system [5] are known to be present at high concentrations; (ii) a growing list of aaRSs are 
capable of charging D-amino acids onto their respective tRNAs [6-12]; and (iii) D-aa-tRNA 
deacylase enzymes are highly conserved from bacteria to human [13]. Furthermore, the 
a. b.
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fundamental question as to why protein synthesis occurs exclusively with achiral or 
L-amino acids remains unresolved, with conflicting reports in the literature as to whether or 
not D-aa-tRNAs are substrates for the TM [2,7,14,15]. Thus, we evaluated the ability of 
D-aa-tRNAs to participate in multiple rounds of translation elongation. Directly 
contradicting contemporary interpretations of the Adaptor Hypothesis, we have found that 
D-aa-tRNAs are significantly discriminated by the ribosome. Surprisingly, we have 
discovered that rather than rejecting the D-aa-tRNA during the canonical aa-tRNA selection 
steps, as is the case for mutant tRNAs, the TM instead responds to the D-aa-tRNA at a later 
step in the elongation cycle, increasing the frequency with which the elongating ribosome 
engages a previously undetected step that gates the chemistry of peptide-bond formation at 
the PTC.  
 
3.2.1 Dipeptide Synthesis Translations 
We began by determining the yield and rate of synthesis of dipeptide fMet-D-Phe, 
measuring the percent of f-[35S]Met-tRNAfMet converted to peptide product versus time 
using eTLC [16] (Figure 3.3.a). Dipeptide synthesis assays measure the ability of the 
D-aa-tRNA to navigate through aa-tRNA selection and to act as a peptidyl-tRNA acceptor 
in the ribosomal A-site (Section 1.3, Figure 1.3) Consistent with the published literature 
[17], the control fMet-L-Phe dipeptide synthesis reaction is complete at the earliest 15 
second timepoint. However, conflicting with universal reports from the unnatural amino 
acid mutagenesis community [2,18-19], D-Phe-tRNAPhe is unambiguously competent as a 
substrate for the TM (Figure 3.3.a, 3.3.b), converting 81% f-[35S]Met to f-[35S]Met-D-Phe 
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dipeptide, versus 87% conversion of f-[35S]Met to f-[35S]Met-L-Phe dipeptide (Figure 
3.3.a, 3.3.b). However, the apparent rate for synthesis of the f-[35S]Met-D-Phe dipeptide 
Figure 3.3. Dipeptide synthesis translation. eTLCs of dipeptide synthesis reaction for 
fMet-D/L-Phe (a) Plot of dipeptide timecourse reaction demonstrates that D-Phe-tRNAPhe (b), 
converts 81%, of f-[35S]Met-tRNAfMet to dipeptide, despite a slow rate of dipeptide synthesis for 
f-[35S]Met-D-Phe (kapp=0.02 s-1). Reactions were run in duplicate, and the standard error between 
the two measurements is reported. 
 
Figure 3.4. EF-Tu dependance of fMet-D-Phe dipeptide formation. eTLC analysis of dipeptide 
timecourse translations of fMet-D/L-Phe in the absence of EF-Tu (a). Plot of eTLC (b) reveals 
that the rate of dipeptide formation of f-[35S]Met-D-Phe in the absence of EF-Tu is 40 fold slower 
than the rate of the EF-Tu catalyzed reaction. Each experiment was performed in duplicate and the 
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(kapp = 0.020 sec-1) (Figure 3.3.b) is three orders of magnitude slower than reported rates of 
protein synthesis with natural substrates (20 peptide bonds per second [17]). The slow rate 
of dipeptide formation may in part be attributable to EF-Tu, as the absence of this 
elongation factor slowed f-[35S]Met-D-Phe dipeptide synthesis ~40-fold (Figure 3.4.a, 
3.4.b). 
 
3.2.2 Tripeptide Synthesis Translations 
The dipeptide synthesis reactions (Figure 3.3) showed that D-Phe-tRNAPhe is 
kinetically discriminated during some step of aa-tRNA selection, but could not explain the 
yield differences that had been previously reported with D-aa-tRNAs. Therefore, we next 
examined the behavior of D-Phe-tRNAPhe in a tripeptide synthesis reaction. In addition to 
measuring the ability of the D-aa-tRNA to undergo one round of aa-tRNA selection and to 
act as a peptidyl-tRNA acceptor in the ribosomal A-site, the tripeptide synthesis reaction 
further measures the ability of the incorporated peptidyl-D-aa-tRNA to translocate from the 
A- to the P-site and then to act as a peptidyl-tRNA donor to the incoming aa-tRNA once 
translocated into the P-site (Section 1.3, Figure 1.3)  Most surprisingly, but perhaps 
resolving conflicting reports regarding the translation of D-aa-tRNAs from disparate fields 
[2,19], synthesis of fMet-D-Phe-Lys tripeptide does not go to completion, instead 
plateauing at an apparent endpoint of 18% f-[35S]Met converted to f-[35S]Met-D-Phe-Lys 
tripeptide (Figure 3.5.a). Intruigingly, significant accumulation of unreacted dipeptide, or 
dipeptide that could not complete the conversion to tripeptide, was observed. The rate of 
f-[35S]Met-D-Phe-Lys tripeptide synthesis (kapp = 0.004 sec-1) (Figure 3.5.b) is more than 
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three orders of magnitude slower than rates observed with L-amino acids [17]. Because the 
tripeptide synthesis translation was performed on naturally, fully modified tRNAPhe, and  
 
Figure 3.5. Tripeptide synthesis translation. eTLC of tripeptide synthesis reaction for 
f-[35S]Met-D/L-Phe-Lys (a) and individual plot for D/L-Phe-tRNAPhe tripeptide timecourse 
translations (b) demonstrate that D-Phe-tRNAPhe converts 18% f-[35S]Met to f-[35S]Met-D-Phe-Lys 









Figure 3.6. fMet-D-Phe-Lys tripeptide synthesis rate and endpoint are independent of 
increased concentration of the third position amino acid, Lys-tRNALys. Plot of eTLC 
demonstrates that increasing the concentration of the third amino acid, Lys-tRNALys, did not 
increase the rate or the endpoint of the f-[35S]Met-D-Phe-Lys tripeptide synthesis reaction. 
Tripeptide synthesis reactions with 1x  Lys-tRNALys (1 µM final), 2.5x Lys-tRNALys (2.5 µM 
final), and 5x Lys-tRNALys (5 µM final) were performed in duplicate.   
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due to the fact that the discrimination was occurring after formation of the first peptide 
bond, the observed discrimination must be intrinsic to the ribosome itself. This finding 
clearly shows that the ribosome is capable of discrimination based solely on the structure of 
the amino acid, directly contradicting the contemporary view that the ribosome is blind to 
the structure of the amino acid. 
The effect of increasing the concentration of the third amino acid, Lys-tRNALys, was 
also examined. Figure 3.6 demonstrates that neither a 2.5-fold excess of Lys-tRNALys nor a  
5-fold excess of Lys-tRNALys significantly effected the rate (kapp=0.004s-1) or the endpoint 
(31% f-[35S]Met converted to f-[35S]Met-D-Phe-Lys tripeptide) of the tripeptide synthesis 
reaction. 
 
3.2.3 Tetrapeptide Synthesis Translation 
    Having observed that the yield defect with D-Phe-tRNAPhe occurs during the 
conversion of di- to tripeptide, we next investigated if this impaired conversion could be 
overcome by further rounds of elongation. To test this possibility, we performed a 
tetrapeptide synthesis reaction analyzing the conversion of f-[35S]Met to tetrapeptide 
f-[35S]Met-D-Phe-Lys-Glu. As shown in Figure 3.7, inclusion of Glu-tRNAGlu in our 
standard tripeptide synthesis reaction using an mRNA encoding for fMet-Phe-Lys-Glu 
results in the full conversion of f-[35S]Met-D-Phe-Lys tripeptide to 
f-[35S]Met-D-Phe-Lys-Glu tetrapeptide, but the accumulated f-[35S]Met-D-Phe dipeptide 
product remains and is unaffected by the additional round of elongation. Together with the 
results presented above, this finding suggests that the primary step causing the yield defect 
 52     Chapter 3 The Ribosome Discriminates the Structure of the Amino Acid at its Peptidyl-Transferase Center 
in the incorporation of D-aa-tRNAs occurs during the conversion of di- to tripeptide, and 
the outcome of D-amino acid incorporation is prematurely truncated peptide product at the 
position where the D-amino acid was encoded. Moreover, because of the use of natural, 
fully modified tRNAs, this discrimination cannot be attributed to the tRNA and must be 
due to the ribosome itself. 
 
 
3.7. Tetrapeptide synthesis translation. Addition of Glu-tRNAGlu to the f-[35S]Met-D-Phe-Lys 
tripeptide synthesis translation, along with an mRNA encoding fMet-Phe-Lys-Glu, demonstrates 
that tripeptide f-[35S]Met-D-Phe-Lys is converted to tetrapeptide f-[35S]Met-D-Phe-Lys-Glu, while 
the unreacted f-[35S]Met-D-Phe is not converted to tri- or tetrapeptide.  
 
3.3 Racemization Controls 
While eTLC is effective for separating f-[35S]Met from dipeptide, and dipeptide from 
tripeptide, it tells us nothing about the chirality of the peptide products synthesized by the  
ribosome. In order to verify that the ribosome synthesized di- and tripeptide products did 
in fact contain D-Phe, we analyzed our translation products alongside chemically 
synthesized authentic marker peptides using high performance liquid chromatography 
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(HPLC). Initially, chemically synthesized marker peptides for fMet-L-Phe, fMet-D-Phe, 
fMet-L-Phe-Lys, and fMet-D-Phe-Lys were mixed and a gradient that effectively 
separated these peptide products with distinct retention times established. Next, ribosome 













Figure 3.8. Tripeptide synthesis translation products co-migrate with authentic marker 
peptides using HPLC analysis. f-[35S]Met-D-Phe-Lys tripeptide translation products were run on 
an HPLC gradient that progressed from 10% MeCN to 12% MeCN over 12 minutes; isocratic 20% 
MeCN from 12-15 minutes; 20% MeCN to 35% MeCN from 15-58 minutes. Major peaks at ~27 
minutes and ~37 minutes co-migrate with fMet-D-Phe-Lys tripeptide marker (bar) and fMet-D-Phe 
dipeptide marker (bar) peptides, respectively, confirming the incorporation of D-Phe into tripeptide. 
Data obtained from [3]. 
 
reaction were quenched with base, removing products from tRNA, and co-injected onto 
HPLC with the authentic marker peptides. Figure 3.8 confirms the formation of 
fMet-D-Phe-Lys tripeptide, as a peak at ~27 minutes co-migrates with the 
fMet-D-Phe-Lys authentic marker (bar). Additionally, this result confirms the buildup of 
unreacted f-[35S]Met-D-Phe, which co-migrated with the authentic fMet-D-Phe marker 
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(bar) peptide at ~37 minutes [3].  
 
3.4 D-Amino Acids Inhibit Catalysis in the PTC 
Based on the build-up of fMet-D-Phe dipeptide in the tripeptide synthesis reaction, we 
hypothesized that D-amino acids perturb translation elongation at some point after they 
have entered the PTC and have acted as a peptidyl transfer acceptor to form 
peptidyl-D-aa-tRNA. Impaired conversion of dipeptide to tripeptide may be explained by: 
(i) an increase in the rate with which dipeptidyl-tRNA dissociates from the ribosome, such 
that the rate of dissociation becomes competitive with the rate of peptidyl transfer to the 
incoming, third position L-aa-tRNA; (ii) a decrease in the endpoint of the translocation 
reaction in which dipeptidyl-tRNA is translocated from the ribosomal A site into the P site, 
(iii) inhibition of the subsequent incorporation of the third position, L-aa-tRNA into the A 
site, and/or (iv) an impaired ability the dipeptidyl-tRNA to act as a peptidyl transfer donor 
(to the third position, L-aa-tRNA) at the PTC. In order to explicitly test these possibilities 
and further pinpoint the mechanism through which D-Phe-tRNAPhe inhibits the conversion 
of di- to tripeptide, we used a series of standard biochemical assays that probe various 
points along the elongation cycle. 
We began by testing the trivial possibility that the rate with which dipeptidyl-tRNA 
dissociates from the ribosome competes effectively with the rate of tripeptide synthesis 
such that the tripeptide yield is diminished. To test this possibility, we used the retention of 
ribosomes on a nitrocellulose filter to measure the percent of f-[35S]Met-D-Phe-tRNAPhe 
bound to ribosomes as a function of time under conditions identical to those used for our 
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dipeptide synthesis reaction (i.e. in the presence of the ribosomal translocase, elongation 
factor G (EF-G)). The nitrocellulose filter binding experiments demonstrate that 
f-[35S]Met-D-Phe-tRNAPhe (Figure 3.9.a) does not dissociate from the ribosome with a rate 
that is significantly different than that of f-[35S]Met-L-Phe-tRNAPhe (0.0003 sec-1 versus 
0.0005 sec-1, respectively) or that is competitive with the observed rate of fMet-D-Phe-Lys 
synthesis (Figure 3.5.a and 3.5.b, 0.004 sec-1). In fact, simple inspection of the plot of the 
reaction time courses shows that at 10 minutes the f-[35S]Met-D-Phe-Lys tripeptide 
synthesis reaction has nearly plateaued at 18% conversion of f-[35S] to f-[35S]Met-D-Phe-Lys 
(Figure 3.5.a and 3.5.b), while at that same time point nearly all of the 
f-[35S]Met-D-Phe-tRNAPhe remains bound to the ribosome (Fig. 3.9.a).  
Having established that fMet-D-Phe-tRNAPhe remains stably bound to the ribosome 
(Figure 3.9.a), we next sought to determine whether translocation of this dipeptidyl-tRNA 
from the A to the P site was impaired. The primer extension inhibition, or toeprinting, 
experiment [20-23] demonstrates that a pre-translocation ribosomal complex containing 
fMet-D-Phe-tRNAPhe at the A site is translocated with a yield of 78% (Figure 3.9.b and 
3.9.c) thus not accounting for the 18% yield in the fMet-D-Phe-Lys (Figure 3.5.a and 3.5.b) 
tripeptide synthesis translation.  
Based on the observation that fMet-D-Phe-tRNAPhe is fully translocated into the P 
site and is stably bound to 70S ribosomes, we hypothesized that this dipeptidyl-tRNA is 
impaired as a peptidyl transfer donor to the third, incoming amino acid, Lys-tRNALys. To 
directly test this hypothesis, we reacted P site-bound f-[35S]Met-D-Phe-tRNAPhe with the 
antibiotic puromycin (Pmn) (Figure 3.9.d and 3.9.e). Pmn, an aminoacyl-mononucleotide 
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mimic of the 3’-terminus of aa-tRNA, has been extensively employed to monitor the 
reactivity of P site-bound peptidyl-tRNAs as donors in the peptidyl transferase  
Figure 3.9. D-Phe-tRNAPhe inhibits catalysis in the PTC. (a) Nitrocellulose filter binding assays 
were performed by running f-[35S]Met-L-Phe and f-[35S]Met-D-Phe dipeptide synthesis reactions 
for up to 60 min in the presence of EF-G. Aliquots were removed at the indicated time points and 
applied to nitrocellulose filters and washed extensively with chilled Stop Buffer (50 mM 
Tris-hydrochloride, pH25ºC 7.5; 1M ammonium chloride; 15 mM magnesium acetate). Counting of 
filters after washing reveals that 34% of the f-[35S]Met is retained on the filters as ribosome-bound 
f-[35S]Met-D-Phe-tRNAPhe (gold squares) versus 52% for f-[35S]Met-Phe-tRNAPhe (black squares) 
at the 60 min time point. Reactions were run three times, and the standard deviation between the 
measurements is reported. All data were fit to a single exponential function yielding the indicated 
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kapp. (b) Primer extension inhibition assays were performed by translating an mRNA template 
pre-annealed with a DNA primer to generate a dipeptide product. Reactions were run for up to 20 
min in the presence of EF-G. Subsequent reverse transcription of the mRNA template reveals that, 
in the presence of EF-G, 70S initiation complexes harboring tRNAfMet in the P site and 
fMet-D-Phe-tRNAPhe in the A site are efficiently translocated. (c) Plot of toeprinting data from (b) 
shows that 78% of ribosomes carrying fMet-D-Phe-tRNAPhe at the A site translocate. (d) 
Puromycin reactivity of dipeptidyl- f-[35S]Met-L-Phe-tRNAPhe (left) and 
f-[35S]Met-D-Phe-tRNAPhe (right). Dipeptide synthesis reactions in the presence of EF-G were 
allowed to proceed for 2.5 minutes (L-Phe-tRNAPhe) and 10 minutes (D-Phe-tRNAPhe), such that 
dipeptidyl-tRNA was fully synthesized (0 time point) and translocated into the P-site. 
Subsequently, puromycin was added to a final concentration of 24 mM and the reactions allowed 
to proceed for the indicated time points before quenching with potassium hydroxide to liberate 
unreacted f-[35S]Met or dipeptide products. The inability of dipeptidyl-f-[35S]Met-D-Phe-tRNAPhe 
to react with puromycin, combined with the filter binding and toeprinting data which demonstrate 
that dipeptidyl-f-[35S]Met-D-Phe-tRNAPhe remains stably bound to 70S ribosomes and translocated 
efficiently, respectively, strongly suggests that dipeptidyl-fMet-D-Phe-tRNAPhe is inhibiting 
catalysis in the PTC. (e) Plot of puromycin reactivity data from (d) demonstrates that 
f-[35S]Met-D-Phe-Pmn reaches an endpoint of 18% f-[35S]Met converted to dipeptide-pmn.  
 
reaction [24] and is efficiently reactive only when peptidyl-tRNAs have fully translocated 
into the P-site [21,24-26]. In striking agreement with the fMet-D-Phe-Lys tripeptide 
synthesis reaction (Figure 3.5.a and 3.5.b), the synthesis of f-[35S]Met-D-Phe-Pmn also 
plateaus at 18% conversion of f-[35S]Met to f-[35S]Met-D-Phe-Pmn. (Figure 3.9.d and 
3.9.e). Because dipeptidyl fMet-D-Phe-tRNAPhe remains stably bound to 70S ribosomes, 
translocates efficiently, yet is unreactive with the antibiotic puromycin, we conclude that 
D-Phe-tRNAPhe inhibits catalysis in the ribosomal PTC. 
 
3.5 Generality of D-Amino Acid PTC Inhibition 
 We next explored the generality of our results by testing D-Val-tRNAVal and 
D-Lys-tRNALys in di- and tripeptide assays (Figure 3.10 and 3.11) as well as in the same 
series of biochemical assays used to mechanistically pinpoint the PTC in discriminating 
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D-Phe-tRNAPhe (Figure 3.15 and 3.16). These D-amino acids span chemical space, varying 
in both size and electrostatics. Moreover, the tRNAs differ in the GC-content of their 
anticodons and the number and type of post-transcriptional modifications. As was the case 
for the fMet-D-Phe dipeptide reaction, the dipeptide reactions of both fMet-D-Val and 
















Figure 3.10. D-Val-tRNAVal and D-Lys-tRNALys dipeptide synthesis translations. eTLCs of 
dipeptide synthesis reactions for f-[35S]Met-D/L-Val (a) and f-[35S]Met-D-Lys (c). Dipeptide 
translations of D-Lys-tRNALys were performed using [f-[35S]Met-tRNAfMet]=0.06 µM and 
[EF-Tu]=3.6 µM; all other conditions were as described in Chapter 5. Plots of dipeptide 
timecourse reactions demonstrate that D-Val-tRNAVal (b) and D-Lys-tRNALys (d) convert 87% and 
81% of f-[35S]Met-tRNAfMet to dipeptide, respectively despite slow rates of dipeptide synthesis for 
f-[35S]Met-D-Val (kapp=0.0052 s-1) and f-[35S]Met-D-Lys (kapp=0.05 s-1). The L-Lys dipeptide 
translation was not performed because the f-[35S]Met-L-Lys-Phe tripeptide synthesis reaction was 
complete at the 15 sec time point (Figure 3.11.c and 3.11.d).  
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the D-amino acid (Figure 3.10.a-d), indicating that both D-Val-tRNAVal and 
D-Lys-tRNALys are competent peptidyl-tRNA acceptors in the ribosomal A-site. 
Examining the behavior of both D-Val-tRNAVal and D-Lys-tRNALys in tripeptide 










Figure 3.11. D-Val-tRNAVal and D-Lys-tRNALys exhibit translation disorders. eTLCs of 
tripeptide synthesis reaction for f-[35S]Met-D/L-Val-Lys (a) and f-[35S]Met-D/L-Lys-Phe (c). 
Tripeptide translations of both D/L-Lys-tRNALys were performed using 
[f-[35S]Met-tRNAfMet]=0.06 µM, [EF-Tu]=3.6 µM and [Phe-tRNAPhe]=0.8 µM ; all other 
conditions were as described above under “Di- and Tripeptide Assays” in Chapter 5. Individual 
plots for D/L-Val-tRNAVal (b) and D/L-Lys-tRNALys (d) tripeptide timecourse translations 
demonstrate that D-Val-tRNAVal converts 11% f-[35S]Met to f-[35S]Met-D-Val-Lys tripeptide with 
kapp=0.0010s-1 whereas D-Lys-tRNALys converts 58% f-[35S]Met to f-[35S]Met-D-Lys-Phe 
tripeptide with kapp=0.024s-1. 
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tripeptide, with D-Val-tRNAVal converting 11% f-[35S]Met to f-[35S]Met-D-Val-Lys 
tripepetide and D-Lys-tRNALys converting 58% f-[35S]Met to f-[35S]Met-D-Lys-Phe 
tripeptide (Figure 3.11a-d). Importantly, the chiral authenticity of these ribosome 
synthesized products was confirmed by HPLC analysis (Figure 3.12). 
 
Figure 3.12. Tripeptide synthesis translation products using D-Val-tRNAVal or 
D-Lys-tRNALys co-migrate with authentic marker peptides using HPLC analysis. (a) 
f-[35S]Met-D-Val-Lys tripeptide translation products were run on an HPLC gradient that 
progressed from 1% MeCN in 0.1% TFA to 20% MeCN over 50 minutes. Major peaks at ~41 
minutes and ~51 minutes co-migrate with fMet-D-Val-Lys tripeptide marker (bar) and fMet-D-Val 
dipeptide marker (bar) peptides, respectively, confirming the incorporation of D-Val into 
tripeptide. (b) f-[35S]Met-D-Lys-Phe tripeptide translation products were run on an HPLC gradient 
that progressed from 10% MeCN in 0.1%TFA to 20% MeCN in 0.1%TFA over 60 min. Major 
peaks at ~27 minutes and ~6 minutes co-migrate with fMet-D-Lys-Phe tripeptide marker (bar) and 
fMet-D-Lys dipeptide marker (bar) peptides, respectively, confirming the incorporation of D-Lys 
into tripeptide. Data obtained from [3]. 
 
Inclusion of D-Lys-tRNALys into fMet-D-Lys-Phe-Glu tetrapeptide demonstrated 
that, like the synthesis of fMet-D-Phe-Lys-Glu tetrapeptide, the arrested subpopulation of 
ribosomes that could not be converted from di- to tripeptide remain unreacted, while the 
tripeptide fMet-D-Lys-Phe is readily converted to tetrapeptide (Figure 3.13). Additionally, 
the arrested fMet-D-Lys dipeptide could not be pushed forward by increasing the 
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concentration of the third amino acid, Phe-tRNAPhe, or by increasing the concentration of 
EF-G (Figure 3.14).  
Mechanistically, both D-Val-tRNAVal and D-Lys-tRNALys remained stably bound to 
70S ribosomes, as measured by the nitrocellulose filter binding assay (Figure 3.15.a and 
3.16.a), and both translocated efficiently, as measured by the toeprinting assay (Figure 
3.15.b-c and 3.16.b-c). Significantly, once translocated into the P site, both D-Val-tRNAVal 
and D-Lys-tRNALys arrested when reacted with puromycin, demonstrating that these 
D-aa-tRNAs are also inhibited as peptidyl transfer donors at the PTC (Figure 3.15.d-e and 









Figure 3.13. Tetrapeptide synthesis of fMet-D-Lys-Phe-Glu. eTLC demonstrates that D-Lys is 
capable of being incorporated into tetrapeptide f-[35S]Met-D-Lys-Phe-Glu. Products from 
tripeptide f-[35S]Met-D/L-Lys-Phe and tetrapeptide f-[35S]Met-D/L-Lys-Phe-Glu synthesis 
reactions were spotted, as indicated. Final concentrations of [f-[35S]Met-tRNAfMet]=0.06 µM, 
[EF-Tu]= 3.6 µM and [Phe-tRNAPhe]= 0.8 µM;  all other conditions were as described above 
under “Di- and Tripeptide Assays” and “Tetrapeptide Assay” in Chapter 5.  
 
depends on the identity of the D-amino acid. D-Phe exhibits a rate of 
f-[35S]Met-D-Phe-Lys synthesis of 0.004 sec-1 and an 18% endpoint in the conversion of 
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limiting f-[35S]Met into f-[35S]Met-D-Phe-Lys (Figure 3.17); D-Val, 0.001 sec-1 rate of 
f-[35S]Met-D-Val-Lys synthesis and 11% endpoint in the conversion of f-[35S]Met into 
f-[35S]Met-D-Val-Lys (Figure 3.17); and D-Lys, 0.024 sec-1 rate of f-[35S]Met-D-Lys-Phe 
synthesis and 58% endpoint in the conversion of f-[35S]Met into f-[35S]Met-D-Lys-Phe 











Figure 3.14. Increased concentration of EF-G or Phe-tRNAPhe does not effect the endpoint of 
the fMet-D-Lys-Phe tripeptide synthesis reaction. A 9-fold increase in the concentration of 
EF-G (Lane 4) or a 9-fold increase in the concentration of Phe-tRNAPhe (Lane 6) could not push 
the f-[35S]Met-D-Lys-Phe tripeptide synthesis reaction to completion. Final concentrations of 
[f-[35S]Met-tRNAfMet]=0.06 µM, [EF-Tu]= 3.6 µM and [Phe-tRNAPhe]=0.8 µM; all other 
conditions were as described above under “Di- and Tripeptide Assays” in Chapter 5 or noted in 
the figure. 
 
translationally stalled by the incorporation of a D-amino acid into the nascent polypeptide 
chain depends on the side chain of the D-amino acid. This dependence on the identity of the 
D-amino acid is consistent with a model in which the presence of a D-amino acid at the 
C-terminus of the peptidyl-D-aa-tRNA sterically interferes in a side-chain dependent 
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Figure 3.15. Peptidyl-D-Val-tRNAVal triggers a proofreading mechanism in which a fraction 
of ribosomes larger than that observed with peptidyl-D-Phe-tRNAPhe partition into a 
non-productive state. Data from nitrocellulose filter binding experiments demonstrates that 
f-[35S]Met-D-Val-tRNAVal remains stably bound to 70S ribosomes (a). Toeprinting experiments 
reveal that fMet-D-Val-tRNAVal is able to translocate efficiently (b and c), as the addition of EF-G 
to ribosomes containing fMet-D-Val-tRNAVal results in a gradual decrease in the intensity of the 
+16 band and an accumulation of intensity in the +18 band (lanes 6-11) (b). eTLC data shows that 
19% of f-[35S]Met is converted to f-[35S]Met-D-Val-Pmn (d and e), in close agreement with the 
11% endpoint in the f-[35S]Met-D-Val-Lys tripeptide synthesis reaction. 
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Figure 3.16. Peptidyl-D-Lys-tRNALys triggers a proofreading mechanism in which a fraction 
of ribosomes smaller than that observed with peptidyl-D-Phe-tRNAPhe partition into a 
non-productive state. Data from nitrocellulose filter binding experiments demonstrates that 
f-[35S]Met-D-Lys-tRNALys remains stably bound to 70S ribosomes (a). Filter binding experiments 
with both D/L-Lys-tRNALys were performed using [f-[35S]Met-tRNAfMet]=0.06 µM and 
[EF-Tu]=3.6 µM.   
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Toeprinting experiments reveal that fMet-D-Lys-tRNALys is able to translocate efficiently, as the 
addition of EF-G to ribosomes containing fMet-D-Lys-tRNALys results in a gradual decrease in the 
intensity of the +16 band and an accumulation of intensity in the +18 band (lanes 6-11) (b). 
Toeprinting experiments with both D/L-Lys-tRNALys were performed using [mRNA]=0.06 µM, 
[fMet-tRNAfMet]=0.5 µM and [EF-Tu]=3.6 µM. Translocation of fMet-D-Lys-tRNALys from the A 
to the P site appears to have a slightly reduced endpoint relative to its fMet-L-Lys-tRNALys 
counterpart (54% translocation of fMet-D-Lys-tRNALys versus 72% translocation of 
fMet-L-Lys-tRNALys)(c). While the difference in these reaction endpoints technically lies outside 
of our experimental error, the similarity of their magnitudes leads us to only cautiously conclude 
at this point that, in addition to arresting the PTC, there is a possibility that A site-bound 
fMet-D-Lys-tRNALys also interferes with the translocation reaction.  Because there was 
significant intensity in the control lane at the +15, +16, +18 and +19 band positions for the 
toeprinting assays testing D/L-Lys-tRNALys, the following correction was employed: from the 
control lane, (intensity +15 band)/(intensity full length mRNA band) was determined. The total 
intensity of the full-length mRNA band in the fMet-tRNAfMet lane was then multiplied by this 
fraction, and this product was subtracted from the intensity at the +15 band position from the 
“fMet-tRNAfMet” experiment to generate a final, corrected intensity value for the +15 band 
position in the “fMet-tRNAfMet” experiment. Similarly, by determining the fraction of the intensity 
in the +16, +18, +19, +21 and +22 bands individually relative to the full-length mRNA band 
intensity in the control lane, corrected values at the respective band positions were obtained in all 
experimental lanes.  Percent translocation was then calculated using the summed intensities of 
the +18, +19, +21 and +22 bands divided by the summed intensities of the +15, +16, +18, +19, 
+21 and +22 bands, multiplied by 100.  All other conditions were as described under 
“Toeprinting Assay” in Chapter 5. 
 
eTLC data shows that f-[35S]Met-D-Lys-tRNALys is unreactive with the antiobiotic puromycin (d 
and e). The endpoints of the puromycin reactions for P site-bound f-[35S]Met-D-Phe-tRNAPhe and 
f-[35S]Met-D-Val-tRNAVal closely match the endpoints of their corresponding tripeptide synthesis 
reactions (18% yield of f-[35S]Met-D-Phe-Pmn (Figure 3.9.d and 3.9.e) versus 18% yield of 
f-[35S]Met-D-Phe-Lys (Figure 3.5.a and 3.5.b) and 19% yield of f-[35S]Met-D-Val-Pmn (Figure 
3.15.d and 3.15.e) versus 11% yield of f-[35S]Met-D-Val-Lys (Figure 3.11.a and 3.11.b), 
respectively). In contrast, the endpoint of the puromycin reaction for P site-bound 
f-[35S]Met-D-Lys-tRNALys is significantly less that the endpoint of its corresponding tripeptide 
synthesis reaction (9% yield of f-[35S]Met-D-Lys-Pmn (Figure 3.16d and 3.16.e) versus 58% yield 
of f-[35S]Met-D-Lys-Phe (Figure 3.11.c and 3.11.d)). Beyond being fully consistent with our 
findings that the presence of a D-amino acid at the C-terminus of the P site-bound 
peptidyl-D-aa-tRNA arrests the PTC in a sub-population of ribosomes, these results further 
suggest that the nature of the incoming A-site substrate (i.e. Phe-tRNAPhe versus Pmn in the case 
of f-[35S]Met-D-Lys-tRNALys) can further modulate the fraction of ribosomes that are arrested. 
Puromycin reactivity experiments with both D/L-Lys-tRNALys were performed using 
[f-[35S]Met-tRNAfMet]=0.06 µM and [EF-Tu]=3.6 µM.  
 
 








Figure 3.17. The fraction of translationally stalled ribosomes depends on the side chain of 
the D-amino acid. Syntheses of f-[35S]Met-D-Phe-Lys, f-[35S]Met-D-Val-Lys, and 
f-[35S]Met-D-Lys-Phe, tripeptides versus time were performed, quenched by addition of 
potassium hydroxide to hydrolyze peptide products from tRNA and reaction products were 
separated using eTLC, as described above. Plot of fraction f-[35S]Met converted to 
f-[35S]Met-X-Lys, where X=D-Phe (gold squares, solid line) or D-Val (gold squares, dashed line), 
and f-[35S]Met-X-Phe, where X=D-Lys (gold squares, dotted line) versus time. The beta-branched 
D-Val exhibits a lower endpoint, 11% f-[35S]Met converted to tripeptide, and a slower rate of 
synthesis, 0.0010 sec-1, than D-Lys and D-Phe, which convert 58% and 18% f-[35S]Met to 
tripeptide at rates of 0.024 sec-1 and 0.004 sec-1, respectively. Syntheses of f-[35S]Met-L-Phe-Lys 
(black squares, solid line), f-[35S]Met-L-Val-Lys (black, dashed line) and f-[35S]Met-D-Lys-Phe 
(black squares, dotted line), tripeptides versus time are also shown for comparison. Reactions 
were run in duplicate, and the standard error between the two measurements is reported. All data 
were fit to a single exponential function yielding the indicated kapp. 
 
manner with structural rearrangements of the PTC, the peptidyl-D-aa-tRNA, and/or the 
incoming aa-tRNA that are likely necessary for catalysis of peptide bond formation. 
Modeling of a peptidyl-D-aa-tRNA into the P site of the PTC suggests that the side chain of 
the D-amino acid sterically clashes with the ribose of C2063, a universally conserved 
nucleotide in 23S ribosomal RNA (rRNA) that is involved in a non-Watson-Crick base pair 
with 23S rRNA nucleotide A2450 [27] (Figure 3.18). Notably, ribosomes in which the 
A2450-C2063  base  pair  has  been  directly  disrupted  by  atomic mutagenesis are  
 
  



















Figure 3.18. Structural models of the PTC containing analogs of either a 
peptidyl-L-aa-tRNA or a peptidyl-D-aa-tRNA at the P site. Structural models were generated 
with the PyMOL molecular visualization software [29] using the X-ray crystallographic structure 
of the 50S subunit from Haloarcula marimortui containing a cytidine-cytidine-hydroxypuromycin 
A-site substrate analog and a cytidine-cytidine-adenoside-L-phenylalanine-caproic acid biotin 
P-site substrate analog (PDB ID: 1VQN) [27]. For clarity, only the ribose sugars of the 
3’-terminal adenosines and the phenylalanine rings of the hydroxypuromycin and the 
L-phenylalanine-caproic acid biotin A- and P-site substrate analogs are shown (purple and red, 
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respectively). Likewise, only a subset of the universally conserved 23S ribosomal RNA (rRNA) 
nucleotides that comprise the PTC are shown (light and dark blue). The PTC nucleotides that are 
shown include: (i) A2451 and C2452 (E. coli numbering, unless otherwise noted), which comprise 
part of the A site; (ii) C2063 and U2585, which protect the ester bond linking the nascent 
polypeptide to the 3’-terminal adenosine of the P-site tRNA from hydrolysis [27]; (iii) A2602, 
which is in close proximity to the catalytic center of the PTC; and (iv) A2450, which forms a 
non-canoncial base pair with C2063. The cytidine-cytidine-adenoside-D-phenylalanine-caproic 
acid biotin used to generate the structural model in Panel B was built in PyMOL starting from the 
cytidine-cytidine-adenoside-L-phenylalanine-caproic acid biotin in the original PDB file (PDB ID: 
1VQN) and inverting the stereochemistry about the α-carbon (by selecting the α-carbon, the 
carbon of the carboxylic acid group, and the nitrogen of the α-amino group and using the “invert” 
command in PyMOL). Analysis of these models suggests a mechanism through which the side 
chain of the D-amino acid in the P-site peptidyl-D-aa-tRNA might arrest the PTC [27]. The side 
chain of the L-Phe in the P-site cytidine-cytidine-adenoside-L-phenylalanine-caproic acid biotin 
packs closely against the ribose sugar ring of C2063 (Panel A). Upon inversion of the 
stereochemistry about the α-carbon, however, the side chain of the D-Phe in the P-site 
cytidine-cytidine-adenoside-D-phenylalanine-caproic acid biotin sterically clashes with the ribose 
sugar ring of C2063 (Panel B). It is possible that this steric clash disrupts the universally 
conserved A2450-C2063 non-canonical base pair (dark blue), a base pair whose disruption has 
been shown to impair translation elongation at a step following the first transpeptidation reaction 
[28], yielding truncated peptide products not unlike those observed in the present work. The 
structures in the insets depict only the ribose sugars of C2063 and the ribose sugars of the 
3’-terminal adenosines and the phenylalanine rings of the P-site 
cytidine-cytidine-adenoside-D/L-phenylalanine-caproic acid biotin. The structures in the insets, 
which were generated by rotating the structures in the main panels by ~90º about the x-axis and 
~120º about the y-axis, show the packing of the L-Phe ring with the ribose ring of C2063 (Panel A 
inset) and the steric clash between the D-Phe ring and the ribose ring of C2063 (Panel B inset) 
from a different angle. 
 
The structural models were made into figures by separately saving as a .png file in pyMOL 1) 
Stick figure model of the L- or D- amino acid and corresponding rRNA nucleotides 2) the electron 
surface density of the C2063 sugar and 3) the electron surface density of either the L- or D-amino 
acid side-chain. To generate the electron surface density around both the sugar and the amino acid, 
the “Surface Quality” and “Surface Mode” specifications were changed to “4” and “3”, 
respectively, in pyMOL after selecting “Settings” and then “Edit All”. Also under “Settings”, the 
transparency was modulated under “Transparencey”. These separate .png files were imported into 
photoshop, and each image was “flattened”. “Select All” and “Copy” were then utilized to paste 
the electron density of the sugar and amino acid onto the stick models. The white space within the 
layer of the sugar and amino acid electron density’s was “Select(ed)” and then “Deleted(ed)”. The 
opacity of the electron density’s were then able to be altered, typically between 40%-50%. 
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significantly impaired in translational activities beyond the first round of peptide bond 
formation and subsequent EF-G action, resulting in an accumulation of dipeptide product 
not unlike that observed here [28]. 
 
3.6 Conclusions 
Our finding that the incorporation of D-amino acids into polypeptides partitions 
elongating ribosomes between subpopulations that are either competent or incompetent for 
further rounds of elongation has significant implications for current efforts to incorporate 
unnatural amino acids into proteins and peptides using misacylated tRNAs. First, it means 
that D-amino acids can be incorporated into proteins. The previous conclusion that 
D-amino acids could not be incorporated was likely an artifact stemming from the use of in 
vitro cell free extracts, which contain D-aa-tRNA deacylase enzymes, and/or some other 
aspect of the engineered system to support the translation of the D-amino acid. By 
extension, it may be the case that other, useful amino acid analogs currently thought not to 
be substrates for the TM, can in fact be incorporated using unnatural amino acid 
mutagenesis. While not investigated here, it will be interesting to determine if the TM is 
capable of synthesizing D-polypeptide oligomers, with multiple D-amino acids in 
succession. Given that the proportion of elongating ribosomes that partition into the 
productive state depends on the identity of the D-amino acid’s side-chain and the 
observation that D-Lys is incorporated into an fMet-D-Lys-Phe tripeptide with a high yield, 
it may in fact be possible to design D-aa-tRNAs that minimally perturb peptide-bond 
formation at the PTC. Finally, our results directly prove that the ribosome does, in fact, 
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significantly discriminate the amino acid structure. Furthermore, they suggest that this 
discrimination occurs at a previously undetected step of the elongation cycle which lies 
beyond the canonical aa-tRNA selection discrimination steps but nevertheless gates the 
chemistry of peptide bond formation at the PTC. This mechanistic insight can now be used 
to guide efforts to engineer the TM to expand its substrate plasticity. It is possible that the 
twenty plus amino acids which form the set of natural substrates of the TM are uniquely 
able to navigate this gating step at the PTC and partition elongating ribosomes into their 
catalytically active state, providing an explanation for why unnatural amino acids appear to 
be incorporated into proteins with lower yields than natural amino acids. 
We have demonstrated that the PTC can utilize D-aa-tRNAs and peptidyl-D-aa-tRNAs 
as substrates for the peptidyl-transfer reaction regardless of their altered stereochemistry. 
Despite this, peptidyl-D-aa-tRNAs arrest the peptidyl-transfer reaction in a subpopulation 
of ribosomes and the size of the arrested subpopulation is dependent on the identity of the 
side chain of the D-amino acid at the C-terminus of the peptidyl-D-aa-tRNA. Based on 
these results, it is tempting to speculate that peptidyl-D-aa-tRNAs arrest the 
peptidyl-transfer reaction by impeding, or even completely blocking, structural 
rearrangements of the PTC, the peptidyl-D-aa-tRNA, and/or the incoming aa-tRNA that 
gate the chemistry of peptide bond formation. Similarly, given the apparent ability of 
events at the PTC to modulate the translocation reaction [30-34], it is possible that 
perturbations of similar structural rearrangements may impair or arrest the ability of 
peptidyl-D-aa-tRNAs to be translocated from the A to the P site; indeed our data with 
D-Lys-tRNALys raises the intriguing possibility that fMet-D-Lys-tRNALys is slightly 
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impaired in its ability to undergo translocation from the A site to the P site of the ribosome 
(Figure 3.16.b and 3.16.c). It is thus possible that the PTC has evolved under selective 
pressure to efficiently undergo these conformational dynamics in the presence of the 
twenty plus natural amino acids and that the C-terminal amino acid of the peptidyl-tRNA 
and, possibly, the amino acid moiety of the aa-tRNA themselves participate directly in 
these structural transitions. Although our data are currently limited to D-amino acids, it is 
possible that our results represent a general mechanism through which unnatural amino 
acids are discriminated by the TM. Assuming that, like the D-aa-tRNAs, other U-aa-tRNAs 
are able to navigate past the aa-tRNA selection steps of the elongation cycle, participate as 
peptidyl-transfer acceptors at the PTC, and translocate from the A site into the P site, the 
resulting peptidyl-tRNAs containing the unnatural amino acid at their C-terminus will still 
need to successfully contend with the conformational dynamics at the PTC to fully 
participate as peptidyl-transfer donors at the P site of the PTC. Our hypothesis that 
unnatural amino acids arrest the peptidyl-transferase reaction by perturbing functionally 
important conformational dynamics at the PTC may inform similar proposals for how a 
growing list of nascent polypeptides modulate the activity of the PTC to trigger nascent 
polypeptide-dependent translation arrest [35-36] and how several small-molecule 
PTC-targeting antibiotics perturb the peptidyl-transfer reaction [36-37]. Indeed, analogous 
to the longstanding use of antibiotics as tools for mechanistic studies of protein synthesis 
by the ribosome [38-39], U-aa-tRNAs provide powerful mechanistic tools for probing PTC 
function that, unlike most antibiotics, can be readily and systematically modified using the 
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considerable arsenal of amino acid synthetic methods that have been developed over the 
last few decades.  
Finally, our results provide a possible mechanism for growing links between 
misacylated tRNAs and human genetic diseases. Recently, Söll and co-workers have used 
mass spectrometry analysis of a reporter protein expressed in E. coli cells producing 
increased levels of misacylated tRNAAsn to demonstrate that E. coli can contend with 
mistranslation, tolerating up to 10% of the mismade protein [40]. Interestingly, E. coli 
apparently copes with mistranslation not by hydrolyzing the misacylated tRNA or by 
invoking a proofreading step during protein synthesis by the TM, but rather by triggering 
the heat shock response in which mistranslated proteins are either assisted to fold properly 
or are targeted for degradation [40]. More severe outcomes have been observed in 
post-mitotic mammalian cells such as neurons, presumably because mismade proteins 
cannot be diluted out by cell division. For example, Ackerman, Schimmel and co-workers 
have demonstrated that production of low levels of misacylated tRNAAla in mice carrying 
the sticky (sti) mutation results in accumulation of misfolded proteins in cerebellar Purkinje 
neurons that is accompanied by upregulation of protein chaperones and induction of the 
unfolded protein response, a cellular stress response that can culminate in apoptosis and 
may underlie the extensive Purkinje cell loss that is observed in mice carrying the sti 
mutation [41]. In addition to misacylation with the canonical amino acids, high-throughput 
analyses show that many non-canonical amino acids, including D-amino acids, are 
competent substrates for the aaRSs [42]. This is significant given that cells must often 
contend with high concentrations of non-canonical amino acids—for example, D-Ser is 
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present at ~30% the concentration of L-Ser in the human central nervous system [5]. 
Speaking directly to the role that misacylation of tRNAs with non-canonical amino acids 
might have in disease, Schimmel and co-workers [43] have recently demonstrated that the 
mistranslation and apoptosis observed in cultured mouse fibroblast cells producing 
increased levels of misacylated tRNAVal was exacerbated by addition to the culture media 
of L-α-aminobutyric acid, a non-canonical amino acid that is known to be efficiently 
activated by ValRS [43]. Interpreted within the context of these studies, we speculate that 
the production of prematurely truncated polypeptides induced by the incorporation of 
D-aa-tRNAs by the TM may result in misfolded proteins that trigger cellular responses 
that, at least in the case of post-mitotic cells such as neurons, can ultimately lead to cell 
death. Further support for this hypothesis is provided by the nearly universal conservation 
of D-aa-tRNA deacylases [13], a family of enzymes that provides a surveillance system 
which specifically hydrolyzes tRNAs misacylated with D-amino acids [7,13]. Notably, 
mammalian D-aa-tRNA deacylase is highly expressed in brain tissues [44] and, in cultured 
human cells, silencing of the dtd gene encoding the D-aa-tRNA deacylase and addition of a 
D-amino acid to the culture media has been shown to cause decreased rates of protein 
synthesis and decreased cell viability [44]. The translational stalling and production of 
truncated proteins that we observe upon the incorporation of a D-aa-tRNA by the TM, 
therefore, provides a plausible molecular mechanism for these effects. 
In conclusion, our results provide direct evidence that the ribosome discriminates 
the amino acid structure, significantly expanding the complexity of aa-tRNA recognition 
beyond that portrayed in the contemporary interpretation of the Adaptor Hypothesis. 
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Surprisingly, discrimination of the amino acid occurs not during the canonical aa-tRNA 
selection steps, but rather at a newly identified step in the elongation cycle which gates the 
chemistry of peptide-bond formation at the PTC of the elongating ribosome. That the 
identity of the D-amino acid side chain modulates the frequency with which the PTC 
accesses the active state at this step of the elongation cycle strongly suggests that this step 
involves a structural rearrangement of the PTC, the peptidyl-tRNA, and/or the incoming 
aa-tRNA that are necessary for peptide-bond formation. The mechanistic insight gleaned 
from our studies resolves long-standing incongruities in the literature as to whether or not 
D-amino acids are competent substrates for the translational machinery; intriguingly, we 
find that the ribosome itself plays a role in enforcing the stereospecificity of polypeptide 
synthesis. This discovery impacts current efforts to engineer the TM to expand the range of 
analogs that can be incorporated into polypeptides using misacylated tRNAs, establishes 
the utility of misacylated U-aa-tRNAs for perturbing and hence providing insight into the 
mechanism of protein synthesis, and provides a plausible molecular mechanism for recent 
reports that tRNA misacylation in vivo leads to protein misfolding diseases.  
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Chapter 4   
The Enforcement of Homochirality 
 
4.1 Implications of In Vitro Results 
The ability of the TM to incorporate D-amino acids into peptides has profound 
implications for our current understanding of protein synthesis and, potentially, human 
disease. By disproving the paradigm that emerged from the unnatural amino acid 
mutagenesis community stating that D-amino acids were not substrates for the TM [1], 
we can now look for phenomenon in vivo with novel hypotheses. Based on the high level 
of incorporation of D-Lys, for example, we can predict that D-Lys-tRNALys would be a 
good substrate for the ribosome and might actually be found in proteins in vivo. Another 
novel hypothesis that emerges from our in vitro work is that the incorporation of other 
D-amino acids, such as D-Phe or D-Val, would result in the generation of truncated 
protein caused by arrest in the PTC. By extension, misincorporation of these and 
potentially other D-amino acids into protein instead of their L-amino acid counterparts 
would fundamentally compromise the fidelity of the genetic code (Section 1.1) resulting 
in genetic code ambiguity, as each codon could then potentially encode both the D- and 
the L-amino acid.  
Several studies are instructive regarding the in vivo consequences of compromising 
the genetic code. Using E. coli transformed with a non-discriminating Asp aaRS capable 
of forming misacylated Asn-tRNAAsp, mass spectrometry analysis demonstrated the 
incorporation of the misacylated Asn into protein where Asp was normally coded for [2]. 
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While this result is not entirely unexpected, given that natural amino acids misacylated 
onto non-cognate, natural tRNAs can be incorporated very efficiently by the ribosome 
and can compete effectively against cognate aa-tRNAs [3], upregulation of the unfolded 
protein response was also observed, and the authors estimated that E. coli can tolerate 
~10% of its proteome being mismade because of the robust cellular response mechanism 
to misfolded protein [2]. In another study investigating the mouse sticky mutation (sti), a 
genomic mutation in the editing site of the alanine synthetase that renders this enzyme 
partially unable to clear mischarged Ser-tRNAAla in vitro [4], the observed phenotype of 
this alteration is severe ataxia and degeneration of Purkinje cells in the brain [4]. 
Induction of the unfolded protein response and an upregulation of cytoplasmic chaperone 
proteins were also observed [4]. Presumably, misacylated Ser-tRNAAla is incorporating 
Ser in place of codons normally coding for Ala, resulting in misfolded protein and disease. 
Finally, a mouse NIH/3T3 fibroblast cell line was induced to express an editing defective 
Val aaRS, which could not remove misacylated Thr-tRNAVal in vitro [5]. This mutant 
synthetase acts as a dominant negative in vivo. After directly demonstrating 
misincorporation of Thr into protein, phenotypic abnormalities included cell contraction, 
membrane blebbing and caspase-3 activation, the latter being consistent with apoptosis, 
the last stage in the unfolded protein response [5]. Based on these data with misacylated 
natural tRNAs, we might therefore predict an accumulation of misfolded protein as a 
result of D-amino acid incorporation to be the underlying mechanistic cause for human 
disease states. Given the high concentration of D-amino acids and the high expression 
levels of racemaces observed in mouse brain and central nervous system [6-7], it is 
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compelling to speculate that the pathologies of neurodegenerative and psychiatric 
diseases in humans might have such a mechanistic origin. Even if D-amino acids are 
rarely incorporated in vivo, the alteration of just one protein due to D-amino acid 
incorporation could be toxic, as any deviation from normal protein structure could cause 
the D-amino acid containing protein to aggregate with other functional proteins, or cause 
other proteins to misfold [8]. 
Three conditions must be met in order for a D-aa-tRNA to be incorporated into 
protein by the ribosome in vivo. First, D-amino acids must be present in vivo. In bacteria, 
D-Ala and D-Glu are prominent components of peptidoglycan, a flexible polymer vital to 
maintaining the cell’s osmotic pressure and shape. E. coli synthesizes these D-amino 
acids using racemase enzymes specific for L-Ala and L-Glu. A multisubstrate racemase 
enzyme in V. cholerae capable of generating D-Met, D-Val, D-Ile and D-Leu has recently 
been discovered [9]. Several other racemase enzymes are known to exist; a D-Asp and 
D-Ser racemase have been identified in mouse brain [6-7], with colocalization of these 
D-amino acids in the same brain regions where these enzymes are expressed [6-7]. The in 
vivo function of these D-amino acids is not well understood  
The second criteria that must be fulfilled for in vivo incorporation of D-amino acids 
into protein is that D-amino acids must also be misacylated onto tRNA. Given the high 
specificity that aaRS enzymes exhibit to discriminate natural amino acids with similar 
side chains (Section 1.1), it is surprising that the Tyr aaRS, Phe aaRS, Trp aaRS, His aaRS, 
Lys aaRS, and Asp aaRS (6 out of 20, or greater than ¼ of the aaRS enzyme have all been 
shown to misacylate tRNATyr, tRNAPhe, tRNATrp, tRNAHis, tRNALys, and tRNAAsp  



















with D-Tyr, D-Phe, D-Trp, D-His, D-Lys and D-Asp, respectively [10-12]. The kinetics  
of D-Tyr misacylation onto tRNATyr by the Tyr aaRS have been investigated, and it was 
found that D-Tyr is charged with a slower rate than L-Tyr, but both amino acids reached 
the same endpoint [10,13].  
Finally, the third criteria for D-amino acid incorporation in vivo is that these 
 
Figure 4.1. Competition experiments between 
D-/L-Phe-tRNAPhe (a), D-/L-Val-tRNAVal (b) 
and D-/L-Lys-tRNALys (c) demonstrate that 
D-aa-tRNAs can compete against L-aa-tRNAs 
in vitro. Ternary complexes containing equal 
concentrations of both D- and L-aa-tRNA were 
delivered to limiting 70S initiation complexes. 
(a) Ratio of L-Phe:D-Phe incorporation into 
dipeptide equaled 100 ± 82 : 1. Experiments 
were performed in triplicate and the standard 
deviation is reported. Dipeptide products were 
separated by HPLC on a gradient that progressed 
from 10% MeCN to 12% MeCN over 12 
minutes; isocratic 20% MeCN from 12-15 
minutes; 20% MeCN to 35% MeCN from 15-58 
minutes [14]. (b) Ratio of L-Val:D-Val 
incorporation into dipeptide equaled 11 ± 1 : 1. 
Experiments were performed in duplicate and 
the standard error is reported. Dipeptide products 
were separated by HPLC on a gradient that 
progressed from 1% MeCN in 0.1% TFA to 20% 
MeCN over 50 minutes [14]. (c) Ratio of 
L-Lys:D-Lys incorporation into dipeptide 
equaled 3.61 ± 0.02 :1. Experiments were 
performed in triplicate and the standard 
deviation is reported. Dipeptide products were 
separated by HPLC on a gradient that progressed 
from 1% acetonitrile in 0.1%TFA to 1.8% 
acetonitrile in 18 minutes, and then to 100% 
acetonitrile in 20 minutes [3].  
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misacylated tRNAs must be competitive with L-aa-tRNAs for incorporation by the 
ribosome. In vitro studies demonstrate that this criteria, too, can be met. Biochemical 
competition experiments, where initiated 70S ribosomes were confronted with ternary 
complexes containing equal concentrations of D- and L-aa-tRNA, revealed that D-Lys 
effectively competed against L-Lys (~4 fold discrimination), and that D-Phe and D-Val, 
though much poorer competitors, were capable of being incorporated in the presence of 
their respective L-aa-tRNAs (Figure 4.1). A study by Hopfield et al. comparing D-Tyr and 
L-Tyr during aminoacylation by the Tyrosine aaRS, binding to EF-Tu and to the ribosome, 
GTPase activation and dipeptide formation showed that D-Tyr was capable of executing 
all these steps of the elongation cycle, though much more slowly than L-Tyr [13]. While 
this evidence suggests that D-Tyr would encounter difficulty incorporating in vivo if 
L-Tyr were also present, much as D-Phe behaved in in vitro competition experiments 
(Figure 4.1.a), the incorporation of D-Tyr by the TM is possible. Moreover, the ability of 
other D-amino acids to be incorporated in vivo is an entirely open question. 
 
4.2 Cellular Defense Network for the Enforcement of 
Homochirality In Vivo 
 It is perhaps because misincorporation of D-amino acids could severely 
compromise the genetic code that a comprehensive defense network exists in cells to 
protect against the potentially harmful effects described above. In E. coli, several 
mechanisms exist to preserve the homochirality of amino acids and aa-tRNAs 
available for protein synthesis. Peptidoglycan is capable of absorbing exogenous 
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D-Met, D-Trp, D-Phe, D-Val and D-Asp into its structure in place of D-Ala [15]. 
D-Serine dehydratase (dsdA) catabolizes both D-Ser and D-Thr, converting both 
these D-amino acids to their respective keto acids and ammonia [16]. D-Cysteine 
desulfhydrase converts D-Cys into pyruvate, H2S and NH3 [17]. Most importantly, 
two multisubstrate enzymes, the D-amino acid dehydrogenase (dadA) enzyme and 
the D-aminoacyl-tRNA deacylase (dtd) enzyme act with broad substrate specificity 
to catabolize D-amino acids and remove D-amino acids that have been 
aminoacylated onto tRNA, respectively. dadA has been demonstrated to catabolize 
D-Ala, D-Met, D-Phe, D-Asn, D-His, D-Ser, D-Pro and D-Val [18-19] to their 
respective keto acids and ammonia. The presence of this enzyme allows E. coli to 
grow on D-Ala as the sole source of carbon and nitrogen [18]. The absence of dadA 
in E. coli cells grown in media containing D-amino acids reduced the degradation of 
D-Met by 1/3 and D-Phe by 2/3’s; a dadA-/dsdA- double mutant reduced the level of 
D-Ser and D-Phe degradation almost entirely [20]. In E. coli, dtd’s substrates include 
D-Tyr-tRNATyr, D-Phe-tRNAPhe, D-Trp-tRNATrp and D-Asp-tRNAAsp [10,21]. Placed 
in this context, the ribosomal PTC must also be added to the arsenal of enzymatic 
defense mechanisms poised for the task of enforcing homochirality in vivo. Indeed, 
our in vitro results demonstrate that the PTC partially inactivates once a D-amino 
acid reaches the P-site, and this inactivation is modulated by the side-chain of the 
D-amino acid. The consequence of this partial deactivation suggests that the 
ribosome is promiscuous in enforcing homochirality in vivo, and that 
misincorporation of D-amino acids into protein might be a harmful result of this 
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promiscuity in vivo.  
 The ability of the dtd- and dadA- single mutant and the dtd-/dadA- double mutant 
strains to grow in both the presence and absence of D-amino acids has been studied in E. 
coli. Whereas the WT strain endowed with both enzyme’s doubled every 90 minutes on 
M9 minimal media supplemented with D-Tyr, the doubling times of the dtd- and dadA- 
strains were slower under the same conditions, doubling every 136 minutes and 106 
minutes, respectively [22] (Table 4.1). The markedly slower 230 minute doubling time of  
 
Table 4.1 Generation times of D-aminoacyl-tRNA deacylase (dtd) and D-amino acid 
dehydrogenase (dadA) null strains grown in the presence or absence of D-Tyrosine.  
 Generation Time (min) 
Strain Control D-Tyrosine (2.4mM) 
WT 80 90 
dtd- 78 136 
dadA- 78 106 
dtd-/dadA- 81 230 
Data reproduced from [22]. Generation times are from an E. coli K37 strain. 
 
the dtd-/dadA- double mutant on minimal media supplemented with D-Tyr (Table 4.1) 
suggests the possibility that these enzyme’s might be acting synergistically to form a 
potent enzymatic defense network against the formation of D-aa-tRNAs in vivo. 
Two studies seeking to identify the cause of the slow growth dtd- phenotype 
specifically examined if D-amino acids were capable of incorporation into protein in this 
genetic background. In the first study using B. subtilis, an organism that has the dtd gene 
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but does not express it, the growth inhibition caused by D-Tyr was claimed to be caused 
by the incorporation of this D-amino acid into protein [23]. After growing B. subtilis on 
minimal media containing 14C-D-Tyr, protein was collected and harvested, and 
radioactivity was indeed found in the protein fractions [23]. However, an effort was made 
attempting to demonstrate that the 14C-D-Tyr had maintained its chirality after 
incorporation into protein. Treatment of hydrolyzed proteins collected from these cells 
grown on minimal media supplemented with 14C-D-Tyr with D-amino acid oxidase 
(dAOO), a eukaryotic homolog of dadA, showed no keto acid formation [23]. As a result, 
it is formally possible that the B. subtilis dadA enzyme converted 14C-D-Tyr to its 
corresponding keto acid, and that this keto acid was then converted to 14C-L-Tyr, which 
was then incorporated into protein. In the second study, the growth inhibition of an E. coli 
dtd- strain caused by D-Tyr present in minimal media was claimed to be a result of the 
production of D-Try-tRNATyr, which removed tRNATyr from the available tRNA pool for 
correct aminoacylation, and thus slowed growth by inhibiting protein synthesis [24]. In 
support of this hypothesis, aminoacylated D-Tyr-tRNATyr was found in these cells, with 
~1/3 of tRNATyr charged with D-Tyr [24]. However, to rule out the possibility that D-Tyr 
was incorporated into protein, the authors reasoned that peptidyl-D-Tyr-tRNATyr would 
not be stable and would therefore dissociate from the ribosome, and therefore only looked 
for this peptidyl-tRNA species by centrifuging lysed E. coli dtd- cells grown on D-Tyr and 
ethanol precipitating the supernatant [24]. Any peptidyl-D-Try-tRNATyr formed that 
remained ribosome bound would therefore have been lost by this procedure. Moreover, no 
effort was made to examine fully-synthesized protein (possibly containing D-Tyr) that 
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had been released from tRNA by release factors. Therefore, this study did not 
conclusively demonstrate that D-Tyr was not incorporated into protein by the TM in the 
dtd- background. 
In the wild-type background of various organisms, an attempt has been made to try to 
quantify the relative amounts of D-amino acids found in proteins in vivo. Ngata et al. took 
protein from the soluble protein fraction of various organisms (thus avoiding D-amino 
acids in peptidoglycan), subjected this protein containing fraction to acid hydrolysis, and 
analyzed the amino acid composition by HPLC after reaction with Marfey reagent [25]. 
The results shown in Table 4.2 demonstrate that across kingdoms of life, D-amino acids   
 
Table 4.2. D-amino acids found in peptides in vivo from various organisms. Percentage of D 
amino acid, as calculated by D/(D+L), for D-Ser, D-Ala, D-Pro, D-Glu and D-Asp found peptides 
from the soluble fraction of various organisms. Table reproduced from [25]. 
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remains largely unexplored.  
In E. coli dtd is found in the cytoplasm and dadA is found within the cytoplasm near 
the inner membrane [19], while in humans dtd is localized within the nuclear pore [26], 
and dAOO, the eukaryotic homolog of dadA, is found in peroxisomes. dtd and its 
homologs are found in all three kingdoms of life and are nearly universally conserved 
[27], suggesting that it is a necessary surveillance mechanism to counter the potential of 
D-aa-tRNA incorporation by the TM. As mentioned above, mouse models demonstrate 
that racemases are expressed in high levels in the brain along with high concentrations of 
D-amino acids. Perhaps not surprisingly, dtd is concentrated in the central nervous system 
of both humans and mice [26]. Silencing of the human dtd enzyme in HeLa cells 
accompanied with D-amino acid treatment resulted in decreased rates of both protein 
synthesis and cell viability [26]. Interestingly, D-Ser is a D-amino acid found in high 
concentrations in the human brain [28]. In contrast to E. coli which possesses both dadA 
and dsdA to degrade D-Ser and where dsdA is more effective in D-Ser catabolism [21], 
only dadA is present in humans to degrade D-Ser. Thus, a better understanding of the 
functional interplay between these defense mechanisms and individual D-amino acids in 
E. coli may lead to profound insights pertaining to human health and disease.  
 
4.3 Future Directions 
In light of our in vitro results and the paucity of in vivo data in the literature 
pertaining to the incorporation of D-amino acids into proteins by the TM, we hypothesize 
that D-amino acids are in fact incorporated into protein by the TM in vivo. We further 
 89     Chapter 4 The Enforcement of Homochirality 
hypothesize that dtd and dadA are the primary enzymatic defense network that preserve 
the homochirality of aa-tRNA substrates for ribosome catalyzed protein synthesis. 
Because the unfolded protein response was a common in vivo mechanism activated upon 
generating misacylated natural aa-tRNAs, and due to the fact that the dtd-/dadA- double 
mutant strain exhibited the most severe growth inhibition phenotype when grown on 
D-Tyr, we have begun to look for the upregulation of the unfolded protein response in the 
dtd-/dadA- double knock-out strain and the single knock-out dtd- and dad- strains. These 
strains were generated (Figure 5.10 and 5.11) according to procedures described in 
Chapter 5. Encouragingly, preliminary results suggest that in the dtd-/dadA- double 
knock-out strain, mRNA encoding for mopA and dnaK are upregulated ~57 fold and ~37 
fold, respectively, compared to WT (Table 4.3) when these strains were grown on D-Tyr, 
and that the upregulation of the mRNA encoding these proteins is more pronounced in the 
double knock-out than in the single knock-out strains (Table 4.3). These results were 
obtained using the 2-∆∆CT methodology [29] to analyze CT values obtained from RT-PCR 
experiments (Table 4.4) probing total mRNA for mopA and dnaK specific mRNA 
transcripts compared to the levels of mRNA encoding for gapA, the internal standard. 
 
 
Table 4.3 Upregulation of mRNA encoding mopA and dnaK heat shock/unfolded protein 
response proteins in the dtd-, dadA-, and dtd-/dadA- mutant strains compared to WT when 
grown on M9 minimal media containing D-Tyr. Relative mRNA levels of mopA and dnaK 
were obtained using the 2-∆∆CT methodology [29] relative to gapA as the internal standard. 
 Strain 
 WT dtd- dadA- dtd-/dadA- 
mopA 1 8.6 7.7 57.6 
dnaK 1 5.7 2.5 37.2 
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It may be the case, though, that mRNA transcripts encoding for gapA are 
down-regulated in these experiments (Table 4.4). 
 
Table 4.4 CT values obtained using RT-PCR to amplify cDNA generated from the total 
mRNA pool from the indicated strains and amplified using primers specific for gapA, mopA, 
dnaK, dtd and dadA, as indicated. Total mRNA was obtained from each of the indicated strains 
after growth on M9 minimal media supplemented with D-Tyr to an OD600 = 0.4-0.8. * indicates the 
gene specific primers utilized in the RT-PCR experiments. 
              Strain 
 WT dtd- dadA- dtd-/dadA- 
gapA*  12.974 15.275 13.680 17.103 
mopA* 20.427 19.614 18.180 18.431 
dnaK* 18.193 17.993 17.581 16.827 
dtd* 20.578 31.134 19.728 30.850 
dadA* 19.983 19.134 32.405 31.970 
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 Methods 
5.1 Ribosomes, Translation Factors, tRNA Synthetases, tRNAs, 
and mRNAs 
Tightly coupled Escherichia coli 70S ribosomes were purified using sucrose 
density gradient ultracentrifugation as previously described [1-2] and then stored in a 
buffer containing 10 mM Tris-acetate, pH25°C 7.5, 60 mM ammonium chloride, 7.5 mM 
magnesium acetate, 0.5 mM ethylenediamine tetraacetic acid, 6 mM 2-mercaptoethanol 
and 40% sucrose at -80 ºC [2-3]. Initiation factors 1, 2, and 3, elongation factors Tu, Ts, and 
G, formylmethionyl-tRNA formyltransferase and methionyl-tRNA synthetase were 
purified as previously described [2,4]. A phenylalanyl-tRNA synthetase containing a 
6x-histidine tag at its N-terminus and a threonine to glycine mutation at position 251 
(T251G) was obtained from an overexpression strain kindly provided by Prof. David 
Tirrell (California Institute of Technology, Pasadena, CA, USA) [5] and purified over a 
Ni2+-nitrilotriacetic acid (NTA) column (Novagen). This mutant aminoacyl-tRNA 
synthetase charged phenylalanine onto tRNAPhe with ~95% efficiency. Lysine-tRNA 
synthetase containing a 6x-histidine tag was obtained from an overexpression strain kindly 
provided by Prof. Takuya Ueda (University of Tokyo, Japan) [6] and purified over a 
Ni2+-NTA column. The lysine aminoacyl-tRNA synthetase charged lysine onto tRNALys 
with ~35% efficiency. 
 All tRNAs used in this study (tRNAfMet, tRNAPhe, tRNALys, and tRNAVal) were from 
E. coli and were purchased from either Sigma or MP Biomedicals. Because control 
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translations with tRNAVal demonstrated that this tRNA, as purchased from Sigma, was 
significantly acylated,  tRNAVal was deacylated by incubation in 1.8 M 
Tris-hydrochloride, pH25ºC 8, for 3 hours at 37 ºC [7] prior to aminoacylating with 
D-valine (Figure 5.1). Control translations with tRNAPhe and tRNALys did not yield any 
 
Figure 5.1. eTLC analysis of tRNAVal acylation state. Left Panel: Buffer, tRNAVal (Sigma) and 
Val-tRNAVal were used to form ternary complexes and translated as described above in “Di- and 
Tripeptide Assays”. The formation of dipeptide in the tRNAVal lane demonstrates that tRNAVal 
(Sigma) was acylated. Right Panel: Buffer, tRNAVal (Sigma) after treatment with 1.8 M 
Tris-hydrochloride, pH25ºC 8 for 3 hours at 37 ºC [7], and Val-tRNAVal were used to form ternary 
complexes and translated as described below in “Di- and Tripeptide Assays”. The absence of 
dipeptide in the 1.8M Tris/tRNAVal lane demonstrates that this treatment efficiently deacylated 
tRNAVal. Control translations with tRNAPhe (Sigma) and tRNALys (Sigma) demonstrated that these 
tRNAs were not acylated prior to ribozyme charging (data not shown).  
 
dipeptide product (data not shown), and consequently, these tRNAs were used without 
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double-stranded DNA templates encoding variants of the bacteriophage T4 gene product 
32 (hereafter referred to as T4gp32) using a protocol described previously [2,4], and 
purified by filtration through an Amicon Centrifugation filter (10,000  MW cut-off) [4]. 
For all experiments except the toeprinting assay, truncated T4gp32 mRNAs encoding the 
first 20 amino acids were used (T4gp321-20). For toeprinting experiments, a longer 
T4gp32 mRNA encoding the first 224 amino acids was employed (T4gp321-224) [4]. The 
specific sequence and length of each T4gp32 mRNA is noted for each experiment 
described below. 
 
5.2 tRNA Aminoacylation 
Aminoacylation and formylation of initiator tRNAfMet with [35S]-methionine and 
unlabeled methionine was performed using methionyl-tRNA synthetase and 
formylmethionyl-tRNA formyltransferase, following a protocol described previously 
[2,4]. For the di- and tripeptide translation experiments described in the text and in detail 
below, ribozyme charged D/L-aminoacyl-tRNAs were used in the second position. The 
eFx ribozyme along with D/L-phenylalanine cyanomethyl esters (CME) and the dFx 
ribozyme along with D/L-lysine or D/L-valine dinitrobenzyl esters (DBE) were used to 
aminoacylate tRNAPhe, tRNALys, and tRNAVal, respectively as described by Suga et al [8]. 
Importantly, the enantiomeric excess (ee) of D-Phe-CME=98.6%, D-Val-DBE=99.8% and 
D-Lys-DBE=99.8%; the synthesis and characterization of these DBEs and CMEs, as well 
as the characterization of ribosome translated products, is demonstrated elsewhere [9]. 1H 
NMR spectra of all CME’s and DBE’s used have been reproduced as Figures 5.2-5.7. The 
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aminoacylation reactions contained 20 µM tRNA, 20 µM dFx or eFx, and 5 mM amino 
acid-DBE or CME substrate in a buffer of 0.1 M HEPES-K, pH 7.5, 0.1 M potassium 
chloride, 600 mM magnesium chloride and 20% dimethyl sulfoxide [8]. Aminoacylation 
reactions for D/L-phenylalanine and D/L-lysine were run for 2 hours on ice; the 
D/L-valine reaction was run for 6 hours on ice. All charging reactions were quenched 
with 3x volumes of 600 mM ammonium acetate, pH 5, followed by ethanol precipitation 
of the aminoacyl-tRNA (aa-tRNA). aa-tRNAs were resuspended and stored in 10 mM 
potassium acetate, pH 5 and were not purified further after aminoacylation [3]. 
To estimate aminoacylation efficiency, analytical scale aminoacylations were 
performed concurrently under the same conditions described above with the exception 
that [32P]-labeled tRNA was used. tRNA was labeled at the 3’ end with [32P]-AMP using 
nucleotidyl-transferase, as previously described [3,10]. After quenching with 3x volumes 
of 600 mM ammonium acetate, pH 5 and ethanol precipitation, aminoacyl-[32P]-tRNAs 
were resuspended in 10 mM potassium acetate, pH 5 and digested with nuclease P1 (Sigma) 
for 10 minutes at room temperature [10]. Subsequent separation of [32P]-AMP and 
aminoacyl-[32P]-AMP was achieved by thin-layer chromatography (TLC) on PEI-cellulose 
plates (EMD Chemicals, Inc) under acidic conditions (100 mM ammonium chloride, 10% 
acetic acid) [10]. TLC plates were exposed to a phosphor imaging screen (Amersham 
Biosciences) overnight, analyzed using a Storm 860 phosphor imager (Molecular 
Dynamics), and quantified using ImageQuant software. Charging efficiencies were 
calculated as the amount of aminoacyl-[32P]-AMP divided by the total of [32P]-AMP plus 
aminoacyl-[32P]-AMP (Figure 5.8). These measured aminoacylation efficiencies were 





















Figure 5.2. 1H NMR of D-Phenylalanine-Cyanomethyl Ester. Data from [9]. 
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Figure 5.3. 1H NMR of L-Phenylalanine cyanomethyl ester. Data from [9]. 
   
 
 






















Figure 5.4. 1H NMR of D-Valine 3,5-dinitrobenzyl ester. Data from [9]. 
 
 





















Figure 5.5. 1H NMR of L-Valine 3,5-dinitrobenzyl ester. Data from [9]. 
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Figure 5.6. 1H NMR of D-Lysine 3,5-dinitrobenzyl ester. Data from [9]. 
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Figure 5.7. 1H NMR of L-Lysine 3,5-dinitrobenzyl ester. Data from [9]. 
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used to calculate the final concentrations of aa-tRNA in the translation reactions  
The third position L-aa-tRNAs in the tripeptide and tetrapeptide experiments were 
aminoacylated with either the phenylalanine or lysine aminoacyl-tRNA synthetases under 
conditions described elsewhere [2]. Typical charging efficiencies were ~35% for tRNALys 
and ~95% for tRNAPhe as noted above. 
 
5.3 Buffer System 
Translation reactions were run in Tris-polymix buffer containing 50 mM 
Tris-acetate, pH25°C 7.5, 100 mM potassium chloride, 5 mM ammonium acetate, 0.5 mM 
calcium acetate, 3.5 mM magnesium acetate, 6 mM 2-mercaptoethanol, 5 mM putrescine, 




 Figure 5.8. TLC analysis of aminoacylation efficiency. The ribozyme aminoacylated 
aa-tRNA species analyzed and the calculated charging efficiencies are indicated at the top of 
the TLC.  
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5.4.1 70S Initiation Complex Formation  
70S initiation complexes were in vitro initiated in Tris-polymix buffer using slight 
modifications of previously published protocols [2,4,11]. The initiation reaction contained 
final concentrations of 1.1 μM tightly coupled 70S ribosomes, 1.2 μM IF1, 1.5 μM IF2, 
1.3 μM IF3, 1.1 mM GTP, 0.5 μM f-[35S]Met-tRNAfMet and 3.6 μM mRNA.. 70S tightly 
coupled ribosomes, IFs, and GTP were incubated first for 10 min at 37 ºC. mRNA was 
added next, followed by another incubation at 37 ºC for 10 min. Finally, 
f-[35S]Met-tRNAfMet was added. The mixture was incubated again at 37 ºC for 10 min and 
was stored on ice until use. 70S initiation complexes were used without further 
purification and were made fresh before each experiment. 
 
5.4.2 Ternary Complex Formation and EF-G 
EF-Tu(GTP)aminoacyl-tRNA ternary complexes were formed in a reaction 
containing final concentrations of 22.3 μM EF-Tu, 2.5 μM EF-Ts, 800 μM  GTP, 2.2 μM 
aa-tRNA, 2.5 mM phosphoenol-pyruvate, and 0.001 units/μL pyruvate kinase in 
Tris-polymix buffer. EF-Tu, EF-Ts and GTP were mixed first and incubated at 37 ºC for 1 
min, then cooled on ice for 1 min. aa-tRNA was then added and the mixture was 
incubated again for 1 min at 37 ºC and stored on ice until use. 
 A separate mixture containing final concentrations of 21 μM EF-G, 1 mM GTP, 3 µM 
phosphoenol-pyruvate and 0.001 units/μL pyruvate kinase in Tris-polymix buffer was 
prepared prior to use and stored on ice without incubation.  
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5.4.3 Di- and Tripeptide Assays 
 Before starting the translation reactions, EF-G was added to 70S initiation 
complexes carrying f-[35S]-Met-tRNAfMet. Ternary complexes containing ribozyme 
aminoacylated D/L-aa-tRNA charged with the second position amino acid (and synthetase 
charged L-aa-tRNA charged with the third position amino acid for tripeptide assays) were 
then added, and the translation reactions were incubated at 37 ºC in Tris-polymix buffer 
for the indicated time points. The final concentrations of reaction components, unless 
otherwise noted, were as follows: [70S]=0.5 μM; [f-[35S]Met-tRNAfMet]=0.25 μM; 
[mRNA]=1.9 μM; [EF-Tu]=10 μM; [2nd position D/L-aa-tRNA]=1.0 μM; [3rd position 
L-aa-tRNA]=1.0 μM; [EF-G]=1.7 μM. Translations were quenched with potassium 
hydroxide to a final concentration of 160 mM. Samples were spotted onto cellulose plates 
(EMD) and products were separated using electrophoretic thin layer chromatography 
(eTLC) in pyridine acetate buffer (5% pyridine, 20% acetic acid, pH 2.8) [12]. For all 
translations, eTLCs were run for 20 minutes at 1200 V, with the exception of 
fMet-D/L-Lys-Phe tripeptide translations, which were run for 30 minutes at 1200 V. 
eTLCs were then dried, exposed to a phosphor imaging screen (Amersham Biosciences) 
overnight, and analyzed using a Storm 860 phosphor imager (Molecular Dynamics). 
Spots were quantified using ImageQuant software. Percent tripeptide formed was 
calculated as (tripeptide counts)/(fMet counts + dipeptide counts + tripeptide counts). 
Similarly, percent dipeptide formed was calculated as (dipeptide counts)/(fMet counts + 
dipeptide counts). Percent fMet converted to di- or tripeptide as a function of time was fit 
to a single exponential function of the form y=A1(e-x/τ1)+y0 using Origin 7. The reciprocal 
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of τ1, measured in minutes, was divided by 60 to obtain kapp in units of s-1. Experiments 
were performed in duplicate, and the standard error between measurements is reported. 
T4gp321-20 mRNAs were used in all di- and tripeptide experiments. 
D/L-phenylalanine translations were performed on wild-type T4gp321-20. The second 
position of this wild-type mRNA, encoding for phenylalanine, was mutated to valine 
(F2V) for the D/L-valine translations. D/L-lysine translations were performed using 
T4gp321-20 (F2K K3F R4E K5V S6Y).  
 
5.4.4 Tetrapeptide Assay 
T4gp321-20 mRNA (R4E K5V S6Y) was used for fMet-D-Phe-Lys-Glu tetrapeptide 
translations. Ternary complexes were formed with Glu-tRNAGlu, D-Phe-tRNAPhe and 
Lys-tRNALys such that these three aa-tRNAs were at a final concentration of 1 μM in the 
translation reaction. The translation reaction was allowed to proceed for 10 minutes at 37 
ºC. Otherwise, conditions were identical to those described above for the Di- and 
Tripeptide Assays.  
 
5.4.5 Toeprinting Assay 
Translation reactions were carried out under conditions identical to those for the 
dipeptide assay described above, with three exceptions. First, fMet-tRNAfMet was added to 
a final concentration of 0.5 μM in the translation reaction. Second, T4gp321-224 mRNA 
variants, encoding the same 1-20 amino acids used for the corresponding di- and tripeptide 
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assays described above, were 1) employed at a final concentration of 0.25 μM in the 
translation reaction 2) annealed at the 3’ end to a γ-[32P]-ATP labeled cDNA primer (see 
below), and 3) limiting in the formation of 70S initiation complexes. Since 0.25 μM 
f-[35S]Met-tRNAfMet was the limiting reagent during formation of 70S initiation complexes 
used in the di- and tripeptide assays, the concentration of fully-initiated 70S ribosomes was 
the same in the di- and tripeptide assays and the toeprinting experiments. Third, reactions 
were quenched with viomycin [13] to a final concentration of 1 mM at the indicated time 
points.  
Primer extension inhibition assays were performed as described previously [13-14]. 
Briefly, to label the DNA primer, a reaction mixture containing 2.4 μM primer DNA 
(TATTGCCATTCAGTTTAG, Integrated DNA Technologies), 1.4 μM  γ-[32P]-ATP 
(Perkin Elmer), and 0.5 units/μL T4 polynucleotide kinase (New England Biolabs) in 1X 
polynucleotide kinase buffer (New England Biolabs) were incubated for 30 minutes at 37 
ºC. This was followed by incubation for 10 min at 75 ºC to inactivate T4 polynucleotide 
kinase and subsequent gel filtration through a G25 sephadex spin column (GE Healthcare) 
to remove unincorporated γ-[32P]-ATP. To anneal the 32P-labeled DNA primer to mRNA, a 
reaction mixture containing 5 μM mRNA and 0.25 μM 32P-labeled DNA primer in 25 mM 
Tris-acetate, pH25ºC 7, was incubated for 90 sec at 90º C and then slow cooled to room 
temperature. 
 The γ-[32P]-ATP primer-annealed mRNA was used at a final concentration of 0.25 
μM in the translation reaction, described above in “Di- and Tripeptide Assays”. Translation 
reactions were quenched with four reaction volumes of Toeprinting Mix (1.25 mM 
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viomycin, 625 μM each dGTP, dCTP, and dTTP, and 2.2 mM dATP in 1.25x Tris-polymix 
buffer, 12.5 mM magnesium acetate). mRNAs were then reverse transcribed by adding 
AMV reverse transcriptase (Promega) to a final concentration of 0.6 units/μL and 
incubated for 15 min at 37 °C. 5’-32P-labeled cDNA reverse transcription products were 
phenol extracted twice and chloroform extracted twice, resuspended in gel loading buffer 
(23 M formamide, 0.09% bromophenol blue and 0.09% xylene cyanol) and separated using 
9% denaturing polyacrylamide gel electrophoresis (PAGE). Gels were dried and analyzed 
by phosphor imaging.  
The toeprinting gels were analyzed using ImageQuant software in order to quantify 
the +15, +16, +18 and +19 gel bands. These bands correspond to the position of the 
ribosome along the mRNA, as the reverse transcriptase enzyme will stop generating cDNA 
when it encounters the ribosome along the message. The band at the +15 position reports on 
the position of 70S initiation complexes carrying fMet-tRNAfMet. Addition of 
D/L-aa-tRNA to 70S initiation complexes shifts the intensity of the band to the +16 
position; subsequent addition of EF-G shifts the intensity of the band again, now to the +18 
position. A reaction without 70S ribosomes was performed, the cDNA products from 
which appear in the control lane of all toeprinting gels, and the bands in this lane represent 
the natural pause sites for the reverse transcriptase enzyme along the mRNA. Unless 
otherwise noted, analysis of this control lane (data not shown) demonstrated that natural 
pausing at the +15 position, the +16 position, the +18 position and the +19 position were 
<2% of fully reversed transcribed mRNA. This analysis showed that natural pausing along 
the mRNA did not contribute meaningfully to the measured intensities in the experimental 
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lanes. In the “fMet-tRNAfMet” lane, both fMet-tRNAfMet and 70S ribosomes were added 
generating 70S initiation complexes carrying fMet-tRNAfMet and an increase in intensity of 
the +15 position. The addition of D/L-aa-tRNA in the absence of EF-G to the translation 
reaction containing 70S initiation complexes carrying fMet-tRNAfMet shifted the intensity 
to the +16 position, and the subsequent addition of EF-G shifted the intensity to the +18 
position. The ability of the ribosome to move 3 nucleotides, or one codon, along the mRNA 
from the +15 to the +18 position demonstrates one round of translocation. Unless otherwise 
noted, percent translocation was defined as the summed intensities of the +18 and +19 
bands divided by the summed intensities of the +15, +16, +18, and +19 bands, multiplied 
by 100.  
Percent translocation as a function of time obtained from toeprinting gels was fit 
to a single exponential function of the form y=A1(e-x/τ1)+y0 using Origin 7. The reciprocal 
of τ1, measured in minutes, was divided by 60 to obtain kapp in units of s-1. Experiments 
were performed in duplicate, and the standard error between measurements is reported. 
 
5.4.6 Nitrocellulose Filter Binding Assay 
Translation reactions were carried out under conditions identical to those 
described above for the dipeptide assay (in the presence of EF-G). 0.5 µL aliquots were 
removed from initiated 70S complexes before addition of ternary complex, representing 
the “0” time point, and from the translation reaction at the indicated time points. These 
0.5 µL aliquots were diluted into 49.5 µL Stop Buffer (50 mM Tris-hydrochloride, pH25ºC 
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7.5, 1 M ammonium chloride, 15 mM magnesium acetate). 30 µL of this mixture was 
then pipetted onto nitrocellulose filters that had been placed over wells of a vacuum 
manifold (Millipore) and pre-wetted with chilled Stop Buffer. Filters were then 
extensively washed with Stop Buffer. A flow rate of ~5 mL/minute was maintained 
through the nitrocellulose filters. Counts of f-[35S]Met bound to nitrocellulose filters were 
determined by scintillation counting. Experiments were performed at least three times and 
the standard deviation between measurements is reported. Percent f-[35S]Met bound to 
nitrocellulose filters as a function of time was fit to a single exponential function of the 
form y=A1(e-x/τ1)+y0. The reciprocal of τ1, measured in minutes, was divided by 60 to 
obtain kapp in units of s-1. 
 
5.4.7 Puromycin Reactivity 
Dipeptide translations were performed as described above. D-aminoacyl-tRNAs 
were allowed to react with f-[35S]Met-tRNAfMet for 10 min such that the dipeptide 
reaction was complete and dipeptidyl-tRNA was fully translocated into the P site. 
Puromycin in Tris-polymix buffer was then added to the translation mixture to a final 
concentration of 24 mM and the reaction was allowed to proceed at 37 ºC until the 
indicated time points. L-aminoacyl-tRNAs were allowed to react with 
f-[35S]Met-tRNAfMet for 2.5 min before puromycin addition. Reactions were quenched at 
a final concentration of 160 mM potassium hydroxide and products were separated using 
eTLC in pyridine acetate buffer (pH 2.8). Percent fMet converted to dipeptide-puromycin 
as a function of time was fit to a single exponential function of the form y=A1(e-x/τ1)+y0. 
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The reciprocal of τ1, measured in minutes, was divided by 60 to obtain kapp in units of s-1. 
Experiments were performed in duplicate, and the standard error between measurements 
is reported. 
 
5.5 Generation of ∆dadA and ∆dtd Single Deletion Strains  
The E. coli genes encoding for the D-aminoacid dehydrogenase (dadA) enzyme and 
the D-aminoacyl-tRNA deacylase (dtd) enzyme are both non-essential and were replaced 
with the antibiotic resistance cassettes for kanamycin and chloramphenicol, respectively 
in separate E. coli BW25113 (rrnB3 ∆lacZ4787 hsdR514 ∆(araBAD)567 ∆(rhaBAD)568 
rph-1) strains. This was achieved using the λ Red Recombinase plasmid system designed 
by Datsenko and Wanner. [15-16] and performed to create single gene knockouts identical 
to those in the Keio collection [15]. Briefly, pKD13 and pKD3 plasmids were used as 
templates to generate kanamycin and chloramphenicol resistant plasmids, respectively by 
PCR amplification. The exact primer sequences for dadA were as follows: 
 
H1 5’GATTAGA TTATTATTCT TTTACTGTAT CTACCGTTAT CGGAGTGGCTATG3’ 
P1 5’CATATGAATATCCTCCTTAGTTCCTATTCCG3’ 
 
H2 5’GCCTGTATCG GACGGGTCAT CTCGTTTCCT TAGCTGTGTG CGCCATGTAA3’ 
P2 5’TGTGTAGGCTGGAGCTGC3’ 
 
(Note: There are 9nt between the end of the dada gene and the beginning of the dadA gene) 
 
The exact primer sequences for dtd were a follows: 
 
 
H1 5’ TACCGCAAA CTAAAACAAG CAGCTGAACA AGAAGAAGAC GACGAACCATG3’  
P1 5’ATTCCGGGGATCCGTCGACC3’ 
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H2 5’TGTTTCCCGT GACAACCCTG GAAGCTGGCT CATACCTGCA ACCAGAATGT3’  
P2 5’TGTAGGCTGGAGCTGCTTCG’3 
 
(dtd ends at 4,075,475. yiiD begins at 4,075,472 (i.e. within dtd, though near the end of the gene)) 
 
Primers were comprised of ~20nt 3’ end for priming upstream (P1) and downstream (P2) of 
the FLP recombinase recognition target (FRT) sites flanking the antibiotic resistance gene 
in pKD13 or pKD3 and ~50nt 5’ ends homologous to upstream (H1) and downstream (H2) 
of chromosomal sequences targeted for insertion (Figure). Primers were designed such that 
the fMet initiation codon and the last 6 amino acids plus the stop codon, or 21 base pairs, 





Figure 5.9. Primer design scheme. Figure reproduced from [15]. 
 
transformed with the Red helper plasmid pKD46 [17]. The PCR reaction was set-up as 
follows:  
4µL 80pg/µL pkD13 (for kanamycin casette) or pkD3 (for chloramphenicol cassette) DNA 
1µL 20µM Primer H1P1 
1µL 20µM Primer H2P2 
90µL Platinum PCR Supermix (Invitogen) 
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PCR Cycles were as follows: 
1. 94ºC, 30 seconds 2. 59ºC, 30 seconds 3. 72ºC, 2 minutes 4. Back to step 1, 29X 
 
PCR products were cleaned-up using the Qiagen PCR purification kit and tested on a 1% 









Figure 5.10. PCR verification of single knock-out dadA and dtd strains. Genomic DNA 
from wild-type and the D-aminoacid dehydrogenase (dadA) null strains were PCR 
amplified with primers 200nt upstream and downstream of the dadA gene, revealing the 1.7 
Kb dadA gene DNA product (Lane 2) in the wild-type strain and the 1.3 Kb 
chloramphenicol resistance gene (CAT) DNA product (Lane 3) in the dadA null strain. This 
1% agarose gel confirms the deletion of the dadA gene and its replacement with CAT. 
Genomic DNA from wild-type and the D-aminoacyl-tRNA deacylase (dtd) null strains 
were PCR amplified with primers 200nt upstream and downstream of the dtd gene, 
revealing the 0.8 Kb dtd gene DNA product (Lane 4) in the wild-type strain and the 1.6 Kb 
kanamycin resistance gene (KAN) DNA product in the dtd null strain. This 1% agarose gel 
confirms the deletion of the dtd gene and its replacement with KAN. Note that the dadA 
gene is ~1.3Kb, but the gene migrates at 1.7Kb because the primers added 0.4Kb, or 200nt, 
upstream and downstream of the PCR product. Similarly, CAT is ~0.9Kb, dtd 0.4Kb, and 
KAN 1.2Kb, but migrate at 1.3Kb, 0.8Kb and 1.6Kb, respectively, due to the primers 
amplifying the genomic DNA 200nt upstream and downstream of each gene. 
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harboring the pkD46 plasmid were electroporated with 750ng of the chloramphenicol 
cassette with sites homologous to the dadA gene or 750ng of the kanamyicn cassette with 
sites homologous to the dtd gene. Cells were grown for 2 hours in SOC medium containing 
1mM arabinose and plated onto plates containing the appropriate antibiotic. To verify gene 
knock-outs, colonies that successfully grew when plated on the appropriate antibiotics were 
picked and grown overnight in 5mL LB supplemented with the appropriate antibiotic. The 
following components were then mixed: 
1µL cells (grown overnight) 
0.4µL 10µM P1 (200nt upstream of gene) 
0.4µL 10µM P2 (200nt downstream of gene) 
18.2µL Platinum PCR Supermix (Invitrogen) 
PCR cycles were as follows: 
1. 95ºC, 5 minutes 2. 94ºC, 30 seconds 3. 55ºC, 30 seconds 4. 68ºC, 1 minute 5. Back to 
step 2, 29X. 
PCR products were cleaned-up using the Qiagen PCR purification kit, run on a 1% gel 
(Figure 5.10) and sent to Genewiz for sequence verification. 
 
5.6 Generation of ∆dadA/∆dtd Double Deletion Strain  
 P1vir transduction (http://openwetware.org/wiki/Sauer:P1vir_phage_transduction)  
was employed to generate the ∆dadA/∆dtd double deletion strain from single ∆dadA 
deletion and ∆dtd deletion strains. The P1 phage was used to infect the ∆dtd (donor) strain 
and transduce the kanamycin resistance cassette into the ∆dadA (recipient) strain, 
generating a ∆dadA/∆dtd strain with resistance to both kanamycin and chloramphenicol. 
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The protocol described below follows similar protocols described at the Sauer website (link 
above) and from Jingyi Fei’s Thesis.  
 
5.6.1 Preparation of Donor Lysate 
5mL of the donor ∆dtd strain was grown overnight in LB media supplemented with 
kanamycin. 30µL of the overnight culture was diluted with 3mL LB (1:100 dilution) 
supplemented with 5 mM CaCl2 and 0.2% glucose. No antibiotics were used in the dilution. 
Cells were grown at 37ºC for 1-3 hours, enough time for the culture to begin to get cloudy 
due to cell growth. At this point, 100µL P1 phage was added. The culture was grown, again 
at 37ºC for 1-3 hours, until the culture became clear again, due to the P1 phage lysing the 
bacterial cells. Several drops of chloroform were then added to the P1 lysed cells. The cells 
were vortexed and then centrifuged at 14,000 rpm for 2 minutes. The supernatant was 
transferred to a fresh eppendorf tube. After adding several more drops of chloroform, the 
∆dtd donor lysate was stored at 4ºC. 
 
5.6.2 Transduction 
 2mL of the recipient ∆dadA strain was grown overnight in LB media supplemented 
with chloramphenicol. The wild-type strain was also grown overnight in a 2mL culture. 
Both cultures were pelleted by centrifuging at 6,000 rpm for 2 minutes. Supernatants were 
discarded and the pellets were resuspended in ~ 700µL of LB supplemented with 100 mM  
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Figure 5.11. PCR verification of P1 phage generated double knock-out dadA null and dtd 
null strain. Primers 200nt downstream and upstream of the D-amino acid dehydrogensase gene 
(dadA) and the D-aminoacyl-tRNA deayclase gene (dtd) were used to probe genomic DNA from 
the wild-type strain (WT, Lanes 1 and 2), genomic DNA from colonies that were able to grow on 
both chloramphenicol and kanamycin after P1 transduction (P1 1, Lanes 3 and 4; P1 2, Lanes 5 
and 6; P1 3, Lanes 7 and 8) and genomic DNA from single deletion strains of dadA (Lane 9) and 
dtd (Lane 10). Lane 1: primers 200nt upstream and downstream of the dtd gene amplifying 
genomic DNA from the wild-type strain demonstrate the migration of the dtd gene. Lane 2: 
primers 200nt upstream and downstream of the dadA gene amplifying genomic DNA from the 
wild-type strain demonstrate the migration of the dadA gene. Lanes 3, 5, 7 and 9: primers 200nt 
upstream and downstream of the dadA gene demonstrate that the chloramphenicol resistance gene 
(CAT) has been inserted in place of dadA in P1 1 (Lane 3), P1 2 (Lane 5), P1 3 (Lane 7) and the 
single knockout dadA null strain as a control (Lane 9). Lanes 4, 6, 8 and 10: primers 200nt 
upstream and downstream of the dtd gene demonstrate that the kanamycin resistance gene (KAN) 
has been inserted in place of dtd in P1 1 (Lane 4), P1 2 (Lane 6), P1 3 (Lane 8) and the single 
knockout dtd null strain (Lane 10). This 1% agarose gel demonstrates that in each of the P1 
transduced strains, the genes encoding for dadA and dtd have been replaced with the antibiotic 
resistance genes for chloramphenicol and kanamyicn, respectively.  
 
 
MgSO4 and 5 mM CaCl2. Four reaction mixtures were set-up as follows: 
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1. 100 μL ∆dtd donor lysate + 100 μL ∆dadA recipient culture 
2. 100 μL 1:10 diluted ∆dtd donor lysate + 100 μL ∆dadA recipient culture 
3. 100 μL donor ∆dtd lysate + 100 μL LB supplemented with 100 mM MgSO4 and      
  5 mM CaCl2 
4. 100 μL LBsupplemented with 100 mM MgSO4 and5 mM CaCl2 
  + 100 μL ∆dadA recipient culture 
The reactions were incubated at 37ºC for 30 minutes, at which point 200µL of 1M sodium 
citrate (pH 5.5) was added along with 1mL of LB. The cultures were incubated at 37ºC   
subsequently made. Verification of the double knock-out ∆dadA/∆dtd strain was 
performed as described for the single-knock out strains using both PCR verification 
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Table 5.1: Fitting Parameters, rates and endpoints for experimental data (a). 
Experiment A1 (%) (b) τ1 (min) (b) y0 (%) (b) R2 (b) kapp (s-1) (c) Endpoint (%) (d) 
fMet-D-Phe-Lys 
Tripeptide 
-17.05 3.79 17.14 0.99 0.004 ± 0.001 18 ± 3 
fMet-D-Val-Lys 
Tripeptide 
-10.01 17.01 11.21 0.98 0.0010 ± 0.0001 11 ± 1 
fMet-D-Lys-Phe 
Tripeptide 
-52.71 0.69 53.49 0.98 0.024 ± 0.001 58 ± 5 
fMet-D-Phe 
Dipeptide 
-73.56 0.84 77.94 0.97 0.020 ± 0.004 81 ± 3 
fMet-D-Val 
Dipeptide 
-81.86 3.18 84.70 0.99 0.0052 ± 0.0004 87 ± 1 
fMet-D-Lys 
Dipeptide 
-75.56 0.34 76.82 0.98 0.05 ± 0.01 81 ± 5 
fMet-D-Phe 
Filter Binding 
45.19 61.96 34.70 0.97 0.0003 ± 0.0003 34 ± 8 
fMet-L-Phe 
Filter Binding 
24.78 33.76 56.82 0.99 0.0005 ± 0.0003 52 ± 8 
fMet-D-Val 
Filter Binding 
N/D(e) N/D(e) N/D(e) N/D(e) N/D(e) 50 ± 9 
fMet-L-Val  
Filter Binding 
N/D(e) N/D(e) N/D(e) N/D(e) N/D(e) 65 ± 13 
fMet-D-Lys 
Filter Binding 
28.61 13.73 55.09 0.83 0.0010 ± 0.0002 34 ± 8 
fMet-L-Lys 
Filter Binding 
24.19 21.08 53.71 0.87 0.0012 ± 0.0001 52 ± 8 
fMet-D-Phe 
Toeprinting 
-77.08 0.87 77.20 0.99 0.019 ± 0.001 78 ± 5 
fMet-D-Val  
Toeprinting 
-56.70 5.15 58.01 0.99 0.0032 ± 0.0003 59 ± 4 
fMet-D-Lys 
Toeprinting 
-50.64 1.46 48.71 0.96 0.011 ± 0.002 42 ± 8 
fMet-D-Phe 
Puromycin 
-16.04 0.18 16.20 0.92 0.09 ± 0.08 18 ± 1 
fMet-D-Val 
Puromycin 
-14.66 1.38 17.59 0.91 0.012 ± 0.018 19 ± 1 
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(a) All data were fit to the following equation using Origin 7: y=A1(e-x/τ1)+y0. 
(b) Reported fitting parameters were obtained by plotting and fitting the average of each time point in two (dipeptide, 
tripeptide and puromycin) or three (filter binding) experimental trials. 
(c)The error for the kapp was calculated in the following manner. First, each of the two runs were plotted and fit to the 
above equation, generating individual τ1 values and individual kapp’s for each run. The standard error from these kapp’s is 
reported. 
(d) The 60 min timepoint for each of the two (dipeptide, tripeptide and puromycin) or three (filter binding) experimental 
trials were averaged in order to determine the endpoint. The standard error is reported for experiments with two trials 
and the standard deviation is reported for experiments with three trials. 
(e) The change in percent f-[35S]Met-Val-tRNAVal bound to ribosomes changes very little as a function of time during 
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Appendix 
 
This appendix is a compilation of protocols that I have used during the course of my 
Ph.D., and gives comprehensive information as to how to perform the experiments 
described in Chapter 5. 
 
A.1 Ribosome Purification  
 
Note: The protocol for this preparation is reproduced in its entirety from the Gonzalez 
laboratory protocol and is also described in [1]. This protocol describes a procedure for 
the purification of tight-coupled 70S ribosomes from Escherichia coli strain MRE600 and 
30S and 50S subunits derived from tight-coupled E.coli MRE600 ribosomes. While the 
protocol can be easily adapted for the purification of these ribosomal particles from other 
strains of E.coli, other bacterial species, and even eukaryotic species, experience has 
shown that the definition of “tight-coupled” will vary. Typically “tight-coupled” 70S 
ribosomes are those 70S ribosomes that persist complexed as 70S ribosomes (rather than 
splitting into 30S and 50S subunits) at some defined concentration of Mg2+. In the case of 
E.coli MRE600 the Mg2+ concentration used to define “tight-coupled” 70S ribosomes is 5 
mM; this will need to be re-optimized when applying this protocol to other strains or 
species. This protocol is primarily based on previously published protocols: 
 
Robertson, J.M. and Wintermeyer, W. (1981) Effect of translocation on topology and 
conformation of anticodon and D loops of tRNAPhe. J Mol Biol. 151(1):57-79.  
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Powers, T. and Noller, H.F. (1991) A functional pseudoknot in 16S ribosomal RNA. 
EMBO J. 10(8):2203-14. 
 
Blanchard S.C., Kim H.D., Gonzalez R.L. Jr, Puglisi J.D. and Chu S. (2004) tRNA 




Buffer A   Stock  Volume per 500 mL  Notes: 
20 mM Tris HCl, pH=7.2 @ 4°C 1 M 10 mL  Needd 100 mL for 
100 mM NH4Cl  3 M 16.7 mL harvesting cells 
10 mM MgCl2  4.9 M 1020 µL and 20 ml for lysis 
0.5 mM EDTA  0.5 M 500 µL 
6 mM BME   14.3 M 210 µL* 
 
Buffer B + Sucrose  Stock Volume per 250 mL  Notes: 
20 mM Tris HCl pH=7.2 @ 4°C 1 M 5 mL Need 35 ml for 
500 mM NH4Cl  3 M 41.7 mL sucrose cushion. 
10 mM MgCl2  4.9 M 510 µL 
0.5 mM EDTA  0.5 M 250 µL 
6 mM BME   14.3 M 105 µL* 
37.7% Sucrose  60% 157.1 mL 
 
Buffer C ± sucrose  Stock Volume per 250 mL Notes: 
10 mM Tris OAc pH=7.5 @ 4°C 1 M 2.5 mL Need 100 ml for 
60 mM NH4Cl  3 M 5 mL resuspending  
7.5 mM Mg(OAc)2  1 M 1.88 mL ribosomes and  
0.5 mM EDTA  0.5 M 250 µL     filling Ti70. 
6 mM BME   14.3 M 105 µL* Six SW28 gradients 
If + 10% Sucrose  60% 41.7 mL require 125 ml of  
If + 40% Sucrose  60% 166.7 mL each 10% and 40%  




Buffer D ± sucrose  stock volume per 250 mL
 Notes: 
10 mM Tris OAc pH=7.5 @ 4°C 1 M 2.5 mL 
60 mM NH4Cl  3 M 5 mL 
1 mM Mg(OAc)2  1 M 250 µL 
0.5 mM EDTA  0.5 M 250 µL 
6 mM BME   14.3 M 105 µL* 
If + 10% sucrose  60% 41.7 mL 
If + 40% sucrose  60% 166.7 mL 
 123     Appendix 
 
* BME must be added just prior to use 
 
Making SW28 Gradients 
1. All solutions must be at room temperature. 
2. Add 52.5 µL BME to 125 ml 10% sucrose solution. 
3. Add 52.5 µL BME to 125 ml 410% sucrose solution. 
4. Prepare six SW28 tubes by marking using the aluminum holder. 
5. Pipet 20 ml 10% sucrose solution into each tube. 
6. Using syringe with needle, place 40% sucrose solution underneath 10% sucrose 
solution until the interface between solutions reaches the mark line (~19 ml). 
7. Close tubes with rubber caps carefully to expel all air. 
8. Level Biocomp Gradient Master. 
9. Set Gradient Master: 
 SW28 short sucrose 10-40% wv 
 step 1 of 2 6:00/52.0°/25 rpm 
 step 2 of 2 0.07/76.0°/25 rpm 
10. Chill gradients to 4°C in cold room overnight. 
 
Making SW41 Gradients 
1. All solutions must be at room temperature. 
2. Add 21 µL BME to 50 ml 10% sucrose solution. 
3. Add 21 µL BME to 50 ml 410% sucrose solution. 
4. Prepare six SW41 tubes by marking using the aluminum holder. 
5. Pipet 6 ml 10% sucrose solution into each tube. 
6. Using syringe with needle, place 40% sucrose solution underneath 10% sucrose 
solution until the interface between solutions reaches the mark line (~6 ml). 
7. Close tubes with rubber caps carefully to expel all air. 
8. Level Biocomp Gradient Master. 
9. Set Gradient Master: 
 SW41 short sucrose 10-40% wv 
 step 1 of 1 1:48/81.5°/17 rpm 




Growing Cells    Notes: 
 
Day 1 
Inoculate 3 mL 2xYT/carb with MRE600 cells from frozen       Time required: 1 hr 
Stock. Culture might grow better if it’s inoculated from a freshly  
streaked plate. Shake at 37°C overnight (~16 h). 
 
Day 2 
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Inoculate 1.5 L 2xYT/carb prewarmed at 37°C with 0.5 mL       Time required: 10 hr 
overnight culture. Have two 1.5 L cultures, each in a 4 L 
flask, total culture = 3 L. Shake at 37°C until A600 = 0.5 
 
Pour entire 1.5 L culture from each flask into a big plastic beaker 
with 1.5 L crushed ice to rapidly cool cells down to 4°C 
 
Transfer to a big 1 L tube     
Spin in JLA-8.1 ( use JA-10 instead) rotor at 5000g for 10 min      
 
Resuspend and combine pellets in 100 mL Buffer A 
Transfer to preweighed JA-10 tube 
 
Spin in JA-10 rotor at 5500g for 10 min JA-10 rotor can be 
 set to 5500 g 
Discard supernatant and weigh pellets (usually 3 to 4 g) 
 
If necessary, freeze pellets in liquid nitrogen and store at -80°C 
Ideally however, one would continue with the purification without freezing
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Ribosome Purification  Notes:     
 
Day 1 
Add 20 mL Buffer A to frozen pellet  Time required: 3 hr 
Thaw and resuspend cells with 25 mL pipette 
  Protease Inhibitors                            
Add 100 μL of each protease inhibitor  100 µL AEBSF (10x) 
Add 50 µL of RNase inhibitor (30 u/µL)  100 µL bestatin (10x) 
Transfer to 50 mL Falcon tube  100 µL pepstatin A (10x) 
   100 µL E-64 (10x) 
 
Rinse French press with NanoPure H2O 
Lyse cells with pressure 1800 psi (gauge pressure of  
1000 psi at medium ratio)Collect lysate into 50 mL  
Falcon tube with 50 µL RNase inhibitor (30 u/µL) 
Transfer to JA-20 tube and rinse Falcon tube with  
2 mL Buffer A 
 
Spin in JA-20 rotor at 16000 rpm (use JA-17 at  
12800 RPM) for 15 min.   For JA-20 rotor 
Transfer supernatant into clean JA-20 tube  16000 rpm = 30000 g 
Rinse pellet with 5 mL Buffer A 
Combine with supernatant 
Spin in JA-20 rotor at 16000 rpm for 15 min 
 
Layer clear supernatant (~ 28 mL) onto 35 mL Buffer 
B sucrose cushion in Ti45 tube 
Fill tube to shoulder with Buffer A and balance 
Spin in Ti45 rotor at 33000 rpm for 22 h 
Here use Ti70 instead. The sucrose cursion should be  
15ml and the supernatant should be 8-9ml Centrifuge  
at 33000 rpm for 22h.   
                           Ti45 rotor (fixed angle) (Ti70 rotor) 
   33000 rpm (30000rpm) 
    accel = max 
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Day 2 
Discard supernatant = high salt wash 
Circle ribosome pellet 
Invert Ti45 (Ti70) tube on clean paper towel in cold room 
Allow to drain for 10 min 
 
Add ~ 2 mL Buffer C to pellet 
Place tube at an angle on the rotary shaker in cold room 
Shake for 2-6 h at speed 7-8 until resuspended 
 
Dilute 1:1000 in H2O and take A260 reading          Time required: 1hr 
 
         1 A260 unit = 1/15 mg/mL 
           1 A260 unit = 20 nM 
 
Remove small volume of sucrose from top of SW28 
Gradients Apply ~ 15 mg resuspended ribosomes per gradient 
Spin in SW28 rotor at 22000 rpm for 17 h   SW28 rotor 
    22000 rpm 
    accel = slow (7) 
    decel = no brake (0)
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Day 3 
Analyze gradients   Time required: 6 hrs 
 
 wavelength = 260 nm 
 pathlength = 1 mm 
 sensitivity = 2.0 
 flow rate = 1.5 mL/min 
 chart speed = 15 cm/h 
 reference cell = H2O 
 1/4 open 
 
Collect 70S and polysome peaks from each gradient 
Volume collected ~8 mL per gradient 
 
Place in Ti70 tubes 
Fill tubes with Buffer C 
 
Spin in Ti70 rotor at 45000 rpm for 20 h   Ti70 rotor 
    45000 rpm 
    accel = max 
    decel = max 
Day 4 
Discard supernatant and circle ribosome pellets  Time required: 1 hr 
Invert Ti70 tubes on clean paper towel in cold room 
Allow to drain for 10 min 
 
Add ~1 mL Buffer C to each pellet 
Place tubes at an angle on the rotary shaker in cold room 
Shake for 1-2 h at speed 7-8 until resuspended 
 
Take A260 of 1:1000 dilution 
 
Remove small volume of sucrose from top of SW28 gradients Time required: 1 hr 
Apply ~ 15 mg resuspended ribosomes per gradient 
Spin in SW28 rotor at 22000 rpm for 17 h   SW28 rotor 
    22000 rpm 
    accel = slow 
    decel = no brake
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Day 5 
Analyze gradients   Time required: 6 hrs 
 
Collect 70S and polysome peaks from each gradient 
Volume collected ~ 8 mL per gradient 
 
Place in Ti70 tubes 
Fill tubes with Buffer C 
 
Spin in Ti70 rotor at 45000 rpm for 20 h   Ti70 rotor 
    45000 rpm 
    accel = max 
    decel = max 
Day 6 
Discard supernatant and circle ribosome pellets  Time required: 1 hr 
Invert Ti70 tubes on clean paper towel in cold room 
Allow to drain for 10 min 
 
Add total ~ 400 μL Buffer C to each pellet 
Place tubes at an angle on the rotary shaker in cold room 
Shake for 1-2 h at speed 7-8 until resuspended 
 
Take A260 of 1:1000 dilution    Time required: 3 hr 
 
Make ~ 25 µL aliquots of resuspended 70S 
Freeze in liquid nitrogen 
Store at -80°C
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Preparation of 30S and 50S Subunits   Notes: 
 
Day 6 (Continued) 
Dialyze resuspended 70S against 500 mL Buffer D for 3 h Time required: 1 hr 
This low Mg2+ buffer should dissociate 70S into 30S and 50S 
Alternatively you can filter resuspended 70S through P30  
column (BioRad)or Sephadex G50 column (Amersham) 
 prewashed with 3 mL Buffer D 
 
Remove volume of sucrose from top of SW28 gradient made  
with Buffer D. Apply entire dialyzed or filtered sample to this  
gradient. Spin in SW28 rotor at 22000 rpm for 17 h  SW28 rotor    
    22000 rpm 
    accel = slow 




Collect 30S and 50S peaks from low Mg2+ gradient 
Volume collected ~ 5 mL 30S and ~ 5 mL 50S 
 
Place into separate Ti70 tubes 
Adjust Mg2+ concentration to final 5 mM with 1 M Mg(OAc)2 
Fill all tubes with Buffer C 
Spin in Ti 70 rotor at 45000 rpm for 24 h   Ti70 rotor 
    45000 rpm 
    accel = max 




Discard supernatant and circle ribosome pellets  Time required: 1 hr 
Invert Ti70 tubes on clean paper towel in cold room 
Allow to drain for 10 min 
 
Add ~ 250 µL Buffer C to each pellet 
Place tubes at an angle on the rotary shaker in cold room 
Shake for 1-2 h at speed 7-8 until resuspended 
 
Take A260 of 1:500 dilution    Time required: 3 hr 
 
  30S: 1 A260 unit = 79 nM 
  50S: 1 A260 unit = 38 nM 
  70S: 1 A260 unit = 20 nM 
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Make ~25 µL aliquots of resuspended 30S and 50S 
Freeze in liquid nitrogen 
Store at -80°C 
 
A.2 Tev Protease, EF-Tu, EF-Ts and EF-G Protein Purifications  
Note: The protocol for this preparation is reproduced in its entirety from the Gonzalez 
laboratory protocol and is also described in [1]. 
 
Reagents 
Terrific Broth (TB) Growth Media (4 x 2L in 6L flasks) 
Autoclave 45min 
Italics denote recipe’s for EF-Tu prep. 
 
Cell Storage Buffer (250 ml)    Recipe for 250 ml: 
10 mM Tris-HCl, pH4°C =7.5    2.5 ml 1 M Tris-HCl, pH4°C =7.5 
100 mM NaCl       12.5 ml 2 M NaCl 
2 mM β-mercaptoethanol (BME)   35 µl 14.3 M BME 
 
Lysis and Equilibration Buffer (200 ml)  Recipe for 200 ml: 
20 mM Tris-HCl, pH4°C =7.5    4 ml 1 M Tris-HCl, pH4°C =7.5  
300 mM NaCl       30 ml 2 M NaCl 
10 mM Imidazole, pHRT=8.0    1 ml 2M Imidazole, pHRT=8.0 
2 mM BME      28 µl 14.3 M BME 
200uM GDP      200uL 200mM GDP, pH 7 
0.5mM MgCl2     100uL 1M MgCl2 
 
 
Wash Buffer (100mL )    Recipe for 100 ml: 
20 mM Tris-HCl, pH4°C =7.5    2 ml 1 M Tris-HCl, pH4°C =7.5  
300 mM NaCl       15 ml 2 M NaCl    
30 mM Imidazole, pHRT=8.0    1.5 ml 2M Imidazole, pHRT=8.0  
2 mM BME      14 µl 14.3 M BME    
200uM GDP      100uL 200mM GDP, pH 7 
0.5mM MgCl2     50uL 1M MgCl2 
 
 
Elution Buffer (15 ml)    Recipe for 15 ml: 
20 mM Tris-HCl, pH4°C =7.5    0.3 ml 1 M Tris-HCl, pH4°C =7.5 
500 mM NaCl       3.75 ml 2 M NaCl 
250 mM Imidazole, pHRT=8.0   1.875 ml 2M Imidazole, pHRT=8.0 
2 mM BME      2.1 µl 14.3 M BME 
200uM GDP      15uL 200mM GDP, pH 7 
0.5mM MgCl2     7.5uL 1M MgCl2 
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1x Tev Protease Buffer (1 L)    EF-Tu:1L dialysis buffer (1x) 
20 mM Tris-HCl, pH4°C =7.5    20mL 1M Tris-HCl 
0.2 M NaCl       100mL 2M NaCl 
0.1% Triton-X      1mL 100% Triton X 
2 mM BME      140uL 14.3M BME  
200uM GDP      1mL 200mM GDP 
0.5mM MgCl2     500uL 1M MgCl2 
 
 
Translation Factor Buffer (1x)   Recipe for 500mL (2x): 
10 mM Tris(OAc), pH4°C =7.5   10 ml 1 M Tris-OAc,  
50 mM KCl       25 ml 2 M KCl 
5 mM BME      350 µl 14.3 M BME 
50% Glycerol       
200uM GDP      1mL 200mM GDP, pH 7 
0.5mM MgCl2     500uL 1M MgCl2 
 
 
Tev Protease Cell Growth and Harvesting 
• Grow fresh 5 ml overnight culture of Tev Pro in TB Growth Media containing 100μg/ml 
carbenecillin and 50μg/ml chloramphenicol at 37 °C with vigorous shaking. 
• Use the 5 ml culture to innoculate 2 L of TB Growth Media containing 100μg/ml 
carbenecillin and 50μg/ml chloramphenicon and grow cells at 37 °C with vigorous 
shaking. Doubling time was ~20min.  
• Induce cells by adding 2ml 1M IPTG solution to the 2L culture (1mM final [IPTG]) 
when cells reach an A600 of 0.8-1.0. 
• Grow for 2 hours post induction at 37 °C with vigorous shaking. 
• Harvest cells using 1L bottles and centrifuging at 4,000 RPM in a JLA for 20min. 
• 1L cell pellets were washed with cold Cell Storage Buffer and stored at –20 °C. 
• Run a protein gel to check for induction. 
 
EF-Tu, EF-TS and EF-G Cell Growth and Harvesting 
• Grow fresh 5 ml overnight cultures of each cell strain in TB Growth Media containing 
100μg/ml carbenecillin at 37 °C with vigorous shaking. 
• Use the 5 ml cultures to innoculate 2 L of TB Growth Media containing 100μg/ml 
carbenecillin and grow cells at 37 °C with vigorous shaking. Doubling times were 
~25min with EF-Tu growing significantly slower than EF-Ts and EF-G.  
• Induce cells by adding 2ml of a 1M IPTG solution to each 2L culture (1mM final 
[IPTG]) when cells reach an A600 of 0.8-1.0. Upon induction, lower the temperature to 
30 °C and grow overnight with vigorous shaking. 
• Harvest cells using 1L bottles and centrifuging at 4,000 RPM in a JLA for 20min. 
• 1L cell pellets were washed with cold Cell Storage Buffer and stored at –20 °C. 
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• Run a protein gel to check for induction. 
 
Note: Tev Protease may be produced as an approximately 50kDa pre-protein that is later 
cleaved (autocatalytically?) into the final active 27.5kDa protease. 
 
Tev Protease Purification 
Cell Lysis 
• All steps from here on are done at 4 °C or on ice. 
• Resuspend cell pellet in 20ml of Lysis and Equilibration Buffer. 
• Save 2 μl of resuspended cell pellet for SDS-PAGE analysis. 
• Sonicate on ice for 10 sec with a sonicator equipped with a microtip at maximum 
setting.  
• Allow cooling on ice-water for 30 sec to avoid overheating the sample. Repeat 
sonication-cooling cycle six times or until extract is clear. 
• Clarify lysate by centrifugation at 10,000xg for 30 min. 
• Save 2 μl of cleared lysate for SDS-PAGE analysis. 
 
Ni-NTA Column Equilibration 
• Pour 5ml of Ni-NTA column material (QIAGEN) into a disposable column 
• Equilibrate the Ni-NTA media by running 50 ml Lysis and Equilibration Buffer through 
the column. 
 
Batch Binding of 6His-Tagged Proteins to Ni-NTA 
• Plug the bottom of the column and pour 5 ml of the cleared lysate into the column with 
the pre-equilibrated Ni-NTA column material. Mix Ni-NTA column material and 
cleared lysate by pipetting up and down and transferring to a 50 ml Falcon tube. Add 5 
more ml of cleared lysate to the disposible column, mix and transfer to the Falcon tube. 
Do this until all of the Ni-NTA column material from the disposable column is mixed in 
the Falcon tube with all of the cleared lysate. 
• Place the Falcon tube on a rotator in the cold room and allow to mix/rotate for 30 min. 
• When mixing is done, pour the mixture back into the disposable column and collect the 
flow thru. 




• Wash the column with 2x50 ml of Wash Buffer—collect flow thru into 2 tubes. 
 
Elution 
• Elute the Tev Protease 4 times with 2.5 ml Elution Buffer. Collect the eluate in 4 tubes 
and analyze cell pellet, lysate supernatant, column binding flow thru, equilibration wash 
flow thru, both wash flow thrus, and the four eluate fractions by SDS-PAGE. 
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Dialysis and Concentration 
• Pool relevant fractions (I pooled fractions 1 and 2) and dialyze against 1x Tev Protease 
Buffer. 
• Use Bradford assay to determine concentration and yield. Concentrate Tev protease 
using Amicon filtration devices to 2 mg/ml, add 100% glycerol to make it 1x in Tev 
Protease Buffer, 50% glycerol and 1mg/ml final concentration. Store at –20 °C. My 
final yield was 7 ml @ 1 mg/ml (10 units/μl) per 1 L of culture.  
• Bradford Assay for EF-Tu prep of 12/8/06 indicated an estimated 44mg of protein.  
 
 
EF-Tu, EF-Ts and EF-G Purification 
Cell Lysis, Column Equilibration, Batch Binding, Wash and Elution 
• Cell lysis, column equilibration, batch binding, wash and elution of the translation 
factors were performed identically to that described above for Tev Protease. The only 
difference was that the lysate was cleared by centrifugation at 35,000 rpm in a Ti45 
Rotor for 30 min (or 10,000g for 30 min). SDS-PAGE gel analyses are shown below. In 
all cases I pooled fractions 2 and 3 resulting in ~5 ml volume of each factor. 
 
6His-Tag Cleavage 
• The pooled fractions of each purified translation factor dialyzed against 1x Tev Protease 
Buffer to remove imidazole. Save 5 μl of each uncleaved translation factor for 
SDS-PAGE analysis. 
• 5,000 units of Tev Protease were then added to each dialysis bag. The cleavage reaction 
was allowed to progress in the dialysis bag while continuing to dialyze overnight 
against fresh 1x Tev Protease Buffer. 
• In the morning run SDS-PAGE to assess cleavage. If necessary, add an additional 5,000 
units to each dialysis bag and allow the reaction to progress while dialyzing against 
fresh 1x Tev Protease Buffer @ room temperature for 2-3 hours. 
• Cleavage is complete when >90% of the protein is cleaved as determined by SDS-PAGE. 
As seen on the gel below, due to the different molecular weights of the translation 
factors and the different changes in molecular weight upon cleavage, cleavage of EF-Ts 
is easiest to visualize and EF-G is hardest. 
 
Removal of Tev Protease and 6His-Tags 
• The translation factors were transferred from the dialysis bags to 50 ml Falcon tubes and 
2.5 ml of Ni-NTA (pre-equilibrated against 1x Tev Protease Buffer) was added to each 
Falcon tube. NOTE: If the volume of the translation factor is larger than 10ml then 
concentrate to 10ml using an Amicon filtration device before adding the 2.5 ml of 
Ni-NTA. 
• Place the Falcon tube on a rotator in the cold room and allow to mix/rotate for 1 hr. 
• When mixing is done, pour the mixture into a 10ml disposable column and collect the 
flow thru. 
• Wash column with 5 ml of 1x Tev Protease Buffer to collect any remaining unbound 
protein. 
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• Dialyze elution in 500mL 2x Translation Factor Buffer overnight. After dialysis, remove 
contents from bag. Add an equal volume of 100% glycerol. 
 
• Use Bradford Assay to determine final concentration after dialysis. • Bradford Assay 
for EF-Tu prep of 12/8/06 indicated an estimated 8mg of protein after Tev Protease 
cleavage, removal of His-tags, and elution from second column. 44mg-8mg=~37mg 
grams of protein lost between these steps. One possible explanation: Tev protease 
not cleaving all EF-Tu, since cleavage steps done at 4ºC. GDP present will make 
using A280 readings difficult. If the solution must be concentrated, pre-cool the Sorvall 
centrifuge to 4ºC. Spin at 3600g. When removing concentrated protein, make sure to 
pipette up and down and along the sides of the tube. Protein will pellet at bottom and 
can stick to sides, so be sure to pipette to allow for all the protein to go into solution. 
Once all protein is collected and placed in a fresh eppendorf tube, measure the 
volume and add an equal volume of 100% glycerol. Mix by inversion (or pipetting) 
– Do Not Vortex! • Bradford Assay for EF-Tu prep of 12/8/06 indicated an 
estimated 5mg of protein after removing concentrate and adding an equal volume 
of 100% glycerol. One possible explanation: I did not pipette up and down to make 
sure that EF-Tu that may have settled on the sides of the concentrating centrifuge 
tube and at the bottom was removed. Another explanation is that EF-Tu may have 
settled at the bottom of my final solution. Inverting multiple times and measuring 




• Uncleaved, cleavage reactions and the final (Tev protease and 6His-Tag removed) 
purified factors were analyzed by SDS-PAGE, factor concentrations were determined by 
absorbance ((EF-Tu)ε280 = 18,600 M-1cm-1, (EF-Tu·GTP)ε280 = 26,400 M-1cm-1, 
(EF-Ts)ε280 = 3,900 M-1cm-1, (EF-G)ε280 = 58,600 M-1cm-1, (EF-G·GTP)ε280 = 66,400 
M-1cm-1) and factors were buffer exchanged and concentrated using Amicon filtration 
devices and Translation Factor Buffer. Store at –20 °C. 
• Typical yields are 25-50mg of EF-Ts and EF-G/L of culture and 10-20mg of EF-Tu/L of 
culture. 
 
A.3 T7 RNA Polymerase Purification  





Lysis Buffer       100mL total 
50mM Tris-Hcl(pH8.0)    5mL 1M Tris-HCl 
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100mM NaCl      5mL 2M NaCl     
5mM beta-mercaptonethol   35uL 14.3M BME 
5% glycerol       5mL 100% glycerol 
1mM Imidazole      50uL 2M Imidazole 
3mL Protease Inhibitor Cocktail 
 
Wash Buffer       300mL 
50mM Tris-Hcl(pH8.0)    15mL 1M Tris-HCl 
300mM NaCl      45mL 2M NaCl 
5mM beta-mercaptonethol   105uL 14.3M BME 
5% glycerol       15mL 100% glycerol  
10mM Imidazole     1.5mL 2M Imidazole      
 
Elution Buffer      50mL (need 2 volumes of this) 
50mM Tris-Hcl(pH8.0)    2.5mL 1M Tris-HCl    
100mM NaCl      2.5mL 2M NaCl 
20mM beta-mercaptonethol   70uL 14.3M BME 
20% glycerol      10mL 100% glycerol 
100mM Imidazole     2.5mL 2M Imidazole 
1mM EDTA       100uL 0.5M EDTA 
0.1% Triton X-100     50uL Triton X-100 
 
Storage Buffer      1L (need 2 volumes of this) 
50mM Tris-Hcl(pH8.0)    50mL 1M Tris-HCl 
100mM NaCl      50mL 2M NaCl 
20mM beta-mercaptonethol   1.4mL 14.3M BME 
50% glycerol      500mL 100% glycerol 
1mM EDTA       2mL 0.5M EDTA 
0.1% Triton X-100     1mL Triton X-100 
Protocol 
Starter culture: 5mL LB, 5uL 100mg/mL Carbanecillin, new pipette tip dipped in T7 
strain using ethanol cleaned pipette and new gloves. 
 
Cell growth/induction (2L cell culture): 2mL 100mg/ml carbanecillin added to 2L LB 
media (Do not weigh out antibiotic powder!)  5mL starter culture added to 2L media 
containing carbanecillin (2L media in 6L giant flasks). Use two 1L flasks. 
 
Grow cells 37C to O.D.=0.6 at 600nm wavelength (cells are amp resistant). Place 1mL in 
a blank cuvette as background, and compare 1mL samples from 2L culture over time. 
 
Remove 1mL of sample for gel analysis (-IPTG). 
 
Induce with 1mM IPTG (grow another ~3hrs) (0.47662g IPTG per 2L (FW 238.31g/mol)) 
 
 136     Appendix 
Remove 1mL of sample for gel analysis (+IPTG). 
 
Harvest cells by spinning for 20 minutes at 4,000rpm. Pellet and freeze (if desired) 
 
Lysis 
Prepare French Press night before: 1) wash with water and ethanol 2) leave in 4ºC. 
Resuspend cells in lysis buffer (~35mL). 
Place large barrel on tri-pod. Put bead in hole using small lever/screw, then connect 
tubing. Insert large piston from bottom (it has a mark for where it should be when you 
start, and where it should be when you finish).  
 
Fill large barrel with sample slightly above hole. Slightly open screw/bead, then place lid 
on top of large barrel and twist/push down. Place tube in container to catch sample that is 
squeezed out. Once sample is in, retighten screw/bead. Lift large barrel complex off of 
tri-pod, flip over so that large piston is now on top, and place in French Press so that large 
barrel is touching all three small metal pegs. Turn knob on lower left to “medium” from 
“down”. Turn power on, and use dial on right to more quickly raise large barrel. Pressure 
should be slightly above 1100psi. Slowly untighten screw/bead so that sample drips out 
(ideally) into clean eppendorf tube. If pressure drops below 1100, use dial on right to 
increase pressure. When finished, turn knob on lower left from “medium” to “down” so 
that the large barrel comes down.  
 
Centrifuge 10,000g x 30min  
 
Get Supernatant (1mL supernatant for gel). Transfer quickly to falcon tube so cell pellet 
does not get into supernatant. Add 1mL Protease Inhibitor Cocktail (or 500uL to each 
falcon tube if two falcon tubes are needed). 
 




Use remaining ~65mL lysis buffer to run through column to equilibrate. 
 
Ni-NTA column (10 ml bed volume) 
20mL Ni-NTA agarose (this solution is 50% Ni-NTA) into column. Let equilibrate at 4ºC. 
The Ni-NTA agarose has a 5-10mg/mL binding capacity.  
 
Plug the bottom of the column and pour cleared lysate into the column with the 
pre-equilibrated Ni-NTA column material. Mix Ni-NTA column material and cleared 
lysate by pipetting up and down and transferring to a 50 ml Falcon tube. Add 5 more ml 
of cleared lysate to the disposable column, mix and transfer to the Falcon tube. Use two 
falcon tubes so that effective mixing can occur! Do this until all of the Ni-NTA 
column material from the disposable column is mixed in the Falcon tube with all of the 
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cleared lysate. 
 
Place the Falcon tube on a rotator in the cold room and allow to mix/rotate for 30 min. 
 
When mixing is done, pour the mixture back into the disposable column and collect the 
flow thru. 
 
Flow Through 1 
 
Wash 
Wash with 300mL wash buffer 
 
Wash 1, 2, 3, 4, 5, 6 
 
For wash 1 and wash 2, fill column with wash buffer, then add 1mL Protease 
Inhibitor Cocktail for each of the first two washes. For washes 3, 4, 5, 6 this is not 
necessary. 
 
Elute with 50ml elution buffer - 4x with 12.5mL, and collect into separate tubes.  
 
Elution 1, 2, 3, 4 (5, 6)  
 
90uL sample (Elution 1, 2, 3, then 4 separately) 
10uL 0.15M NaCl salt solution 
900uL commasie blue Bradford reagent 
Aborbance at 595nm 
 
Mix highest fractions together. Place these fractions in dialysis bag. Tie top and bottom 
(tie bottom before adding sample). Place in 1L storage buffer. Let go overnight at 4C. 
 
Cut ~12 inch dialysis bag. Keep wet in storage buffer. Combine fractions ( ~20ml) and 
dialyze o/n in storage buffer (final ~6ml). Change storage buffer after one day, and let 
dialyze again overnight. 
 
Store at –20C 
 
Use 0.5ul of enzyme in 50 ul transcription reaction. 
  
A.4 E. coli CCA Enzyme Purification  
Note: The protocol for this preparation is reproduced in its entirety from the protocol 
obtained from Dr. Ya-Ming-Hou, Thomas Jefferson Medical School. 
 
Sonication buffer (SB, 1x): [Suggestion: make 2x SB, 100 mL] 
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20 mM Tris-HCl, pH 8.0 
500 mM NaCl 
6 mM MgCl2 
10 mM imidazole 
3 mM β-Me 
5% glycerol 
0.1 mM PMSF 
 
Elution buffer (EB, 1x): [Suggestion: make 2x EB, 100 mL] 
20 mM Tris-HCl, pH 8.0 
2M NaCl 
6 mM MgCl2 
10 mM imidazole 
 
Varying concentrations of imidazole (stock of 1 M) as follows 
 
1x EB/50 mM imidazole 
1x EB/100 mM imidazole 
1x EB/200 mM imidazole 
1x EB/400 mM imidazole 
1x EB/600 mM imidazole 
 
Growth of culture: 3.2 L ( 0.8L of 2L-flask X 4 ) 
 
1. Inoculate a 40-mL overnight culture at 37 oC  
 
2. Transfer 0.8 mL of the overnight culture to each of 0.8 L of LB + Ampiciliin 
media.  
 
3. Grow at 25 oC ( room temp.) until OD(600) = 0.4-0.6. Remove 1 mL culture into 
an Eppie tube  (the “(-) IPTG” sample).  
 
4. Add IPTG (240 uL of 1 M) to 0.3 mM. Continue to grow .) until OD(600) = 1.0 ~ 
1.2 .  
 
5. Remove 1 mL culture, which is the “(+) IPTG” sample.  
 
6. Centrifuge down the 3.2 L culture, 4,000 rpm, 30 min, in Sorvall RC3B Plus.  
 
7. Resuspend the cell pellet with 10 mL of saline solution(0.9% NaCl). Transfer the 
resuspended cell paste to two of 50-mL Falcon tubes. 
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8.  Spin the cell paste down in the Falcon tube, 5,000 rpm 10 min in the table-top 
centrifuge (J-20 XP Beckman) and weigh the harvested cell(gram). 
 
9. Store cells at –80 oC.  
 
10. Spin down the “-IPTG” and “+IPTG” cells, add 100 µL of 2 x Lammeli buffer 
respectively, heat at 100 oC for 2 min. Load 10 µL on an SDS-PAGE to examine 




1. Add 10-mL SB into the cell paste of 1.8 L. Add 20 µL of PMSF (0.1 M freshly 
made in 95% ethanol), 1.5 mL of lysozyme (10 mg/mL freshly made in water). 
Gently shake at room temperature for 20 min. Option: you may add 1 tablet of the 
protease inhibitor cocktail (EDTA-free, Roche, 187358) to the lysate. 
 
2. Transfer the cell suspension to a metal beaker and sonicate (at intensity 7) for 10 
sec of 5 times. Alternatively, test OD595 in the BioRad assay on a titer plate with 
a 10-fold reduction in scale. Keep sonication until no further increase in OD595.  
 
3. Spin at SS35 at 17,000 rpm for 30 min. Keep the sup as the “cell lysate”. 
 
4. During spinning in step 3, equilibrate a metal resin (Nickel charged His-link) as 
follows: 
a. Pipet 1.5 mL of suspended resin to each of 50-mL Falcon tubes. 
b. Add water to 30 mL. Spin in the table-top at 3,000 rpm for 10 min. 
c. Decant water. Repeat step b again.  
d. Decant water, add 1x EB to 30 mL, spin as in b.  
e. Decant EB and the resin is ready to use.  
 
5. Incubate cell lysate from step 3 with equilibrated resin from step 4. Gently shake 
at 4 oC for 2 hours. Spin at 3,000 rpm, 10 min on a table-top centrifuge. Keep the 
sup as “Flow through”. 
 
6. To the resin, to which the His-tag enzyme should bind, add 10 mL of 1xEB, repeat 
spinning as in step 5. Keep the sup as “wash I”.  
 
7. Repeat washing the resin as in step 6. Keep the sup, successively, as “wash II”, 
“wash III”, “wash IV”, and “wash V”.  
 
8. After “wash V”, pour the resin into a BioRad mini column. Let the remaining 
solution in the resin drip out to the resin bed. Do not dry out the resin.  
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9. Start elution by adding 6 mL of 1xEB/50 mM imidazole. Collect elution in 1.5 mL 
in an Eppie tube.  
 
10. Continue elution with 6 mL of 1x EB/100 mM imidazole, followed by 1x EB/200 
mM imidazole, 1x EB/400 mM imidazole and by 1x EB/600 mM imidazole.  
 
11. Run 10% SDS-PAGE to analyze the quality of purification. The gel should have 
the following samples, as shown in the next page: 
 
12. 10% SDS-PAGE: 
 
M.Wt markers 
The “-IPTG” cell lysate, 10 µL 
The “+IPTG” cell lysate, 10 µL 
Cell pellet in 1 X SDS-dye buffer after sonication, 10 µL 
Supernatant after sonication (step 3), 10 µL 
Flow-through (step 5), 10 µL 
Wash I (step 6), 10 µL 
Wash II (step 7), 10 µL 
Wash III (step 7), 10 µL  
Wash IV (step 7), 10 µL 
Wash V (step 7), 10 µL 
 
Elution 1 with 50 mM imidazole, 10 µL 
Elution 2 with 50 mM imidazole, 10 µL 
Elution 3 with 50 mM imidazole, 10 µL 
Elution 4 with 50 mM imidazole, 10 µL 
            
      Elution 1 with 100 mM imidazole, 10 µL 
Elution 2 with 100 mM imidazole, 10 µL 
Elution 3 with 100 mM imidazole, 10 µL 
Elution 4 with 100mM imidazole, 10 µL 
Elution 1 with 200 mM imidazole, 10 µL 
Elution 2 with 200 mM imidazole, 10 µL 
Elution 3 with 200 mM imidazole, 10 µL 
Elution 4 with 200 mM imidazole, 10 µL  
Elution 1 with 400 mM imidazole, 10 µL  
Elution 2 with 400 mM imidazole, 10 µL 
Elution 3 with 400 mM imidazole, 10 µL 
Elution 4 with 400 mM imidazole, 10 µL 
 
Elution 1 with 600 mM imidazole, 10 µL 
Elution 2 with 600 mM imidazole, 10 µL  
Elution 3 with 600 mM imidazole, 10 µL  
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Elution 4 with 600 mM imidazole, 10 µL 
Enzyme-bound Resin in1 X SDS-dye buffer 10 µL 
 
13. Pool fractions that contain the highest purity of the enzyme. Adjust the pooled 
fraction to 10% glycerol, and 100 mM glycine, pH 9.0.  
 
14. Dialyze against 100 mM glycine pH 9.0, , 50 mM NaCl, 2 mM MgCl2, 1 mM 
β-mercaptoethanol, 10 % glycerol. 
 
15. Concentrate down to about 3 mL carefully by Amicon Centrifugal Filter, avoiding 
white precipitation and adjust the glycerol concentration to 40 % with 80% 
glycerol to stabilize.  
 
16. Store as aliquots at –20 oC.  
 
17. Determine the protein concentration by Bradford assay (concentration averaged 
by at least triplet quantification) and calculate yield. 
 
 Yield: 227 µM (10.2 mg/mL), 6.72 mL (total 68 mg) 
 From 7.9 g cells (3.2 L culture) 
 Stabilized in 50% glycerol to 500 µL aliquots at –20 oC.  
 
 
18. Run 10% SDS-PAGE to evaluate the quality of the enzyme. 
 
19. Perform the Enzyme Activity assay under steady-state condition. 
 
20. Ready to perform Transient State Kinetic Assay. 
 
 
A.5 Ribozyme Preparation (eFx & dFx) 
Note: This protocol was developed based off of [2]. 
 
Primers for dFx extension and amplification reactions: 
1. dFx 5’ ACCTA ACGCC ATGTA CCCTT TCGGG GATGC GGAAA TCTTT CGATC C 3’ 
2. P3 5’ GCATA TGTAA TACGA CTCAC TATAG GATCG AAAGA TTTCC GC 3’  
3. dFxR19 5’ ACCTA ACGCC ATGTA CCCT 3’ 
4. P4 5’ GCATA TGTAA TACGA CTCAC TATAG 3’ 
 
Primers for eFx extension and amplification reactions: 
1. eFx 5’ ACCTA ACGCT AATCC CCTTT CGGGG CCGCG GAAAT CTTTC GATCC 3’ 
2. P3 eFx 5’ GCATA TGTAA TACGA CTCAC TATA  GGATC GAAAG ATTTC CGC 3’ 
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3. eFxR18 5’ ACCTA ACGCT AATCC CCT 3’ 
4. P4 eFx 5’ GCATA TGTAA TACGA CTCAC TATA G 
 
I. Extension of oligo’s (the protocol is the same for dFx or eFx; dFx is used as the 
example): 
1. 500nM dFx, 500nM P3 in 100µL total volume PCR mixture. This corresponds to       
0.5µL 100µM dFx, 0.5µL 100µM P3, and 99 µL PCR mix.  
2. 30 PCR cycles as follows: 1 minute at 95ºC, 1 minute at 55ºC, 1 minute at 72ºC. 
 
II. PCR amplification of extension products 
1. ~75% of 100µL mixture will be recovered from extension, probably due to 
evaporation during heating cycles.  
2. The amplification rxn will be scaled up 10 fold from the extension rxn. So if ~75% 
of 100µL are recovered, let’s say 78µL, then 3.9µL 100µM P4, 3.9µL 100µM 
dFxR19, and 694.2µL primer mix should be added to the 78µL recovered from 
extension rxn. 
3. This will correspond to 500nM P4, 500nM dFxr19 in 780µL total rxn volume. 
 
III. Phenol/Chloroform Purification of PCR amplified product 
1. add 500µL saturated phenol to 500µL chloroform in an eppendorf tube. Mix by 
vortexing, then centrifuge for 10 seconds. Water will rise and form a top layer. 
Remove this layer. 
2. add phenol/chloroform in 1:1 ratio to PCR amplified volume. Example above 
would call for 780µL phenol/chloroform to 780µL PCR amplified volume. 
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3. Vortex on max RPM for 5 seconds, then centrifuge for 10 seconds. 
4. Remove top (aqueous) layer and put into a fresh tube. Note: remove this layer in 
two portions to make sure it is done accurately. 
5. Add 780µL chloroform to aqueous layer just collected (1:1 ratio, keeping above 
example) 
6. Vortex for 5 seconds, then centrifuge to separate. 
7. Again, remove top (aqueous) layer and put into a fresh eppendorf tube. 
8. Measure the volume of this solution 
9. Add enough 3M NaOAc, pH 5 to make 0.3M final concentration. In keeping with 
the above example, let’s say the volume of extracted solution totaled 700µL. Add 
100µL 3M NaOAc, and 200µL ddH2O. 
10. To every 500µL of 0.3M NaOAc/extracted solution, add 1mL 95% EtOH (from    
-20º). Mix each tube by inverting 20X. Continuing the above example, we have 
1mL of 0.3M NaOAc/extracted solution. This should be split into two eppendorf 
tubes, 500µL into each eppendorf tube. Then add 1mL 95% EtOH. 
11. Put in -80ºC to precipitate (4 hours to overnight) 
12. Centrifuge samples at 13,000 RPM for 20 minutes in the cold room (4ºC). 
13. Remove supernatant carefully making sure to know where pellet is. 
14. Wash the pellet with 0.5mL cold 70% EtOH (to get rid of salt). Note: pellet can be         
easily dislodged during removal of the supernatant or during addition of 70% EtOH. 
Try to be aware of where the pellet is at all times. 
15. Centrifuge for 1 minute, 14,000 RPM. Remove the 70% EtOH carefully. 
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16. Dry the pellet for at least 40 minutes under vacuum. Place parafilm over top of 
eppendorf tube, and poke a whole with pipette tip. Then use lyophilizer. 
17. Spin down the pellet after drying to make sure none of the material is lost when 
tube is opened. 
18. Dissolve pellet in 6.25µL TE Buffer, pH 7.95 per 500µL 0.3M NaOAc/extracted 
solution. The above example had two eppendorf tubes, each containing 500µL 0.3M 
NaOAc/extracted solution plus 1mL 95% EtOH, before drying. So each eppendorf 
tube would require 6.25µL TE Buffer, pH 7.95.  
 
IV. In vitro transcription of ribozyme 
1. See A.8 for details of in vitro transcription reactions. Note that ribozyme 
transciptions are quenched with 2x loading buffer (see A.10) and is purified using 8% 
PAGE. 
 
V. Purification of ribozyme using 8% PAGE  
1. 50mL 8% acrylamide solution, 50µL TEMED, 500µL 10% APS mixed to     
polymerize gel. 
2. For scale up rxn, one massive lane needed, so top of comb used for lane. 
3. 1X TBE buffer used (75mL 10X TBE plus 675mL ddH2O). 
4. Samples loaded as follows: To each 20µL transcription rxn, 40µL 2X buffer added 
(8M Urea, 20mM EDTA, 2mM Tris, pH 7.5), and 2µL Jiangning’s blue buffer. 
5. Incubate samples at 95ºC for three minutes. Wait ~5 minutes so solution is not 
terribly hot, then load into gel. 
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6. Run at 300V until marker is a good distance from top of gel (anywhere between 2 
and 5 hours). 
 
VI. Removal of dFx from gel 
1. UV shadow to visualize ribozyme in gel.  
2. Cut out, but have a ruler in hand to measure the length and width of band being cut 
out. Ruben’s gel plates are .2cm thick, so multiplying .2cm by length and width of 
gel band will give an approximate volume in cm3, which equals mL’s. 
3. add 3x 0.3M NaCl to gel band in a 50mL falcon tube. For example, if you calculate 
gel band to be 2.5cm3, which equals 2.5mL, then add 7.5mL 0.3M NaCl. 
4. Place falcon tube on shaker and let shake overnight. 
5. To retrieve dFx, pour fluid into 50mL centrifuge tube leaving gel slices in falcon 
tube. Invert falcon tube to force liquid and gel slices towards the cap. Take the cap 
off without spilling, and pour liquid contents into 50mL centrifuge tube. A 1000mL 
pipette can also be used to go toward bottom of falcon tube to get any remain 
liquid at the bottom of the falcon tube. 
6. Add 2.5X 100% cold (-20ºC) EtOH to 50mL centrifuge containing ribozyme. 
Precipitate overnight in -20ºC.  
7. Spin down 50mL centrifuge tube in JA-17 rotor for 1 hour. Set at 12,000g ~ 
14,000RPM, 4ºC. 
8. Pellet should be visible at bottom of centrifuge tube. Remove supernatant, and 
allow for ethanol to evaporate. 
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9. Resuspend pellet in supernatant that remains in centrifuge tube. It should be very 
difficult to remove all the supernatant, so use what is left to transfer to an 
eppendorf tube. 
10. Add 250µL cold 75% EtOH to wash/rinse the bottom of the centrifuge. Transfer to 
eppendorf tube with dFx. Do this twice, the result being dFx in 500µL 70% EtOH 
plus the small amount of 0.3M NaCl/100% EtOH that was difficult to entirely 
remove from step 9. 
11. Spin eppendorf tub at 14,000 RPM for 3 minutes. A very visible white pellet 
should be observed. Remove supernatant with pipette. Place eppendorf tube in 
hood to allow for ethanol to evaporate. 
12. Dissolve dFx pellet in 50µL ddH20 and measure concentration by UV. 
 
VII. Aminoacylation reaction using dFx 
1. The following ratio’s should be maintained when using dFx or eFx to 
aminoacylate  tRNA, and is also described in A.8: 
 
 2.5µL 40µM tRNA (in 0.2M Hepes-K buffer, pH 7.5; 0.2M KCl) 
 1µL 3M MgCl2 
 0.5µL 200µM dFx 
 1µL 25mM amino acid DBE (in DMSO) 
 5µL Total Rxn Volume 
 
The procedure is as follows: 2.5µL 40µM tRNA place in eppendorf tube and heated at 
95ºC for 3 minutes and cooled to room temperature (25ºC) for 5 minutes. 1µL 3M 
MgCl2 and 0.5µL 200µM dFx should then be added to mixture and stored at room 
temperature (25ºC) for 5 minutes. The reaction is initiated by adding 1µL 25mM 
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amino acid DBE to mixture, and then incubated on ice. For DBE-alanine, 2 hours on 
ice is required. 
2. A total rxn volume of 5µL requires 15µL 0.6M sodium acetate, pH 5 to stop the 
rxn. 3X 100% EtOH is then added (60µL) and precipated at -80ºC for a minimum 
of 3 hours. 
3. Rinse with 70% EtOH and then dissolve pellets in 2.5uL of 10mM sodium acetate 
pH 5. Mix all 2.5µL of this solution with 2.5µL loading buffer  (50mM sodium 
acetate, 8M urea) 
4. To best visualize results of aminoacylation reaction on an acid page gel, the 
following proved successful: 
 
40µM tRNAPhe                 4.5uL         4.5uLuL     
3M MgCl2                     1.8uL         1.8uL  
200µM dFx                    -------         0.9uL                  
25mM DBE             1.8uL         1.8uL                 
ddH20                        0.9uL         -------      
Total Volume       9uL        9uL           
 
~8% acid page gel run as follows: 
15.5mL ddH20 
6.1mL 40% Acrylamide/Bis solution 19:1 
1.25mL 3M NaOAc, pH 5 
18g urea 
 
Stir until urea is completely in solution, then add 
 
500µL 10% APS 
25µL TEMED 
 
Long plates (16cm x 24cm) with 0.75mm spacers are used. Gels are run for 16 hours at 
190V in 4ºC cold-room. Running Buffer: 33.34mL 3M NaOAc, pH 5.21; 966.6mL ddH20 
(fill up to 1000mL). All 9µL of each sample run on gel in 9uL loading buffer. 
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A.6 aaRS Aminoacylation Reactions 
 
Hot and cold fMet-tRNAfMet aminoacylation: 
 
10µL 14mM 5:10 methyltetrahydrofolate 
1µL 1M KOH 
0.5µL 1M Tris-HCl, pH 7.5 
11.5µL Total Volume (12.5mM 10 methyl tetrahydrofolate) 
 
15 minutes, room temperature. This reaction should turn from yellow to white, and is 
added to the reaction below.  
 
20µL 5x AF Buffer (recipe below)       
7.12µL 281µM tRNAfMet  
36µL S35methionine (8.69µM, Perkin Elmer) 
1.6µL 1mM cold methionine [add after reaction has incubated for 5 minutes, 37ºC]  
2.5µL 12mM 10-methyl tetrahydrofolate)       
0.3µL 6.9µM methionyl aaRS 
3µL 6.6µM transformylase 
30.8µL ddH20 
100µL Total Volume 
 
The hot S35methionine is reacted at 37ºC for 5 minutes before addition of the cold 
methionine, so as to allow for the hot S35methionine to aminoacylate. After addition of the 
cold methionine, the reaction should incubate for an additional 5 minutes at 37ºC. For the 
cold reaction only (no S35methioninea) , 2µL 1mM methionine is added instead of adding 
the hot S35methionine, and the amount of ddH20 added is increased. The hot and the cold 
reaction are done side by side, can be scaled up or down accordingly, and the cold 
reaction is run on FPLC (see below) to gauge the aminoacylation efficiency of the hot 
reaction. 
 
After incubation at 37ºC, reactions are phenol extracted twice and chloroform extracted 
twice. 30µL 3M NaOAc, pH 5 added to a final volume of ~0.3M NaOAc, pH 5 (250µL 
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total reaction volume + 30µL 3M NaOAc, pH 5). Subsequently, 840µL 100% ETOH (3x 
volume) added and precipitated overnight at -80ºC. Samples were spun down for 10 
minutes, 14,000rpm at 4ºC, the supernatant removed, followed by addition of cold 70% 
ETOH and a 1 minute spin, 14,000rpm at 4ºC. Samples were then resuspended in 10mM 
KOAc, pH 5 and passed through a P6 filter pre-equilibrated with 10mM KOAc, pH 5 by 
adding the aa-tRNA to the P6 column and spinning for 5 minutes, 3,500rpm at 4ºC. 
 
5x AF Buffer      
125µL 1M Tris-HCl, pH 7.5-7.6   
7.14µL 4.9M MgCl2 
375µL 2M KCl   
1µL 0.5M EDTA 
5µL 1M DTT 
250µL 50mM ATP 
236.86µL ddH2O 
1mL Total Volume 
 
 
Phe-tRNAPhe and Lys-tRNALys aminoacylation: 
 
 
50µL Tris-HCl, pH 7.5       
3.125µL 2M KCl 
3.75µL 1M MgCl2:  
0.5µL 1M BME 
12.5µL 0.1M ATP       
4.995µL 0.3M PEP 
1.2µL 1x pyruvate kinase 
15.64µL 240µM tRNA (Sigma) 
4.2µL 2mM amino acid 
2.5µL 37.5µM aaRS 
101.59µL ddH20 
250µL Total Volume 
 
This protocol has been used for aminoacylating tRNAPhe and tRNALys with their 
respective aaRS enzymes and can be scaled up or down accordingly. Reaction is 
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incubated for 10 minutes at 37ºC, followed by phenol extracting twice and chloroform 
extracting twice. 30µL 3M NaOAc, pH 5 added to a final volume of ~0.3M NaOAc, pH 5 
(250µL total reaction volume + 30µL 3M NaOAc, pH 5). Subsequently, 840µL 100% 
ETOH added (3x volume) and precipitated overnight at -80ºC. Samples were spun down 
for 10 minutes, 14,000rpm at 4ºC, the supernatant removed, followed by addition of cold 
70% ETOH and a 1 minute spin, 14,000rpm at 4ºC. Samples were then resuspended in 
10mM KOAc, pH 5 and passed through a P6 filter pre-equilibrated with 10mM KOAc, 
pH 5.by adding the aa-tRNA to the P6 column and spinning for 5 minutes, 3,500rpm at 
4ºC. 
 
Glu-tRNAGlu and Val-tRNAVal aminoacylation: 
 
1x AF Buffer 
20µM tRNA 
80µM amino acid 
0.2µM aaRS 
(x) ddH20 
50µL Total Volume 
 
Reactions were incubated at 37ºC for 10 minutes and phenol and chloroform extracted, 
etc. as described for Phe-tRNAPhe and Lys-tRNALys. 
 
 
A.7 Analysis of aaRS Aminoacylation Reactions 
A.7.1 FPLC  
Cold fMet-tRNAfMet was added to Buffer A and injected onto the FPLC and passed 
through a HIC (hydrophobic interaction chromatography) column (Tosoh Tsk Gel 
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Phenyl-5PW) using a gradient that went from 0% Buffer B to 100% Buffer B over 70 
minutes. An A260 peak at ~14 minutes corresponds to deacylated tRNAfMet. An A260 peak 
at ~21.8 minutes corresponds to aminoacylated fMet-tRNAfMet. 
 
Phe-tRNAPhe was added to Buffer A and injected onto the FPLC and passed through a 
HIC (hydrophobic interaction chromatography) column (Tosoh Tsk Gel Phenyl-5PW) 
using a gradient that went from 0% Buffer B to 100% Buffer B over 70 minutes. An A260 
peak at ~21 minutes corresponds to deacylated tRNAPhe. An A260 peak at ~31 minutes 
corresponds to aminoacylated Phe-tRNAPhe. 
 
Buffer A (1.7M NH4SO4, 10mM NH4OAc, pH 6.19) 
224.638g NH4SO4 (132.14g/mol) 
10mL 1M NH4OAc, pH 6.19 
Fill to 1L with ddH20 
 
Filter before use 
 
Buffer B (10mM NH4OAc, pH 6.19, 10% methanol) 
 
100mL methanol 
10mL 1M NH4OAc, pH 6.19 
Fill to 1L with ddH20 
 
Filter before use 
 
A.7.2 Acid PAGE Gels  
Lys-tRNALys, Glu-tRNAGlu and Val-tRNAVal aminoacylation was quantified using 8% 
Acid PAGE gels run at 4ºC overnight. 
 
8% Acid PAGE gel run as follows: 
15.5mL ddH20 
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6.1mL 40% Acrylamide/Bis solution 19:1 
1.25mL 3M NaOAc, pH 5 
18g urea 
 
Stir until urea is completely in solution, then add 
 
500µL 10% APS 
25µL TEMED 
 
Long plates (16cm x 24cm) with 0.75mm spacers are used. Gels are run for 16 hours at 
190V in 4ºC cold-room. Running Buffer: 33.34mL 3M NaOAc, pH 5.21; 966.6mL ddH20 
(fill up to 1000mL). All 9µL of each sample run on gel in 9uL loading buffer. 
 
 
A.8 Labeling of tRNA with α-32P-ATP 
Note: This protocol was developed based off of [3-4]. 
 
 
A typical labeling reaction described below. The amounts of tRNA and α-32P-ATP can be 
varied. 
 
25µL 100mM Glycine, pH 9 
0.5µL 1M MgCl2 
10µL 335.6µM tRNA 
6µL 3000Ci/mmol α-32P-ATP (Perkin Elmer) 
0.5µL 5mM sodium pyrophosphate 
2.75µL 0.546 µg/µL nucleotidyl tranferase 
5.25µL L ddH20 
50µL Total Volume 
 
5 min, 37°C 
 
1x phenol extraction 
1x chloroform extraction 
 
125µL 100% EtOH added, -80°C overnight 
 
After spinning at 14,000rpm for 10 minutes and removing the supernatant, samples are 
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washed with 70% EtOH, resuspended in ~20µL ddH20, and filtered through a P6 column 
pre-equilibrated with ddH20 in order to remove unincorporated α-32P-ATP. 
 
A.9 Ribozyme Aminoacylation Reaction 
Note: This protocol was developed based off of [2]. 
 
A typical ribozyme aminoacylation reaction is described below. Note that analytical scale 
charging reactions were done using α-32P-ATP labeled tRNAs alongside the larger 
charging reactions to be used for experiments. 
 
Analytical        Scale-Up 
1.67µL 60µM α-32P-tRNAPhe    13.6 µL 240µM tRNAPhe 
1uL 3M MgCl2       32.7µL 3M MgCl2 
0.5µL 200µM eFx      16.35µL 200µM eFx 
1µL 25mM D-/L-Phe CME    32.7µL 25mM D-/L-Phe CME 
0.5µL 1M Hepes-K, 1M KCl, pH 7  16.35µL 1M Hepes-K, 1M KCl, pH 7 
0.33µL ddH20       51.8µL ddH20 
5µL Total Volume      163.5µL Total Volume 
 
First, tRNA is incubated at room temperature for 5 minutes. Next, magnesium, ribozyme, 
water, and 1M Hepes-K/1M KCl are added, and the mixture is allowed to incubate at 
room temperature, again for 5 minutes. Finally, aa-CME is added and the reaction is 
placed on ice, for 2 hours in the case Lysine and Phenylalanine aminoacylation reactions, 
6 hours for Valine aminoacylation reactions. 
 
After the appropriate incubation time on ice, reactions are quenched with 3 volumes of 
3M NaOAc, pH 5, and then precipitated in 3 volumes of 100% ETOH at -80°C overnight 
(example: 5µL analytical charging reaction is quenched with 15µL 3M NaOAc, pH 5 and 
then precipitated by adding 60µL 100% EtOH). 
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Samples are spun at 14,000rpm for 10 minutes at 4°C and then washed with 70% EtOH, 
then resuspended in 10mM KOAc, pH 5. No filtering through a P6 column was used 
 
A.10 TLC Analysis of Ribozyme Aminoacylation Efficiency 
Note: This protocol was developed based off of [3-4]. 
 
4µL 1U/µL P1 nuclease (P1 nuclease in 200mM NaOAc, pH 5) 
1µL D/L-aa-α-32P-tRNA 
5µL total volume 
 
10 minutes at room temperature 
 
45µL 200mM NaOAc, pH 5 is then added to dilute the sample. 0.5µL-2µL can be spotted 
onto PEI Cellulose Plates (plates need to be pre-wetted in ddH20 and allowed to dry). 
TLC plates were run in galacial acetic acid/1M NH4Cl/ddH20 (5:10:85). 
 
 
A.11 In Vitro Transcriptions  
The following ratio’s have been optimized for MgCl2 and T7 RNA polymerase 
concentrations and should be maintained for both analytical and scaled up transcriptions. 
This procedure is the same for transcription of mRNA, tRNA or ribozyme from DNA 
templates. Small-scale analytical reactions are carried out at 37ºC for a minimum of 3 
hours, and typically only two different volumes of DNA, 0.5µL and 1.0µL, are necessary 
for the reaction to work: 
 
1µL T7 Buffer (40mM Tris, pH 8; 10mM spermidine; 0.1% Triton-X)       
1 µL 0.1M DTT 
0.84µL 1M MgCl2:  
6.4 µL NTP mix (12.5mM, each NTP)  
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0.5µL 0.16µg/µL T7 RNA polymerase 
0.5µL DNA in TE Buffer [and 1.0µL for second analytical] 
9.76µL [and 9.26µL for second analytical] ddH20 
20 µL Total Rxn Volume 
     
From the analytical reactions, scale up depending on the amounts of DNA that worked 
bested in the analytical. For example,   
 
25µL T7 Buffer (40mM tris, pH 8; 10mM spermidine; 0.1% Triton-X)  
25 µL 0.1M DTT 
25µL DNA (in TE Buffer) 
21µL 1M MgCl2 
160µL NTP mix (12.5mM each NTP) 
12.5µL 0.16µg/µL T7 T7 RNA polymerase 
231.5µL ddH20 
500µL Total Rxn Volume 
 
Transcription reactions involving mRNA are quenched with 0.5M EDTA to a final 
volume of 50mM EDTA. Quenched reactions are then filtered through a 10,000MW 
cut-off Amicon filter into 1x mRNA storage buffer (10 mM Tris–OAc (pH25ºC=7.5), 
10mM KCl, 0.1M EDTA). As described above, ribozyme transcription reactions are 
quenched with two volumes of 2x loading buffer (8M urea, 20mM EDTA, 2mM Tris pH 
7.5). 
 
Note: Rxn mixture should turn white/cloudy due to pyrophosphate. NTPs should be    
3.75-4mM in transcription rxn. NTPs were made so that ATP, GTP, UTP, and CTP would 
be 12.5mM in 4mL (27.6mg 551.1g/mol ATP; 26.16mg 523.2 g/mol GTP; 26.36mg 
527.12 g/mol CTP; 27.5mg 550.1g/mol UTP). NTPs were weighed individually and then 
placed in a 15mL falcon tube and then dissolved in ~2mL ddH20. 1M NaOH added until 
solution was pH 7, and then ddH20 was added until the volume in the falcon tube was 
4mL. Aliquouts were then placed in RNase free eppendorf tubes.  
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A.12 Translation Reaction Protocol 
Note: The protocol for this preparation has been slightly altered from the Gonzalez 
laboratory protocol and is also described, though not exactly, in [1]. 
 
70S initiation complexes: 
 
7.71µL 2.36µM 70S ribosomes 
0.7µL 30µM IF-1   (0.5µL 232.5µM IF-1 + 7.25µL 1x polymix, -Mg2+) 
1.11µL 23µM IF-2  (1.0µL 103µM IF-2 + 4.35µL 1x polymix, -Mg2+) 
0.61µL 36µM IF-3  (1.0µL 126µM IF-3 + 2.5µL 1x polymix, -Mg2+) 
0.37µL 50mM GTP 
1.465µL 5x polymix (-Mg2+) 
 
10 min, 37°C 
 
0.73µL 93.8µM mRNA 
1.474µL ddH20 
1.938µL 5x polymix (-Mg2+) 
 
10 min, 37°C 
 
0.908µL 10µM S35fMet-tRNAfMet 
17.015µL Total Volume 
 
10 min, 37°C 
10 min on ice 
 
Note that the final concentration of Mg2+ is 3.58mM for the 70S initiation complexes. 
This includes the Mg2+ from the 70S ribosomes, IF-1, IF-2, and IF-3 which are prepared 
in 7.5mM, 5mM, 10mM, and 5mM Mg2+, respectively. The 70S initiation complexes are 






1.4µL 290.7µM EF-Tu 
2.6132µL 5x polymix (15.35mM Mg2+) 
0.61µL 75µM EF-Ts 
1.09668µL 5x polymix (-Mg2+) 
2.74µL ddH20 
1.5µL GTP Charging Mix (6µL 1x Buffer 6, 2µL 50mM GTP, 1µL 0.3M PEP, 1µL 1x 
pyruvate kinase) 
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3.7µL 1x Buffer 6 
13.66µL Total Volume 
 
1 min, 37°C 





0.5µL 16.6µM D/L aa-tRNA 
0.435µL 19µM Lys-tRNALys 
3.75µL Total Volume 
 
1 min, 37°C 
1 min on ice 
 
Note that the final concentration of Mg2+ is 3.48mM for ternary complexes. This includes 
the Mg2+ from EF-Tu, which is prepared in 200µM Mg2+. The ternary complexes are in 






1.06µL 5x polymix (15.35mM Mg2+) 
0.54µL GTP Charging Mix 
0.45µL 250µM EF-G 
5.3µL Total Volume 
 
Note that the final concentration of Mg2+ is 3.38mM and is in 1x polymix, final. 
 
 
A.12.1 Translation Reaction (for eTLC): 
0.6µL of EF-G is added to 3.6µL of 70S initiation complexes in one eppendorf “reaction” 
tube and stored on ice until use. The “reaction tube” and the ternary complexes are 
pre-warmed at 37°C for 2-3 minutes, at which point 3.445µL of ternary complex is added 
to the “reaction tube”, thus beginning the translation reaction (7.445 µL total volume). 
The final concentration of Mg2+ is 3.5mM in the translation reaction, as the 70S initiation 
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complexes, ternary complexes, and EF-G are at approximately 3.5mM Mg2+. 0.6µL of 
each translation is removed at the indicated timepoints and quenched into 2µL 200mM 
KOH. 0.5µL of the quenched translation is then spotted onto the middle of the eTLC plate. 
The eTLC plate is then wetted in pyridine acetate buffer (recipe below), using capillary 
action to slowly engulf the spotted samples in the middle of the eTLC plate. This is 
achieved by pipetting pyridine acetate buffer onto the ends of the TLC plate and then 
using a 5mL serological pipet to roll the pyridine acetate buffer up toward the location of 
where the TLC plate was spotted with sample.  
 
A.12.2 Filter Binding:  
0.5 µL aliquots were removed from the translation reactions described above (7.445 µL 
total volume) and added to 49.5 µL chilled stop buffer (50mM Tris-HCl, pH 7.5, 1M 
NH4Cl, 15mM Mg(OAc)2). 30 µL of the translation reaction quenched in chilled stop 
buffer was then passed through the nitrocellulose filter on the vacuum manifold and 10µL 
was pippeted onto a dry nitrocellulose filter to obtain the total counts in the sample (i.e. 
the counts on the filter represent 1/5 of the total counts in the tube, because 10µL was 
used out of a total volume of 50µL 
 
A.12.3 Toeprinting Exceptions:  
 
Labeling of the DNA primer is achieved as follows: 
 
0.71µL 100µM gp32toeprintprimer 
1.53µL 27.8µM γ-32P-ATP (Perkin Elmer) 
3µL 10x T4 polynucleotide kinase (PNK) buffer 
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1.43µL 10U/µL polynucleotide kinase 
23.33µL ddH20 
30µL Total Volume 
 
 
Reaction incubated for 30 minutes at 37ºC, and then 10 minutes at 75ºC, followed by 
filtration through a G-25 Sephadex column and storage at -80ºC.  
 
Annealing of the radioactive primer to the mRNA is achieved as follows: 
 
33.5µL 6µM gp32mRNA 
4.15µL 2.37µM γ-32P-ATP-toeprintprimer (from 30µL labeling reaction above) 
0.98µL 1M Tris-OAc, pH 7 (RT-room temperature) 
(Optional: 0.37µL 100µM cold primer) 
38.62µL Total Volume 
 
Reaction incubated for 90 seconds at 90ºC, then slow cooled to room temperature and 
either used immediately or stored at -80ºC. This mixture is 5.2µM γ-32P-ATP-primer 
annealed mRNA. 1.75µL of 5.2µM γ-32P-ATP-primer annealed mRNA was added to the 
70S initiation complexes generating a final concentration of γ-32P-ATP-primer annealed 
mRNA = 0.25µM in the translation reaction. Another difference in the toeprinting 
translation from the eTLC translation is that each toeprinting translation was done at a 
scale of 5.1µL, comprised of 2.4µL 70S initiation complex, 2.3µL ternary complexes, and 
0.4µL EF-G. The protocol for the Toeprinting Mix, used to quench the toeprinting 
reactions, is as follows: 
 
50µL 5x sequencing buffer (100µL 5x polymix, 5µL 1M Mg(OAc)2, 0.21µL 14.3M BME) 
3.1µL 100mM ATP 
25µL 10x dNTP mix 
2.5µL 100mM viomycin 
119.4 µL ddH20 
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200µL Total Volume 
 
Each 5.1 µL translation was quenched with 20 µL toeprinting mix, at which point 0.63 µL 
AMV reverse transcriptase was added (Promega) and incubated for 15 minutes at 37ºC. 
The reaction was phenol extracted twice and chloroform extracted twice. 2.5µL 3M 
NaOAc, pH 5.2 and 82.5 µL 100% ETOH were then added, and this mixture was 
incubated at room temperature for 10 minutes. After centrifugation at room temperature 
for 10 minutes, samples were washed with 70% ETOH and resuspended in 5µL 
Denaturing Page Loading Buffer. 
 
A.12.4 Puromycin Reactivity:  







6.25mL 1M Tris-Oac, pH 6.9 
6.25mL 2M KCl 
0.125mL 5M NH4Oac (Fluka) 
0.5mL ddH20 
0.0625mL 1M Ca(Oac)2 
0.025mL 0.5M EDTA, pH 8.2 
0.25mL 0.5M spermine 
1.25mL 0.5M putrescine 
 
To make 5x Tris-polymix (15.35mM Mg2+): 
 
0.591mL 8.46x Tris-polymix  
15.35µL 1M Mg(Oac)2 (Sigma) 
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0.39159mL ddH20 
2.1µL 14.3M BME 
 
To make 5x Tris-polymix (-Mg2+): 
 
0.591mL 8.46x Tris-polymix 
0.4069mL ddH20 
2.1µL 14.3M BME 
 
1x Buffer 6: 
 
2.5mL 1M Tris-Oac, pH 7.5 
0.5mL 5M NH4Oac (Fluka) 
0.3728g KCl (MW 74.5 g/mol) 
0.25mL 1M Mg(Oac)2 (Sigma) 
0.025mL 1M Ca(Oac)2 
0.010mL 500mM EDTA 
 
Fill to 50mL with ddH20. 
 
 
Pyridine acetate buffer (for eTLC): 
 
200mL acetic acid 
5mL pyridine (anhydrous) 
795mL ddH20 
1L Total Volume 
 
A.13 Total mRNA Purification and RT-PCR 
 
5mL starter cultures of M9 minimal media (recipe below) containing the WT, dtd-, dadA-, 
or dtd-/dadA- strains and the appropriate antibiotic(s) were grown overnight at 37ºC. 
250µL of cells from these cultures were used to inoculate 20mL M9 minimal media (no 
antibiotics used). Cells were grown until OD600 = 0.1, at which point D- or L-Tyr was 
added to the flask such that the final concentration of amino acid was between 2.5-10mM. 
Cells were grown on M9 minimal media containing the D- or L-amino acid at 37ºC until 
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OD600 = 0.4-0.8. Six aliquots of 500µL were removed from each experimental flask and 
1mL RNA protect (Qiagen) was then added to each 500µL aliquot. The resulting 1.5mL 
aliquot was stored according to the RNA protect (Qiagen) protocol. Total mRNA was 
purified using the RNAeasy minikit (Qiagen) and treated with DNase 1 (Qiagen) on the 
Qiagen column. 
 
M9 Minimal Media 
200mL 5x M9 salts (recipe below) 
2mL 1M MgSO4 
20mL 20% glucose 
0.1mL 1M CaCl2 
ddH20 added to 980mL 
 





1L ddH2O Total Volume 
 
Everything is autoclaved before use with the exception of glucose, which is added after 
filtering. 1.5g Bacto Agar is used per 100mL plates. 
 
Total mRNA was reverse transcribed using random hexamer primers as follows:  
 
5µg RNA 
20µL 0.4µg/µL random hexamer primer (Qiagen) 
3µL 10mM dNTP mix 
12µL 5x First Strand Buffer 
3µL 0.1M DTT 
6µL 200U/µL reverse transcriptase (Invitrogen) 
(x) ddH20 
60µL Total Volume 
 
The hexamer primer, mRNA and ddH20 were added first and heated at 72ºC for 5 minutes 
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to denature the mRNA, and then cooled for 2 minutes on ice. All other components, with 
the exception of the reverse transcriptase enzyme, were then added and incubated at 42ºC 
for 1 minute. Finally, the reverse transcriptase enzyme was added and the reaction was 
incubated at 32ºC for 90 minutes. The reverse transcriptase enzyme was then heat 
inactivated at 70ºC for 15 minutes. The 60µL reactions, now containing cDNA and 




1µL 2U/µL RNaseH (Sigma) 
0.2µL RNase A (Sigma) 
100µL Total Volume 
 
10 minutes, 37ºC. 
 
The 100µL RNase digested cDNA samples were cleaned up using the Qiagen PCR 
purification kit and eluted into 50µL Elution Buffer (EB). This step also removes the 
random hexamer primer which could interfere with the PCR amplification, described 
below. 
 
12.5µL 2x SYBR Green (Qiagen) 
125ng cDNA 
0.75µL 10µM primer 1 
0.75µL 10µM primer 2 
(x) µL ddH20 
25µL Total Volume 
 
Primers were designed using ecocyc (the Encyclopedia of E. coli K12 genes and 
metabolism) and primer3. Tm=60ºC and the primers spanned 200bp of each gene.  
  
gapA: 
5’ GGCATCATCGAAGGTCTGAT 3’ forward 
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5’ GGAACGCCATACCAGTCAGT 3’ reverse 
 
mopA: 
5’ TCAGATCCGTCAGCAGATTG 3’ forward 
5’ AGCAACCACGCCTTCTTCTA 3’ reverse 
 
dnaK: 
5’ GGTGAACCGGTAACTGAAGC 3’ forward 
5’ CCACCACCCAGGTCATAAAC 3’ reverse 
    
dadA: 
5’ GGCGGAGATTGTTGGTTTTA 3’ forward 
5’ CCGGTATTCAGCCACAGATT 3’ reverse 
 
dtd: 
5’ ATTGGGTGTCGAAAAGGATG 3’ forward 
5’ GCACCTTTGGAGAAACTTGG 3’ reverse 
 
 
As per the SYBR Green (Qiagen) protocol, the following cycles were used for RT-PCR 
using the Applied Biosystems 7300 Real-Time PCR System: 
 
1. 95ºC, 15 minutes 
2. 95ºC, 15 seconds 
3. 55ºC, 30 seconds 
4. 72ºC, 30 seconds 
5. Go to step 2, 45 cycles 
 
 
A.14 Plasmid Preps, Linearization and Mutagenesis 
 
For each large scale plasmid prep, 5mL starter cultures were used to inoculate 500mL LB 
cultures that were then grown overnight at 37ºC. Plasmids were purified using the Qiagen 
Hi-Speed Midi Plasmid Purification kit. After elution, samples were frozen and then 
lyophilized over-night so that only DNA and salts remained and subsequently 
resuspended in ~100µL ddH20 to increase the concentration of the DNA before digestion. 
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Plasmids (for mRNAs) were linearized using BamHI as follows: 
  
875ng plasmid DNA 
45µL BamHI (20U/µL 
30µL 10x BamHI buffer 
3µL 100x BSA 
(x) µL ddH20 
300µL Total Volume 
 
Digested plasmids were phenol/chloroform extracted twice. 3M NaOAc, pH 5 was added 
to a final concentration of 0.3M NaOAc, pH 5, and 2-3 volumes of 100% ETOH was 
added before precipitating samples overnight at -20ºC. Samples were then spun for 15 
minutes, 14,000rpm at 4ºC, the supernatant subsequently removed, and samples were then 
washed with 70% ETOH. After removing the supernatant with a pipette, the remaining 
fluid was removed by lyophilization, at which point samples were resuspended in ~50µL 
ddH20 or TE Buffer prior to transcribing. Digested DNA samples were run on 1% agarose 
gels to confirm cutting (0.5g agarose in 50mL 1x TAE Buffer) 
 
Mutagenesis reactions were done as follows using QuikChange Site-Directed 
Mutagenesis Kit: 
 
5µL 10x reaction buffer 
1µL 50ng/µL plasmid DNA 
0.7µL 10µM primer 1 
0.7µL 10µM primer 2 
1µL dNTP Mix 
41.6µL ddH2O 
50 µL Total Volume 
 
After addition of 1µL pfuturbo and PCR cycling and subsequent digestion of parent 
plasmid using dpn1, reactions were cleaned up using Qiagen PCR purification kit and 
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